The role of neuroinflammatory mechanisms in post-stroke recovery by Heindl, Steffanie
 
Aus dem Institut für Schlaganfall- und Demenzforschung am  



















zum Erwerb des Doctor of Philosophy (Ph.D.) in Medical Research  
an der Medizinischen Fakultät der 




The Role of Neuroinflammatory Mechanisms  











Mit Genehmigung der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
First Supervisor: Prof. Dr. med. Arthur Liesz 
Second Supervisor: Prof. Dr. med. Marco Düring 
Dean: Prof. Dr. med. Thomas Gudermann 
Date of Defense: 











The Role of Neuroinflammatory Mechanisms in Post-Stroke Recovery 
Confirmation of congruency 
 
 3 
Confirmation of congruency  
 





The Role of Neuroinflammatory Mechanisms in Post-Stroke Recovery 
Table of content 
 
 4 
Table of content  
Affidavit ....................................................................................................................... 2 
Confirmation of congruency ....................................................................................... 3 
Table of content ........................................................................................................... 4 
List of abbreviations ................................................................................................... 5 
List of publications ...................................................................................................... 6 
1. Introductory summary ..................................................................................... 7 
1.1 The global burden of stroke ................................................................................ 7 
1.2 The main subtypes of stroke ............................................................................... 7 
1.3 Available therapies for ischemic stroke .............................................................. 7 
1.4 Post-stroke neuroinflammation ........................................................................... 8 
1.5 Microglial response to stroke.............................................................................. 8 
1.6 Leukocyte infiltration after stroke....................................................................... 8 
1.7 Gut-brain interaction after stroke ........................................................................ 9 
1.8 Aim of the thesis ................................................................................................ 9 
1.9 Summary of the included publications .............................................................. 10 
1.9.1 Chronic T cell proliferation in brains after stroke could interfere with the 
efficacy of immunotherapies. ........................................................................... 10 
1.9.2 Microglia monitor and protect neuronal function through specialized somatic 
purinergic junctions. ......................................................................................... 12 
1.9.3 Short-Chain Fatty Acids Improve Poststroke Recovery via Immunological 
Mechanisms. .................................................................................................... 14 
1.10 Concluding summary ....................................................................................... 16 
2. Personal contribution to the included publications ...................................... 17 
3. References ....................................................................................................... 18 
4. Publication I – Chronic T cell proliferation in brains after stroke could 
interfere with the efficacy of immunotherapies. ........................................... 22 
5. Publication II - Microglia monitor and protect neuronal function through 
specialized somatic purinergic junctions. ...................................................... 38 
6. Publication III - Short-Chain Fatty Acids Improve Poststroke Recovery 
via Immunological Mechanisms. ................................................................. 116 
7. Acknowledgements ....................................................................................... 133 
8. Scientific publications .................................................................................. 134 
List of abbreviations 
 
 5 
List of abbreviations 
 
ADP     adenosine diphosphate 
ATP     adenosine triphosphate 
BDNF    brain derived neurotrophic factor 
CD*     cluster of differentiation 
DALYs    disability-adjusted live years 
DAMPs    damage associated molecular patterns 
DREADD   designer receptor exclusively activated by designer drugs 
EphA2    ephrin type-A receptor 2 
HMGB1    high-mobility group box protein 1 
i.c.m.     intra cisterna magna injection 
IL-10     interleukin 10 
Ki67     nuclear proliferation marker 
Kv2.1     voltage-gated potassium channel 
NADH    nicotinamide adenine dinucleotide hydride 
P2Y12    chemoreceptor for adenosine diphosphate 
PSB     PSB0739, selective P2Y12 receptor blocker 
PT     photothrombosis 
Rag1     recombination activating gene 1 
RNA     ribonucleic acid 
ROS     reactive oxygen species 
SCFAs    short chain fatty acids 
tPA     tissue plasminogen activator 
TrkB     tropomyosin receptor kinase B  
UTP     uridine triphosphate 
VGlut1    vesicular glutamate transporter 1 
   
List of publications 
 
 6 
List of publications 
 
Heindl S, Ricci A, Carofiglio O, Zhou Q, Arzberger T, Lenart N, Franzmeier N, Hortobagyi 
T, Nelson PT, Stowe AM, Denes A, Edbauer D, Liesz A. (2021). Chronic T cell 
proliferation in brains after stroke could interfere with the efficacy of immunother-
apies. J Exp Med. doi: 10.1084/jem.20202411. doi: 10.1084/jem.20202411 
 
 
Cserép C, Pósfai B, Lénárt N, Fekete R, László ZI, Lele Z, Orsolits B, Molnár G, Heindl S, 
Schwarcz AD, Ujvári K, Környei Z, Tóth K, Szabadits E, Sperlágh B, Baranyi M, 
Csiba L, Hortobágyi T, Maglóczky Z, Martinecz B, Szabó G, Erdélyi F, Szipőcs R, 
Tamkun MM, Gesierich B, Duering M, Katona I, Liesz A, Tamás G, Dénes Á.  
(2020). Microglia monitor and protect neuronal function through specialized so-




Sadler R, Cramer JV, Heindl S, Kostidis S, Betz D, Zuurbier KR, Northoff BH, Heijink M, 
Goldberg MP, Plautz EJ, Roth S, Malik R, Dichgans M, Holdt LM, Benakis C, 
Giera M, Stowe AM, Liesz A. (2020). Short-Chain Fatty Acids Improve Poststroke 
Recovery via Immunological Mechanisms. J Neurosci. Jan 29;40(5):1162-1173. 







1. Introductory summary 
 
1.1 The global burden of stroke 
Despite the growing effort of stroke research for the development of therapeutic strategies, 
stroke remains an increasing health problem with a vast socioeconomic burden worldwide 
[1]. According to the World Health Organization’s latest report, published in December 
2020, stroke caused 11 % of total deaths worldwide, which makes it the second leading cause 
of death [2]. Moreover, the number of stroke-related long-term disabilities increased tremen-
dously in recent years: In 2000, stroke was the fifth most common global cause for disabili-
ties with 125.9 million and the third in 2019 with 139.4 million DALYs (disability-adjusted 
live years) [2].  
1.2 The main subtypes of stroke 
Stroke can be classified in two main subtypes: Ischemic stroke, the subject of this thesis, is 
the most frequent form causing 88 % of global stroke cases and is triggered by an obstruction 
of a brain supplying artery by blood clots, or atherosclerotic plaques [3]. The second main 
subtype, hemorrhagic stroke, is caused by the rupture of a cerebral blood vessel, which pro-
vokes bleeding in the subarachnoid space or intracerebral parenchyma and makes up a 
smaller proportion of 12 % yet results in more deaths and disabilities [4-6]. 
1.3 Available therapies for ischemic stroke 
To date there is only a limited number of clinically approved treatment options for ischemic 
stroke, including acute recanalization strategies, focusing on rapid reperfusion to reduce cer-
ebral tissue damage (“time is brain”) [3, 7]. The first choice of treatment is intravenous 
thrombolysis using tissue plasminogen activator (tPA), which is only applicable within 4.5 
hours after symptom onset [8-10]. Mechanical thrombectomy can be applied for a longer 
time period after ischemia and is often combined with tPA administration [11-13]. However, 
both treatment options reach only 5-10 % of stroke patients due to the narrow treatment 
window, contraindications or the hazard of severe complications [14-16]. Thus, the devel-
opment of treatment strategies with an extended applicability for the subacute and chronic 




1.4 Post-stroke neuroinflammation 
Neuroinflammation is a key pathomechanism of stroke, contributing substantially to second-
ary tissue damage and exacerbation of the lesion [17-20]. Neuroinflammation is initiated by 
rapid neuronal cell death within the ischemic territory due to hypoxic stress, intracellular ion 
disturbances, mitochondrial failure and loss of intracellular structures [21]. In the surround-
ing, still partially perfused tissue (penumbra) neurons undergo delayed cell death by uncon-
trolled release of neurotransmitters, resulting in excitotoxicity [21]. Dying and injured cells 
release danger molecules, including nucleotides (ATP, UTP), reactive oxygen species (ROS) 
and damage associated molecular patterns (DAMPs), such as high-mobility group box pro-
tein 1 (HMGB1) and heat shock proteins, triggering a rapid inflammatory response involving 
local and peripheral immune cells [20, 22-25].  
1.5 Microglial response to stroke 
Microglia, the resident cerebral macrophages, are the first cell type reacting to stroke induced 
tissue injury and DAMPs within minutes to hours [26-28]. Under physiological conditions, 
microglia are continuously surveilling the brain with fine, ramified processes, allowing them 
to recognize disturbances in the cerebral microenvironment [29-32]. The recognition of 
DAMPs initiates rapid activation and morphological transformation of microglia from ram-
ified to amoeboid, enabling them to migrate towards the injured tissue and phagocytose cell 
debris [33-35]. In addition, microglial activation is characterized by an increased cytokine-
release and changed expression of surface molecules [36, 37]. Due to their essential role in 
synaptic remodeling in the developing and adult brain by synaptic pruning and the release 
of neurotrophic factors, such as brain derived neurotrophic factor (BDNF), microglia became 
a major target for stroke research [34, 38, 39]. Moreover, direct contact between microglia 
and neurons was described to be neuroprotective after stroke [40, 41]. Hence, microglial 
responses might play an essential role in post-stroke regeneration and have a high potential 
as therapeutic targets. 
1.6 Leukocyte infiltration after stroke 
In addition to the acute microglial response, circulating myeloid cells infiltrate into the post-
stroke brain and secrete additional chemokines and cytokines [21, 42]. This expanding in-




stroke, which peaks after 3-5 days [23, 43]. During the acute phase, T cells can provoke 
thromboinflammation, resulting in exacerbation of the tissue damage [44-48]. Moreover, 
cytokine driven effector functions of CD4+ T helper cells and CD8+ cytotoxic T cells can 
have further detrimental effects, leading to extensive lesion expansion and disease progres-
sion [20, 22, 49-51]. In contrast, regulatory T cells exert anti-inflammatory functions after 
stroke – by secreting the neuroprotective cytokine IL-10 – and play crucial immunosuppres-
sive roles [52-54]. Thus, T cells possess both neuroinflammatory and neuroprotective func-
tions, which play essential roles in regeneration after stroke [42].  
1.7 Gut-brain interaction after stroke 
Besides neuroinflammation in the brain, ischemic stroke evokes changes in remote organs, 
including the lung [55], heart [56], and intestine [57]. Previous studies demonstrated an im-
portant role for the gut microbiome for stroke outcome, driven by brain-invading lympho-
cytes originating from the intestine [49, 57-59]. In particular, metabolites from the gut mi-
crobiota, such as short-chain fatty acids (SCFAs), can cross the blood-brain barrier and in-
fluence brain function during physiological and pathological conditions [60-63]. Previous 
studies investigating the role of SCFAs in modulating the immune system demonstrated a 
pivotal role in T cell polarization towards an anti-inflammatory subset and the maturation of 
microglial cells [64-66]. However, the mechanisms by which SCFAs contribute to these ef-
fects and how to utilize them for therapeutic approaches, still requires further investigation. 
1.8 Aim of the thesis 
In the search of novel therapeutic approaches to promote post-stroke outcome, neuroinflam-
mation became a major focus of current stroke research [18, 54, 67-69]. Therefore, the over-
arching aim of this doctoral thesis was to investigate the role of neuroinflammatory mecha-
nisms in post-stroke recovery and the evaluation of potential targets for the development of 
immunomodulatory treatment strategies. This goal was comprehensively addressed from 
three different perspectives. The first aim was to evaluate the efficacy of an immunomodu-
latory treatment strategy for stroke, which failed in clinical trials, and investigate the under-
lying mechanism that led to their failure. The second aim focused more specifically on the 
direct communication between microglia and neurons and their possible neuroprotective 
function. The third aim focuses on the role of gut microbiota-derived metabolites in changing 




1.9 Summary of the included publications 
1.9.1 Chronic T cell proliferation in brains after stroke could interfere 
with the efficacy of immunotherapies. 
T cells have been widely described as key drivers of post-stroke neuroinflammation and 
secondary disease progression [22, 47]. Consequently, lymphocyte invasion became a major 
target for several therapeutic strategies, including the use of antibodies against key adhesion 
molecules or reducing the absolute number of circulating lymphocytes [42, 47, 70]. A prom-
inent example for this translational approach is the treatment with anti-CD49d, which re-
duced acute lymphocyte invasion and lesion size in preclinical studies [18, 71, 72]. Follow-
ing these promising results, a first phase 2 clinical trial (ACTION), testing the efficacy of 
the humanized antibody Natalizumab, showed significantly improved functional outcomes 
in the subacute phase (30 days), but this effect was no longer apparent in the chronic phase 
(90 days) [69]. These effects were replicated in a follow-up phase 2b clinical trial (ACTION-
II) which also failed to demonstrate improvement following Natalizumab treatment at 
chronic time-points [68]. Even though the effect of anti-CD49d treatment in preclinical stud-
ies was very well characterized, the reasons of this discrepancy were manifold between the 
outcome of the preclinical and clinical trials. Importantly, different time points were ana-
lyzed: In contrast to the clinical trials, which investigated acute infarct progression as a pri-
mary endpoint, but were subsequently extended to assess chronic post-stroke outcome, the 
preclinical studies focused solely on the acute phase. Therefore, we conducted a reverse 
translational approach and tested whether the treatment with anti-CD49d would have shown 
chronic efficacy in an experimental animal model [73].  
In this study, a photothrombotic stroke (PT) model with consistent lesion size in the acute 
phase was used to evaluate the efficacy of anti-CD49d in the chronic phase after stroke. 
Using a panel of sensitive in vivo and histological techniques, we assessed cortical plasticity, 
behavioral deficits, quantification of lesion involution and synaptic plasticity over a period 
of 3 months after stroke. Anti-CD49d treatment did not improve long-term lesion involution 
or histologically confirmed lesion volume in the chronic post-stroke phase. Additionally, 
functional behavioral recovery or neuronal network connectivity, measured by in vivo wide-
field calcium imaging [74], remained equally unaffected by anti-CD49d treatment over 3 
months. Consistent with these results, there was no significant treatment-effect on synaptic 




together, anti-CD49d treatment did not improve post-stroke recovery in the chronic phase in 
our preclinical approach – comparable to the results of the clinical trials testing the chronic 
efficacy of Natalizumab [68, 69].  
Thus, we aimed to evaluate the biological efficacy of anti-CD49d treatment in reducing lym-
phocyte invasion in the chronic phase after stroke. As previously demonstrated, anti-CD49d 
treatment reduced the number of infiltrating T cells in the acute phase in our study [18], but 
not in the chronic phase after stroke. Instead, we found that T cells accumulated over time 
within the ischemic lesion in both treatment groups, with a consequent loss of the anti-
CD49d associated treatment effect in the chronic phase. Moreover, we observed a close clus-
tering of T cells within the lesion, which led us to the assumption that the accumulation we 
found in the ischemic brain was the result of local proliferation, rather than delayed chronic 
infiltration.  
To test this hypothesis, we performed an in vivo proliferation assay, which allowed us to 
quantify the proliferation rate of T cells by flow cytometry. We found that T cell-prolifera-
tion in the ischemic hemisphere was still significantly elevated in the chronic phase after 
stroke compared to peripheral organs. This observation was confirmed by immunohisto-
chemical analysis for both the anti-CD49d and control-group. In conclusion, a small number 
of T cells could have evaded the antibody treatment and infiltrated into the brain in the acute 
phase after stroke, where local proliferation resulted in the observed chronic intracerebral 
accumulation of T cells. However, this mechanism is not targeted by the anti-CD49d treat-
ment, and thus, leads to the loss of treatment effect. 
To examine the translatability of this mechanism to stroke patients, the number of T cells 
was quantified in tissue samples from human stroke patients. We detected elevated numbers 
of T cells in the tissue samples of all patients, specifically located within the lesion area. 
Comparable to our results in the animal model, we also found dense local clustering and a 
strong correlation of T cell numbers with time after stroke onset. Using immunofluorescence 
staining (for CD3+ T cells and the proliferation marker Ki67), we detected proliferating T 
cells in the lesion of the most chronic patient sample (124 days after stroke), confirming that 
the mechanism of local, intracerebral T cell proliferation in the chronic post-stroke phase 
also applies for human stroke patients. 
Taken together, the study describes the chronic accumulation of T cells after stroke in brains 
of mice and stroke patients, most likely due to local and persistent proliferation of T cells 
invading the brain in the acute phase. As a key limitation, the direct association between T 




stroke outcome has not been covered by this study and remains to be investigated. To achieve 
this, genetic or pharmaceutical models for complete T cell depletion could be an option for 
investigating the role of T cells in chronic post-stroke recovery. In addition, this study mainly 
focused on CD3+ T cells, whereas the underlying composition of T cell subpopulation was 
only briefly introduced and their chronic functions, which could be both detrimental and 
neuroprotective, remained uninvestigated. Thus, this study needs to be followed up by addi-
tional comprehensive investigations of the roles of T cell proliferation and T cell subpopu-
lations in chronic post-stroke recovery. Nevertheless, chronic T cell proliferation after stroke 
could be a previously unrecognized confounder for immunotherapies and interfere with 
many currently conducted clinical trials that target lymphocyte circulation, endothelial ad-
hesion or cerebral invasion. Thus, these findings have a high clinical relevance, urging the 
strong reconsideration of current similar immunomodulatory approaches for stroke therapy. 
 
1.9.2 Microglia monitor and protect neuronal function through 
specialized somatic purinergic junctions.  
Microglia constantly surveil the brain parenchyma and regularly contact neurons with their 
motile, finely branched processes [33, 75]. While most studies of microglia-neuron commu-
nication focused on synaptic interactions between neurons and microglial processes, alter-
native mechanisms of microglia-neuron contact remain widely unexplored [76, 77]. How-
ever, synaptic structures are highly dynamic and distant from the neuronal soma, which 
might allow microglia to only insufficient monitor changes in neuronal activity or injury in 
neuropathological conditions [65, 78]. Thus, mechanisms of microglia-neuron communica-
tion need to be further investigated to understand microglial responses to neuronal injury, 
such as ischemic stroke, and to target these potentially protective mechanisms for therapeutic 
interventions. 
In this study, we described a newly discovered form of microglia-neuron contact via so 
called somatic microglia-neuron junctions in mice and human brain tissue. Using in vivo 
two-photon imaging of fluorescently labeled microglia and neurons, the contact between 
microglial processes and neuronal somata in layer 2 to 3 neurons was revealed first in adult 
mice. In comparison with previously described synaptic connections between microglia and 
neurons, the newly discovered somatic contacts even surpassed the number of synaptic con-
nections (89-95 % vs 9-11%) in mice and human neocortex and persisted for a longer con-




The specialized architecture of these contact sites was characterized using high resolution 
electron-tomography. The sites of somatic microglia-neuron contacts comprised clusters of 
Kv2.1 in the neuronal somatic membrane, a voltage-gated potassium channel, which is (in 
its clustered form) associated with providing exocytotic surfaces and cellular processes for 
cell-to-cell communication [80, 81]. In addition, mitochondria, reticular membrane struc-
tures, intracellular tethers and vesicle like membrane structures are part of the nanoarchitec-
ture of the somatic microglia-neuron junctions. The membrane of microglial processes con-
tacting the neuronal soma showed clusters of P2Y12, a purinergic receptor exclusively ex-
pressed by microglia sensing ATP and ADP [82].  
In vivo and in vitro 2-photon imaging has shown that the recruitment of microglial processes 
to the somatic junctions is dependent on metabolic activity of neuronal mitochondria and 
nicotinamide adenine dinucleotide hydride (NADH) release. Further in vitro experiments 
revealed that neurons release ATP-containing vesicles at the somatic junction site in an ac-
tivity-dependent manner, which are then converted to ADP and sensed by microglia via 
P2Y12 receptors. Inhibition of P2Y12 receptor signaling by intra cisterna magna (i.c.m.) 
administration of the selective P2Y12 receptor blocker PSB0739 (PSB), reduced the lifetime 
of somatic junctions by 45 %, without affecting synapse counts or dendritic contacts between 
microglia and neurons. Moreover, chemogenetic increase in neuronal signaling, using a de-
signer receptor exclusively activated by designer drugs (DREADD) approach, led to an in-
crease in the number of microglial processes covering the neuronal soma, which was abol-
ished by P2Y12 receptor blockage using PSB. Thus, microglia respond dynamically to 
changes in neuronal activity at somatic microglia-neuron junctions via P2Y12 receptor sig-
naling.  
The role of somatic microglia neuron junctions under neuropathological conditions was 
tested in an ischemic stroke model (middle cerebral artery occlusion). Ischemic stroke led to 
the loss of molecular and cellular structures, such as fragmentation of mitochondria and de-
clustering of Kv2.1 in morphologically intact penumbral neurons. As a response, the somatic 
coverage with microglial processes was 4-fold increased, which was completely abolished, 
when P2Y12 receptor signaling using PSB or mitochondrial ATP production was blocked. 
In vivo widefield-calcium imaging revealed, that P2Y12 receptor inhibition via PSB in-
creased the area of neuronal disconnection in the ipsilateral hemisphere after middle cerebral 
artery occlusion. Moreover, seed-based connectivity of the contralateral sensory hindlimb 
area was significantly increased after PSB administration, accompanied by a substantial and 




with these results, the calcium load at the single neuron level was significantly increased. 
Furthermore, P2Y12 receptor inhibition led to increased lesion volumes and neurological 
impairment after stroke, indicating a protective role of microglia process-coverage at the 
neuronal soma after acute stroke. 
In conclusion, this study describes a novel mechanism of microglia-neuron contact through 
somatic junctions, which are present on most neurons under physiological conditions. These 
somatic contacts allow microglia to constantly monitor neuronal status and to rapidly initiate 
neuroprotective mechanisms under pathological conditions, such as acute ischemic stroke. 
Therefore, microglia-neuron-communication and its neuroprotective role after stroke could 
be a promising target for the development of novel therapeutic strategies to promote stroke 
outcome. 
 
1.9.3 Short-Chain Fatty Acids Improve Poststroke Recovery via 
Immunological Mechanisms.  
In this study, mice were supplemented with SCFAs (mix of acetate, butyrate and propionate) 
for 4 weeks in the drinking water before a photothrombotic stroke was induced. In the fol-
lowing 4 weeks, still under SCFA supplementation, functional behavioral and neuronal re-
covery was assessed using an automated lever-pull task and in vivo widefield calcium imag-
ing. While the lesion size remained unaltered between treatment groups, mice receiving 
SCFA-supplement performed significantly better in the lever-pull task (day 56) and had sig-
nificantly changed cortical network connectivity in the chronic post-stroke phase (day 21 
and 42).  
Analysis of synaptic plasticity using Golgi-Cox staining of pyramidal neurons revealed a 
higher density of dendritic spines in naïve animals receiving SCFAs. 14 days after stroke, 
the density of dendritic spines was still elevated in the contralateral hemisphere of SCFA-
treated animals, but not in the ipsilesional hemisphere. Moreover, SCFA treatment induced 
a shift towards shorter spine length. Synaptic plasticity was further assessed by immunoflu-
orescent co-staining of vesicular glutamate transporter 1 (VGlut1, presynapse) and Homer1 
(postsynapse), revealing a significantly reduced number of colocalized VGlut1 and Homer1 
puncta in the perilesional cortex of SCFA treated mice. Finally, SCFA treatment signifi-
cantly increased the expression of key factors associated with synaptic plasticity, such as 




the receptor for brain derived neurotrophic factor (BDNF), whereas BDNF and receptor ty-
rosine kinase ephrin type-A receptor 2 (EphA2) were unaffected. 
Ribonucleic acid (RNA) sequencing from infarct tissue 14 days after stroke revealed that the 
majority of differentially expressed genes were associated with pathways linked to micro-
glial activation and function, which are essential for synaptic pruning, suggesting microglia 
as the cellular targets of SCFA associated treatment effects [82-86].  
Therefore, the effect of SCFA treatment on microglial activation was studied in more detail 
14 days after stroke using immunohistochemical assessment of microglial activation markers 
and morphology using a fully automated algorithm for microglia morphology analysis, 
which we previously published [35]. In sum, microglia in SCFA treated mice were charac-
terized by a significantly reduced activation profile and inflammatory response after stroke. 
Besides acute microglial response, we characterized the effect of SCFA on brain-invading 
lymphocytes as key drivers of neuroinflammation after stroke [53, 73, 87, 88]. Flow cytom-
etry revealed that SCFA supplementation significantly reduced lymphocyte numbers in the 
brain and spleen of mice 14 days after stroke, suggesting a SCFA associated modification of 
the systemic inflammatory response. In a genetic model in which mice lack functional lym-
phocytes (recombination activating gene 1 (Rag1)-/- mice) SCFA had no effect on microglial 
activation, indicating a messenger role of lymphocytes for the SCFA-triggered anti-inflam-
matory effect on microglia after stroke. 
Taken together, this study describes an immunomodulatory function of SCFAs, which re-
sults in reduced microglial inflammatory response and improved post-stroke recovery. How-
ever, the SCFA associated immunomodulation is indirectly mediated via brain-invading 
lymphocytes through altering their maturation, their egress from primary lymphoid organs 
or polarization of lymphocytic cytokine release after stroke. Thus, the results of this preclin-
ical study indicate an efficacy of SCFA supplementation to improve chronic stroke outcome, 







1.10 Concluding summary 
In summary, this Ph.D. thesis contributes fundamentally to addressing central outstanding 
questions of translational stroke research by investigating neuroinflammatory mechanisms 
and characterizing immunomodulatory therapeutic approaches to improve stroke outcome. 
It highlights the importance of a precisely matched study-design between preclinical and 
clinical studies, especially through the reversed-translational approach of evaluating the 
long-term efficacy of anti-CD49d treatment to improve post-stroke recovery. It describes in 
mice and stroke patient samples, that T cells chronically proliferate in brains after stroke, 
which might interfere with the efficacy of immunotherapies. Therefore, these translational 
findings are of high clinical relevance for multiple planned or ongoing immunotherapeutic 
trials, which target lymphocyte migration or circulation. Moreover, this thesis describes the 
discovery of a previously unrecognized form of communication between microglia and neu-
rons and its potential neuroprotective role during stroke. Previous studies have focused on 
microglia-neuron contact through connections between microglial branches and neuronal 
synapses, which seemed to have an insufficient capability to sense neuronal activity and 
health. Thus, the discovery of somatic contacts between microglia and neurons, which allow 
microglia to monitor and protect neuronal function, has answered an intriguing question of 
fundamental neuroscience. Furthermore, the thesis describes how metabolites from the gut 
microbiome – SCFAs – can influence post-stroke recovery by indirectly modulating immu-
nological mechanisms. The study shows, that SCFA supplementation in mice leads to im-
proved stroke outcome, but in contrast to directly stimulating these effects in the brain, 
SCFA treatment modulates infiltration and polarization of circulating lymphocytes, which 
then indirectly modulate inflammatory responses in the brain. Taken together, this thesis sets 
a framework for numerous future studies in translational stroke research focusing on neu-
roinflammatory mechanisms and immunomodulatory treatment strategies, to improve 
chronic stroke outcome in patients and reduce the global burden of stroke.  
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2. Personal contribution to the included publications 
 
For the first study, where I am first author, I performed the majority of the experimental 
work (Figure 1 A-G, Figure 2 A, D-E, Figure 3 A-E, Figure S1 A-C, E, Figure S2 A-F and 
Figure S3 A). The remaining experimental work was contributed by co-authors (Figure 2 B-
C, Figure 3 D-F, Figure S1 D-F and Figure S3 B-D). Additionally, I performed the statistical 
data analysis, whereby I had some assistance or supervision from co-authors (A.R. and N.F., 
Figure 1 E-F and Figure 2 B-C). Furthermore, I created and designed the figures and wrote 
the first draft of the manuscript.  
For the second study, I was responsible for the in vivo widefield calcium imaging of animals 
receiving the P2Y12 receptor inhibitor PSB0739 by performing the imaging data acquisition, 
computational data analysis and illustration (Figure 5 F-G). Moreover, I wrote parts of the 
manuscript and revised the manuscript draft. 
For the third study, I performed the statistical data analysis of microglial morphology (Figure 
2 B-D), based on a previously published analysis strategy, where I shared the first authorship 
with a colleague [35]. Additionally, I wrote parts of the manuscript and revised the manu-
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Chronic T cell proliferation in brains after stroke
could interfere with the efficacy of immunotherapies
Steffanie Heindl1, Alessio Ricci1, Olga Carofiglio1, Qihui Zhou2, Thomas Arzberger3,4, Nikolett Lenart5, Nicolai Franzmeier1,
Tibor Hortobagyi6, Peter T. Nelson7, Ann M. Stowe7, Adam Denes5, Dieter Edbauer2,8, and Arthur Liesz1,8
Neuroinflammation is an emerging focus of translational stroke research. Preclinical studies have demonstrated a critical role
for brain-invading lymphocytes in post-stroke pathophysiology. Reducing cerebral lymphocyte invasion by anti-CD49d
antibodies consistently improves outcome in the acute phase after experimental stroke models. However, clinical trials
testing this approach failed to show efficacy in stroke patients for the chronic outcome 3 mo after stroke. Here, we identify a
potential mechanistic reason for this phenomenon by detecting chronic T cell accumulation—evading the systemic therapy—in
the post-ischemic brain. We observed a persistent accumulation of T cells in mice and human autopsy samples for more than
1 mo after stroke. Cerebral T cell accumulation in the post-ischemic brain was driven by increased local T cell proliferation
rather than by T cell invasion. This observation urges re-evaluation of current immunotherapeutic approaches, which target
circulating lymphocytes for promoting recovery after stroke.
Introduction
Stroke is one of the leading causes of death and permanent
disability worldwide (World Health Organization, 2017). Despite
the enormousmedical need, specific therapies for stroke patients
are still limited to vascular recanalization approaches within the
acute phase after stroke (Emberson et al., 2014; Fiehler and
Gerloff, 2015; Hacke et al., 2008). In the search for alternative
therapeutic strategies, post-stroke neuroinflammation has come
into focus in current translational stroke research (Iadecola and
Anrather, 2011). Neuroinflammation after stroke is a crucial
pathomechanism contributing to secondary brain injury,
neurodegeneration, and recovery (Iadecola and Anrather,
2011; Moskowitz et al., 2010). While different leukocyte cell
populations have been implicated in the neuroinflammatory
response to stroke, T cells have been consistently shown to be a
key cell population driving secondary brain injury (Chamorro
et al., 2012; Macrez et al., 2011). Consequently, several thera-
peutic strategies targeting the brain invasion of lymphocytes
have been tested using antibodies against key adhesion mole-
cules or by reducing the number of circulating lymphocytes
(Chamorro et al., 2012; Cramer et al., 2019a).
A prominent and controversial example of this translational
approach is the use of anti-CD49d antibodies (Natalizumab),
which reduces the invasion of circulating lymphocytes to the
brain by blocking a key adhesion molecule. The repurposing of
this drug used for patients with multiple sclerosis improved
outcome in the acute phase after experimental stroke in the
majority of preclinical studies (Becker et al., 2001; Langhauser
et al., 2014; Liesz et al., 2011; Neumann et al., 2015; Relton et al.,
2001), which was validated in a first-ever multicenter, ran-
domized preclinical trial (Llovera et al., 2015). In a first phase
2 clinical trial (ACTION), Natalizumab treatment significantly
improved functional outcome (modified Rankin scale) in the
subacute phase (30 d), but this effect was not evident anymore
in the chronic phase (90 d; Elkins et al., 2017). Correspondingly,
a follow-up phase 2b trial (ACTION-II) also did not report any
improvement with Natalizumab treatment in the stroke out-
come at 90 d (Elkind et al., 2020).
Failed translations from promising experimental studies to
clinical trials are commonly attributed to differences in study
design, target engagement, or lack of statistical robustness of the
preclinical findings (Endres et al., 2008; Howells et al., 2014;
Macleod et al., 2014). However, the efficacy of Natalizumab
in preclinical models has been extraordinarily well character-
ized, and clinical trials have closely mimicked the efficient
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therapeutic approaches in animal models in the design of the
treatment regimen and investigated outcome parameters, with
the exception of analyzing different time points after stroke:
Clinical trials analyzed the chronic phase after stroke as the
primary endpoint in contrast to preclinical studies, where only
the acute phase was studied. Therefore, we took a reverse trans-
lational approach and tested whether the design of the clinical
trials—analyzing chronic stroke outcome between patient groups
with similar baseline characteristics after stroke—would have
been efficacious in the murine experimental stroke model.
Confirming a lack of efficacy on chronic post-stroke recovery
also in animal models further prompted us to study the po-
tentially underlying mechanisms of the diverging effects in
acute versus chronic phases after stroke.
Results and discussion
Natalizumab treatment does not improve post-stroke
recovery and neuronal plasticity
To model the clinical study design of Natalizumab treatment for
stroke from the two clinical trials in an animal model, we used a
photothrombotic stroke (PT) model resulting in equal lesion
volumes and behavioral deficits in both treatment groups at the
acute phase, corresponding to the equal characteristics of the
study populations with Natalizumab or control treatment in
the clinical trials. Mice of mixed sex then received anti-CD49d or
an isotype control antibody i.p. 2 h after stroke, followed by
injections every second week over a period of 3 mo, based on
previous reports and the pharmacokinetic analyses of cellular
anti-CD49d saturation (Fig. S1, A–D). We used a panel of in vivo
imaging techniques for cortical plasticity, behavior tests, the
assessment of lesion size and synaptic plasticity, which were
proven to sensitively detect therapeutic effects on chronic post-
stroke recovery (Cramer et al., 2019b; Cserép et al., 2020; Sadler
et al., 2020). Anti-CD49d treatment did not improve long-term
lesion involution based on in vivo widefield imaging (Fig. 1, A
and B; and Fig. S1 D) and also had no effect on histologically
quantified lesion volumes after PT as well as in an independent
stroke model of distal middle cerebral artery occlusion (dMCAo)
used in the majority of previous reports on the effects in the
acute post-stroke phase (Fig. 1 C and Fig. S1 E). Moreover, re-
covery of behavior deficits using a well-established multipa-
rameter neuroscore (Llovera et al., 2015) and cylinder test
(Llovera et al., 2014) also did not differ between treatment
groups throughout the observation period of 3 mo after stroke
(Fig. 1 D). Additionally, we examined functional neuronal con-
nectivity using in vivo widefield calcium imaging. We observed
equal network disturbances in pairwise comparisons of func-
tional cortical areas in both treatment groups after stroke (Fig. 1
E). Moreover, we did not detect anti-CD49d-associated im-
provement in neuronal network connectivity after stroke nei-
ther within the ischemic hemisphere nor across homotopic areas
of both brain hemispheres (Fig. 1 F). Correspondingly, quanti-
fication of synaptic spine density as a marker of synaptic plas-
ticity at 3 mo after stroke did not reveal a difference between
treatment groups, which were both returned to baseline levels
(naive). These results clearly indicate a lack of efficacy for anti-
CD49d to improve functional recovery in the chronic post-stroke
phase in two preclinical stroke models, which is comparable to
the outcome of the clinical trials testing the efficacy of Natali-
zumab in stroke patients (Elkind et al., 2020; Elkins et al., 2017;
Liesz et al., 2011; Llovera et al., 2015).
Anti-CD49d only transiently reduces cerebral lymphocyte
counts after stroke
Therefore, we next aimed to analyze the biological efficacy of
anti-CD49d treatment in reducing long-term lymphocyte inva-
sion to the injured brain, which could not be studied in the
clinical trials. To this end, we performed quantitative flow cy-
tometric analyses at acute and chronic time points after stroke.
Corresponding to previous studies by us and others, anti-CD49d
significantly decreased cerebral lymphocyte invasion at the
acute phase in male and female animals (Fig. 2 A and Fig. S3 A).
In contrast, no difference in cerebral leukocyte count was de-
tectable between treatment groups at 1 mo after stroke for any of
the T cell subtypes, which we quantified in a multidimensional
flow cytometric analysis (Fig. 2, B and C). Interestingly, we
found T cells among leukocyte populations to specifically accu-
mulate in the chronic phase after stroke (Fig. S2). Next, we
performed immunofluorescence labeling of CD3+ T cells to an-
alyze the spatial distribution of T cells after stroke. Consistent
with our flow cytometric results and a previous report (Doyle
et al., 2015), we found dense T cell accumulation within the
chronic lesion but did not detect a difference in intralesional
T cell density between control or anti-CD49d–treated groups at
28 d after stroke (Fig. 2 D). We analyzed the spatial clustering of
T cells by calculating the Clark–Evans agglomeration index (R
index), which indicates cell clustering for an R < 1 (Fig. 2 E).
Interestingly, the R index ranged between 0.3 and 0.7 for both
acute (day 7) as well as for chronic (day 28) time points, re-
gardless of treatment groups. Additionally, chronic T cell accu-
mulation and their local clustering was confirmed in the dMCAo
stroke model for both treatment groups (Fig. S3 B). Thus, the
chronic accumulation of T cells in the post-ischemic brain as-
sociates with local clustering of T cells likely due to local, in-
tracerebral proliferation. This finding could potentially explain
the difference in treatment efficacy of anti-CD49d between the
acute stroke outcome (with transiently reduced cerebral T cell
invasion) and long-term recovery. Taken together, our approach
to monitor the treatment efficacy of anti-CD49d for chronic
recovery in two independent stroke models could have pre-
dicted the inefficacy of Natalizumab in clinical stroke trials.
Moreover, this first-ever analysis of long-term effects of anti-
CD49d treatment on the cerebral lymphocyte pool provides a
mechanistic rationale for the futile treatment effects in the chronic
post-stroke phase.
T cells proliferate intracerebrally after stroke
We next aimed to distinguish chronic recruitment versus local
proliferation as the potential cause of the chronic lymphocyte
accumulation in the post-stroke brain. Therefore, we adminis-
tered 5-ethynyl-29-deoxyuridine (EdU), a thymidine analogue
labeling proliferating cells, in the drinking water over a 7-d time
period, starting either the day of surgery (days 0–7) or 3 wk later
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Figure 1. Longitudinal evaluation of post-stroke recovery in mice receiving anti-CD49d treatment. (A) The lesion area based on autofluorescence after
stroke of individual animals was superimposed to depict the lesion throughout the observation period of 84 d in Thy1-GCaMP6s animals. The color code
indicates the sum of overlapping lesion pixels of individual mice per acquisition time point. Data were generated in two independent experiments. BL, baseline;
D, day. (B) Quantification of the number of autofluorescent pixels seen in calcium imaging of Thy1-GCaMP6s animals. Control (Ctrl): n = 10, anti-CD49d: n = 13,
P = 0.716. Data are shown asmean ± SD, linear-mixed-models, group-by-time interaction. Data were generated in two independent experiments. (C) The lesion
volume was quantified at 7 and 28 d after stroke and shows no difference between treatment groups. Control 7 d: n = 6, control 28 d: n = 11, anti-CD49d 7 d: n = 5,
anti-CD49d 28 d: n = 8, all WT animals. Data are shown as mean ± SD. Ordinary one-way ANOVA + Tukey’s post-hoc test. Data were generated in at least three
independent experiments per time point. (D) Evaluation of the multi-parameter neuroscore and cylinder test shows no difference between treatment groups.
Control: n = 10, anti-CD49d: n = 13, P (neuroscore) = 0.560, P (cylinder) = 0.691. Data are shown as median ± SE, linear-mixed models, group-by-time interaction.
Data were generated in two independent experiments in Thy1-GCaMP6s animals. (E) Illustrative pixelmaps show the group-wise averaged seed-based FC between
eight seeds representing functional cortical areas over an observation period of 84 d after stroke by longitudinal in vivo calcium imaging: 1, left rostral forelimb; 2,
right rostral forelimb; 3, left caudal forelimb; 4, right caudal forelimb; 5, left forelimb sensory area; 6, right forelimb sensory area; 7, left hindlimb sensory area; 8,
right hindlimb sensory area.. Gray squares indicate excluded seed autocorrelation, and white squares indicate excluded seeds due to the stroke lesion, when
excluded in more than three animals. Data are shown as Fisher z-transformed connectivity scores and were generated in two independent experiments in Thy1-
GCaMP6s animals. (F) Schematic illustration for longitudinal in vivo widefield calcium imaging acquisition; left intrahemispheric and whole cortex homotopic FC
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(days 21–28). Then, the rate of proliferating T cells was deter-
mined in blood, spleen, and the ischemic brain hemisphere after
acute (day 7) or chronic (day 28) EdU labeling in untreated mice
(Fig. 3 A). As expected for the acute inflammatory response, we
observed an increase in the proliferation rate (percentage of
EdU+ cells) for cerebral T cells in comparison to splenic and
blood T cells at 7 d after stroke. Surprisingly, the proliferation
rate in the chronic phase was still significantly (more than
twofold) increased for the cerebral T cell population compared
with peripheral organs. In contrast, using systemic antibody
labeling of circulating T cells over 3 d (days 25–28), we detected
only a small number of T cells still de novo–invading the brain in
the chronic phase after stroke (Fig. S3 C). To additionally con-
firm the local proliferation of cerebral T cells, we analyzed
histologically the expression of the direct proliferation marker
Ki67 to quantify the percentage of proliferating T cells within
the chronic stroke lesion (Fig. 3 B). We found independent of the
treatment group a substantial number of >5% Ki67+ T cells,
confirming the local intralesional proliferation of T cells 28 d
after PT (Fig. 3 C), which was also confirmed in the dMCAo
stroke model with comparable findings (Fig. S3 D). These results
suggest that—regardless of anti-CD49d treatment—sustained
and local proliferation of T cells in the post-stroke brain drives
chronic cerebral T cell accumulation after stroke.
Evidence for chronic T cell accumulation in human brain
autopsy samples
To verify chronic T cell accumulation after stroke in brains of
human stroke patients, we obtained 10 individual samples from
two brain banks (Lexington and Debrecen) of six individual
stroke patients dying during the acute and chronic phase after
confirmed cerebral ischemia and excluding other brain dis-
orders or immunological or inflammatory diseases (Table S1).
The area covering the ischemic lesion within the samples was
identified based on H&E staining for quantitative analyses. Us-
ing immunohistochemical staining, we detected CD3+ T cells in
all 10 human brain samples (Fig. 3 D). The number of detected
T cells ranged from ∼300 to >9,000 cells/cm2 of tissue section,
with an average of 80% located within the lesion area. Addi-
tionally, the spatial distribution of T cells within the stroke le-
sions was determined and showed strong local clustering, with
an R index ranging from 0.28 to 0.55 (Fig. 3 E). A Spearman
correlation analysis for T cell density and time since stroke re-
vealed a highly significant positive association. These results
clearly demonstrate that T cells accumulate chronically and
cluster locally in the ischemic lesion of human stroke patients.
We additionally performed immunofluorescence staining for
CD3+ T cells and Ki67 in the most chronically collected patient
sample (124 d after stroke) and detected double-positive cells
(Fig. 3 F), confirming that the phenomenon of local, intracere-
bral proliferation of T cells in the chronic phase after stroke also
applies to human stroke patients.
Taken together, we describe here chronic T cell accumulation
most likely due to local proliferation after ischemic stroke in
mice and human brains, constituting a previously unrecognized
potential confounder for immunotherapeutic studies after is-
chemic stroke. None of the current pharmacological approaches
block completely the cerebral invasion of T cells after stroke (in
contrast to experimental T cell–depletion approaches; Liesz
et al., 2009; Liesz et al., 2011) but rather reduce numbers of
invading T cells by various degrees (Liesz et al., 2011; Llovera
et al., 2015). Therefore, despite the therapeutic intervention,
some T cells invade the ischemic brain. Once in the cerebral
microenvironment, T cells might become autonomous from the
peripheral immune system and establish a tissue-resident pop-
ulation by local proliferation. Here, we confirm chronic T cell
accumulation and local proliferation in two independent ex-
perimental stroke models (PT and dMCAo). However, further
mechanistic studies will be required to explore the biological
function and therapeutic implications of this unexpected
phenomenon.
For this study, wemainly used the PTmodel, which induces a
pronounced cellular neuroinflammatory response and allows for
sensitive analysis of neuromodulatory effects in the chronic
recovery phase after stroke (Cotrina et al., 2017; Sadler et al.,
2020). Key findings on lesion volume, T cell accumulation, and
proliferation have additionally been confirmed in a widely used
dMCAo model with similar findings in male and female animals.
However, considering previous reports on model differences
concerning the extent and dynamics of the neuroinflammatory
response to stroke, future clinical trials need to consider not only
potentially unexpected long-term effects, as reported in this
study, but also potentially drastic differences in the role of
neuroinflammation between stroke subtypes regarding lesion
location, size, and etiology (Cotrina et al., 2017; Cramer et al.,
2019a; Zhou et al., 2013).
As such, our findings have high clinical relevance for many
ongoing or planned immunotherapeutic trials in stroke that
target circulating lymphocytes, their endothelial adhesion, or
cerebral invasion. According to the ClinicalTrials.gov registry of
clinical intervention trials, more than 40 trials are exploring
such strategies with pending outcome as of March 2021. The
therapeutic approaches in these studies cover a broad range of
potential therapies, including (autologous) cell therapies, po-
larization of T cell responses, or modulating lymphocyte mi-
gration. Several of these studies use repurposing of drugs that
of the eight previously defined functional areas. Time course of left intrahemispheric FC (intra FC; P = 0.127) and overall homotopic FC (P = 0.295). Data are
shown as median ± SE, linear-mixed models, group-by-time interaction. Data were generated in two independent experiments in Thy1-GCaMP6s animals.
(G) Representative images of a Golgi-Cox–stained pyramidal neuron layer II/III in a naive animal (scale bar = 30 µm) and 3D reconstruction of pyramidal neuron
dendrites (red) with dendritic spines (blue, scale bar = 5 µm). Dendritic spines were quantified in layer II/III in naive (untreated) animals and 84 d after stroke in
stroke ipsi- and contralateral hemispheres. Naive: n = 5, control: n = 10, anti-CD49d: n = 13. Data are shown as median ± interquartile range. Wilcoxon rank-sum
test with continuity correction and Bonferroni correction for multiple comparisons were used. Data were generated in at least two independent experiments. All
data in this figure were obtained in a mixed-sex cohort (anti-CD49d: four male, nine female; control: three male, seven female), except for C (only male mice).
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have been established and approved for multiple sclerosis, a
disease that not only differs drastically in its pathogenesis but
also has distinct neuroimmunological features. However, the
differences between acute ischemic lesions and chronic auto-
immune brain disorders have not yet been fully characterized
and may pose a threat to the success of immunotherapeutic
stroke trials.
In light of these findings, current clinical trials targeting
lymphocyte migration or brain recruitment (lymphocyte-
depleting antibodies, fingolimod, and cell therapy approaches)
Figure 2. T cells chronically accumulate in the post-ischemic brain independent of anti-CD49d treatment. (A) Flow cytometric quantification of CD4+ T
helper cells and CD8+ cytotoxic T cells per ipsilateral stroke hemisphere at 5 d after stroke. n = 5 per group. Data are shown as mean ± SD, unpaired t test with
Holm–Sidak’s post-hoc test. Data were generated in two independent experiments in WT animals. (B) Quantification of T cell subtypes by multidimensional
flow cytometry 28 d after stroke from the ipsilateral stroke hemisphere was achieved by dimensionality reduction using UMAP (Uniform Manifold Approx-
imation and Projection). The individual clusters were identified as CD3+ T cell subtypes by the MFI of CD8a, CD4, CD62L, CD44, CD69, Foxp3, γδ TCR, and
RORγt, as shown in the heatmap on the right, including activated (act.) CD4+ T helper cells (CD4+CD69+CD62L−), activated CD8+ cytotoxic T cells
(CD8+CD69+CD62L− RORγt+), double-negative T cells (CD4−CD8−), γδ T cells (TCRγδ+CD44+CD69+), naive CD4+ T helper cells (CD4+CD69−CD62L+), naive
CD8+ cytotoxic T cells (CD8+CD69−CD62L+), central memory T cells (TCM; CD8+CD69−CD62L+CD44+), and regulatory T cells (Treg; CD4+FOXP3+).
(C)Quantification of numbers of T cell subtypes per cluster in the ipsilateral stroke hemisphere shown in B. Control: n = 5, anti-CD49d: n = 7. Data are shown as
mean ± SD; unpaired t test and Holm–Sidak post-hoc test. The data were generated in three independent experiments in WT animals. (D) Representative
immunofluorescence images of CD3+ T cells in the brain 28 d after stroke of the whole section with demarcation of the lesion (upper left, scale bar = 1 mm), the
lesion area (lower left, scale bar = 500 µm), and an area within the lesion from control and anti-CD49d animals (right, scale bars = 30 µm). The T cell density
within the lesion (cells per square millimeter) showed no difference between groups. Control: n = 11, anti-CD49d: n = 8. Data are shown as mean ± SD; unpaired
t test. The data were generated in at least three independent experiments in WT animals. (E) Schematic representation of the R index for describing cell
clustering (left) and the R index for CD3+ T cells within the lesion at 7 and 28 d after stroke for both treatment groups (right). Control 7 d: n = 6, control 28 d:
n = 11, anti-CD49d 7 d: n = 5, anti-CD49d 28 d: n = 8. Data are shown as median ± interquartile range. *, P < 0.05; #, P (clustered [R < 1]) <0.0001; ordinary one-
way ANOVA + Tukey’s post-hoc test. Data were generated in at least three independent experiments per time point in WT animals.
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need to be fundamentally reconsidered. Mechanisms of chronic
neuroinflammation after stroke and the consequences for post-
stroke recovery need to be better understood for the rationale
design of efficient immunotherapies in stroke.
Materials and methods
Animals
All experiments in this studywere conducted in accordancewith
the national guidelines for animal experiments and approved
by the German governmental committees (Regierungpraesidium
Oberbayern, Munich, Germany). For flow cytometric and im-
munohistochemical analyses, the animals were 8–12-wk-oldmale
or female C57BL/6J mice (Charles River Laboratories). For in vivo
widefield calcium imaging and dendritic Golgi spine analysis,
the animals were 12–15-wk-old male and female C57BL/6J-
Tg(Thy1-GCaMP6s)GP4.12Dkim/J (here termed Thy1-GCaMP6s;
Dana et al., 2014) heterozygous mice bred at the Institute for
Stroke and Dementia Research, Munich (>12 generations back-
crossed on C57Bl6/J WT mice). The animals were housed under
controlled temperature (22 ± 2°C) with a 12-h light/dark cycle
and access to food and water ad libitum. All animal experiments
were performed and reported in accordance with the ARRIVE
guidelines (Kilkenny et al., 2010).
Stroke surgery
For PT induction, mice were anaesthetized with isoflurane, de-
livered in a mixture of 30% O2 and 70% N2O. Mice were placed
Figure 3. T cells chronically proliferate in the postischemic brain in mice and stroke patients. (A) The percentage of EdU+ T cells was quantified by flow
cytometry in the spleen, blood, and ipsilateral stroke hemisphere at day 7 and day 28 after stroke (n = 5 per group). Data are shown as mean ± SD; ordinary
one-way ANOVA and Tukey’s post-hoc test. Two independent experiments per time point were performed in WT animals. (B) Representative images show
immunofluorescence staining for CD3 and Ki67 within the lesion area for the detection of intracerebral T cell proliferation 28 d after stroke in both treatment
groups (upper row, control; lower row, anti-CD49d). Arrows point to CD3 and Ki67 double-positive T cells. Scale bars = 10 µm. (C) Quantification of the
percentage of Ki67+ T cells from (B) within the lesion 28 d after stroke showed no difference between the treatment groups. control: n = 11, anti-CD49d: n = 8.
Data are shown as mean ± SD. Unpaired t test. The data were generated in at least three independent experiments in WT animals. (D) Representative images
are shown for CD3+ DAB staining on consecutive brain sections from a human sample (124 d since stroke onset). Higher magnification images are shown from
respective indicated areas. Scale bars: left, 1 mm; middle, 400 µm; right, 10 µm. (E) Cell density (cells/square centimeter) of intra- and extralesional CD3 T cells
and cell clustering by R index were quantified. P (clustered [R < 1] <0.0001) for all analyzed samples. Correlation analysis (Spearman) between T cell density
and time since stroke onset per sample. (F) Representative images of immunofluorescence staining for CD3 and Ki67 within the previously histopathologically
identified lesion area are shown for the patient samples with the highest detected T cell count (124 d since stroke onset). Arrows point to CD3 and Ki67 double-
positive T cells. Scale bar = 10 µm. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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into a stereotactic frame, and body temperature was maintained
at 37°C with a mouse warming pad. Dexpanthenol eye ointment
was applied to both eyes. Animals received 10 µl/g body weight
of 1% Rose Bengal (198250-5g; Sigma-Aldrich) in saline i.p. 5 min
before the induction of anesthesia (5% isoflurane). A skin inci-
sion was used to expose the skull. Bregma was located, and the
lesion location was marked in the left hemisphere (1.5 mm lat-
eral and 1.0mm rostral to bregma). For in vivowidefield calcium
imaging experiments, PT was induced as previously described
(Cramer et al., 2019b). In brief, an independent vector analysis
was performed based on baseline resting-state imaging, which
allowed us to define cortical functional regions as independent
components. The independent component in the primary motor
cortex was then used to individually define the lesion location
for every mouse. Shielding was placed on the skull, allowing a
2.0-mm-diameter circular light exposure over the lesion area.
10 min after Rose Bengal injection, the laser (25 mV output) was
applied to the lesion area for 17 min (Cobolt Jive 50, 561 nm
power at 25mV; Fiber Collimation Package: 543 nm, f = 7.66mm,
beam diameter [d] ≈ (4)(0.000561 mm)[7.86 mm/(pi × 0.004
mm)] = 1.4 mm). The sham procedure was performed as de-
scribed previously but without laser illumination.
dMCAo was performed as previously described (Llovera
et al., 2014). Briefly, the mouse was positioned on its side and
skin was incised between the ear and the eye. After, the tem-
poral muscle was detached from the bone and a craniotomy was
performed on top of the middle cerebral artery. The vessel was
permanently coagulated, proximal and distal to the MCA bi-
furcation, with electrocoagulation forceps. Finally, the muscle
was placed back and the wound sutured.
Anti-CD49d antibody treatment
Animals were treated with 300 µg anti-CD49d (clone PS/2,
catalog no. BE0071; Bio X Cell) or isotype control (LTF-2, catalog
no. BE0090; Bio X Cell) in 0.01 M PBS 2 h after PT induction,
followed by injection every second week until termination of
the experiment. The treatment groups were assigned after
randomization, and experimenters were blinded to group
assignment.
Neuroscore
The multiparametric neuroscore was assessed as previously
described (Orsini et al., 2012). Briefly, the score is composed of
the assessment of several subtests of both global and focal def-
icits. Assessment of global deficits included grooming, status of
ears and eyes, posture, spontaneous activity, and epileptic be-
havior. Focal deficits were evaluated by gait, grip, forelimb
asymmetry during tail suspension, circling behavior of the en-
tire body or only a forelimb, body symmetry, and whisker re-
sponse. Total score ranges from 0 to 54 points (26 points for
general and 28 for focal deficits), with a higher score indicating
worse deficits. Data were acquired once before stroke and on
days 3, 7, 14, 21, 28, 42, 56, 70, and 84 after stroke.
Cylinder test
The cylinder test was assessed as previously described (Llovera
et al., 2014). Briefly, the animals were placed in a transparent
acrylic glass cylinder (diameter, 8 cm; height, 25 cm) in front of
two mirrors, and video was recorded for 10 min. The frequency
of forelimb use during a full rear and landing with only one
forelimbwas counted. At least 20 contacts for one forelimbwere
counted using slow-motion or frame-by-frame function. The
ratio was calculated as the total number of left forelimb contacts
divided by the total number of right forelimb contacts with the
cylinder wall.
Flow cytometry
Mice were deeply anesthetized and perfused with 20 ml saline.
Both brain and spleen were dissected, and blood was collected in
EDTA tubes after cardiac puncture. For brain, both hemispheres
were carefully removed, and cells were isolated by mechanical
dissociation. Cell preparation and staining were performed as
previously described (Llovera et al., 2017). Mononuclear cells
were enriched using discontinuous Percoll gradients. Cell stain-
ings were performed using the following antibodies: CD45-eF450
(1:250, 48–0451-82, clone: 30-F11; Invitrogen), CD3-FITC (1:250,
11–0032-82, clone: 17A2; Invitrogen), CD8-PE (1:250, 12–0081-82,
clone: 53–6.7; Invitrogen), CD4-PerCP-Cy5 (1:250, 45–0042-82, clone:
RM4-5; Invitrogen), TCRyd-APC (1:250, 118116, clone: GL3;
BioLegend), NK1.1-PE-Cy7 (1:250, 25–5941-82, clone: PK136; In-
vitrogen), CD19-APC-Cy7 (1:250, 47–0193-82, clone: eBio1D3; In-
vitrogen), CD11b-PerCP-Cy5 (1:250, 45–0112-82, clone: M1/70;
Invitrogen), MHCII-PE (1:250, 12–5322-81, clone: NIMR-4; eBio-
science), Ly6C-APC (1:500, 17–5932-82, clone: HK1.4; eBioscience),
Ly6G-PE-Cy7 (1:333, 25–5931-82, clone: RB6-8C5; eBioscience), and
CD11c-APC-Cy7 (1:250, 117324, clone: N418; BioLegend). Stained
cells were analyzed on a BD FACSVerse flow cytometer (BD Bio-
sciences), and analysis was performed using FlowJo software
(version 10.0).
For high-dimensional flow cytometry (Fig. 2, B and C), mice
were injected i.v. with 3 µg CD45-APC-Cy7 (103116, clone: 30-F11;
BioLegend), 3 min before transcardiac perfusion, to exclude
blood contamination. Mononuclear cells were then isolated as
described above. The samples were stained first with Zombie
NIR Fixable Viability Kit (1:200; BioLegend) and surface mark-
ers, diluted in Brilliant Stain Buffer (BD Biosciences). The fol-
lowing antibodies were used: CXCR3-BV421 (1:100, 126522, clone:
CXCR3-127; BioLegend), CD27-SB436 (1:100, 62–0271-82, clone:
LG.7F9; eBioscience), CD69-BV480 (1:50, 746813, clone: H1.2F3; BD
Biosciences), CD19-BV570 (1:200, 115535, clone: 6D5; BioLegend),
CD11b-BV570 (1:200, 101233, clone: M1/70; BioLegend), PD-1-
BV605 (1:100, 563059, clone: J43; BD Biosciences), CD62L-BV650
(1:100, 564108, clone MEL-14; BD Biosciences), TCR-γδ-BV750
(1:100, 746962, clone: GL3; BD Biosciences), CCR7-BV785 (1:100,
120127, clone: 4B12; BioLegend), CD44-AF532 (1:200, 58–0441-82,
clone: IM7; eBioscience), CD127-PE-CF594 (1:100, 562419, clone:
SB/199; BD Biosciences), NK1.1-AF700 (1:100, 56–5941-82, clone:
PK136; eBioscience), CD8a-BV510 (1:200, 563068, clone: 53-6.7; BD
Biosciences), CD3-FITC (1:200, 11–0032-82, clone: 17A2; eBioscience),
KLRG1-PE (1:200, 138408, clone: 2F1/KLRG1; BioLegend), CD103-PE-
Cy7 (1:200, 121426, clone: 2E7; BioLegend), CD4-PerCP-Cy5.5 (1:200,
45–0042-82, clone: RM4-5; eBioscience). For intracellular staining,
Foxp3 / Transcription Factor Staining Buffer Set was used
following the provider guidelines. The following antibodies
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for intracellular staining were used: FoxP3-AF647 (1:100,
126408, clone: MF-14; BioLegend), T-bet-BV711 (1:100, 644820,
clone: 4B10; BioLegend), ROR-γt-APC (1:100, 17–6981-82, clone
B2D; eBioscience). Stained cells were analyzed on a Norther
Light spectral flow cytometer (Cytek) and analysis performed
by FlowJo software (version 10.0).
In vivo proliferation analysis
For analysis of in vivo cell proliferation, mice were treated with
EdU (0.5mg/ml; Invitrogen) in sucrose-enriched drinkingwater
(5 g sucrose in 100 ml) for 7 d before saline perfusion. EdU was
detected using a Click-iT EdU Alexa Fluor 647 Flow Cytometry
Assay Kit (C10419; Invitrogen) following the manufacturer’s
instructions. Subsequently, FACS antibody staining was per-
formed as described above using the following cell surface
antibodies: CD11b-PE-Cy7 (1:250, 25–0112-82, clone: M1/70;
Invitrogen), CD45-BV510 (1:250, 563891, clone: 30-F11; BD
Biosciences), CD3-FITC (1:250, 11–0032-82, clone: 17A2; In-
vitrogen), CD19-eF450 (1:250, 48–0193-82, clone: eBio1D3;
eBioscience), CD4-PerCP-Cy5.5 (1:250, 45–0042-82, clone: RM4-
5; Invitrogen), and CD8-PE (1:250, Invitrogen, 12–0081-82, clone:
53–6.7). Stained cells were then analyzed on a BD FACSVerse
flow cytometer (BD Biosciences), and analysis was performed
using FlowJo software (version 10.0).
Pharmacokinetic analysis
To determine cellular anti-CD49d saturation levels, venous
blood was collected in EDTA tubes after cardiac puncture, and
mononuclear cells were enriched using a Histopaque-1077 gra-
dient (Sigma-Aldrich). Cells were diluted to a concentration of
106 cells/ml and stained with a mouse anti-Rat IgG2b PE-
conjugated secondary antibody (1:20, clone R2B-7C3; eBio-
science) to detect cell-bound anti-CD49d for 30 min at 4°C. For
determination of anti-CD49d saturation, cells were incubated
with a saturating amount of anti-CD49d (10 µg/ml) for 30min at
room temperature and subsequently stained with the antibody
as described above. Stained cells were then analyzed on a BD
FACSVerse flow cytometer (BD Biosciences), and analysis was
performed using FlowJo software (version 10.0). The anti-CD49d
saturation level was then calculated as percentage of the mean
fluorescence intensity (MFI) from in vivo bound anti-CD49d
from the MFI of in vitro saturated cells by the following
equation:
anti − CD49d saturation "
MFI in vivo bound anti − CD49d
MFI in vitro saturated anti − CD49d × 100.
The number of anti-CD49d molecules per cell was determined
using a PE fluorescence quantitation kit (BD Quantibrite
PE, #340495; BD Biosciences) following the manufacturer’s
instructions.
Mouse anti-rat IgG ELISA
To analyze neutralizing mouse anti-rat IgG antibodies in mice,
we used a customized modification of a commercial ELISA (#88-
50400; Thermo Fisher Scientific). Flat-bottom 96-well ELISA
plates were coated overnight with the same rat anti-CD49d
antibody (100 ng/ml) at 4°C as used for the in vivo treatment
(clone PS/2, Cat. BE0071; Bio X Cell). After washing, the
antibody-coated plates were incubated for 1 h at room temper-
ature with mouse plasma obtained 28 d after stroke (i.e., two
doses of anti-CD49d at 2 h and 14 d) or control plasma from a
naive mouse that had been spiked at ∼10 ng/ml with the capture
antibody of the ELISA kit. Subsequent detection and bio-
chemiluminescent analysis using a microplate reader (Bio-Rad)
was performed following the manufacturer’s instructions.
Dendritic spine analysis
Following saline perfusion, mice were perfused 84 d after PT
with aldehyde fixative solution (003780; Bioenno). Brains were
then carefully removed and placed in fixative solution at 4°C
overnight. Brains were then sliced at 100 µm using a vibratome
and collected in 0.1 M PBS. Slices were placed in impregnation
slice Golgi Kit (003760; Bioenno) solution for 5 d in the dark.
Staining and post-staining was performed as described by the
manufacturer (Bioenno). Images of dendrites were obtained
within 500 µm around the lesion area in cortical layer 2/3. In
total, 25 dendrites per animal (5 dendrites from 5 neurons) in
both hemispheres were recorded using an Axio Imager.M2 and a
100× objective (EC Plan-Neofluar, numerical aperture [NA] =
1.3, oil immersion, acquisition at 18–20°C) using the AxioCam
MRc and AxioVision 4.8.2 software. Dendrites from the images
were then 3D reconstructed and the spine density evaluated on
the reconstructed 3D surface using Imaris x64 (8.4.0; Bitplane).
In vivo widefield neuronal calcium imaging
In vivo widefield calcium imaging was performed as previously
published (Cramer et al., 2019b). Briefly, Thy1-GCaMP6s heter-
ozygous mice were scalped and transparent dental cement was
placed upon the intact skull at least 3 d before start of the ex-
periment. Resting-state in vivo imaging was performed in mild
anesthesia (0.5 mg/kg body weight of medetomidine with 0.75%
isoflurane inhalation). Mice were placed in a stereotactic frame
below a customized macroscopic imaging setup, and mouse
cortex was illuminated with 450-nm blue LED light. Resting-
state calcium activity was recorded for 4 min (6 × 1,000
frames) with a high-precision 2/3” Interline charge-coupled
device camera (Adimec-1000m/D, pixel size 7.4 × 7.4 µm, ac-
quisition at 20–22°C; Adimec) at a 25-Hz frame rate using
longDaq software (Optical Imaging).
In vivo calcium imaging analysis
Functional imaging data were preprocessed as previously de-
scribed (Cramer et al., 2019b). In particular, the seed-to-seed FCs
between eight previously defined seeds were calculated as
Pearson’s correlation between the time course of each of these
seeds and Fisher’s z transformation. For left intrahemispheric
connectivity, the mean of the Fisher’s z-transformed Pearson’s
correlation coefficient of each connection between the seeds
located in the left hemisphere was calculated. The overall ho-
motopic connectivity was calculated as the mean of all Fisher’s
z-transformed Pearson’s correlation coefficients of each homo-
topic connection between the seeds in both hemispheres. The
time course of left intrahemispheric and overall homotopic
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connectivity was displayed from baseline and days 42 to 84 after
stroke, ensuring the visibility of all seeds after disappearance
of the autofluorescent lesion. Fisher’s z-transformed Pearson’s
correlation was calculated using MATLAB (MathWorks R2016b
with Optimization Toolbox, Statistics and Machine Learning
Toolbox, Signal Processing Toolbox and Image Processing
Toolbox; MathWorks).
Lesion involution quantification
The lesion size was determined by autofluorescence of the
ischemic tissue in Thy1-GCaMP6s animals used for in vivo
widefield calcium imaging for every time point of imaging
acquisition. The area of autofluorescent pixels was previously
defined by thresholding and converted into a mask to exclude
autofluorescent tissue from the connectivity analysis. The lesion
was determined as the size of the exclusion mask by quantifi-
cation of all pixels within the mask.
Lesion volumetry
Mice were transcardially perfused 28 d after PT or dMCAo
stroke induction with saline and 4% paraformaldehyde solution.
To protect the cortical lesion from damage, the whole skull was
isolated and stored in 4% paraformaldehyde overnight at 4°C and
then placed in 0.3 M EDTA for 7 d for decalcification. Subse-
quently, the brains were dehydrated for 2 d in 30% sucrose in
0.01 M PBS and then snap-frozen in isopentane. Cresyl Violet
staining for infarct volumetry was performed as previously
described (Llovera et al., 2014), and the lesion size was quanti-
fied using FIJI ImageJ.
Immunohistochemical staining of mouse coronal
brain sections
Fluorescent immunohistochemical staining for CD3+ and Ki67+
to determine the number of proliferating T cells in control
versus anti-CD49d treated animals was performed on 20-µm-
thick paraformaldehyde-fixed coronal sections from mice at 7
and/or 28 d after PT or dMCAo. Sections were fixed with cold
acetone for 10min at room temperature andwashedwith 0.01M
PBS before blocking with goat serum blocking buffer for 1 h at
room temperature. Subsequently, sections were stained over-
night at 4°C with primary antibody (1:200, CD3e, hamster anti-
mouse, clone 500A2; BD PharMingen; and 1:200, Ki-67, rabbit
mAb, clone D3B5; Cell Signaling Technology). After washing with
0.1% Triton X-100 in 0.01M PBS, secondary antibody staining was
applied for 2 h at room temperature (1:200, goat anti-hamster,
Alexa Fluor 594; Thermo Fisher Scientific; and 1:200, goat anti-
rabbit, Alexa Fluor 647; Life Technologies). Nuclei were stained
with DAPI (1:5,000; Invitrogen) for 5 min at room temperature.
Per animal, three images for cell quantification were re-
corded as 6-µm-high tile-scan Z-stacks (slice thickness, 0.4 µm)
on a Zeiss confocal microscope (LSM880) with 25× objective
(LCI Plan-Neofluar 25×, NA = 0.8, ImmKorr differential inter-
ference contrast, water immersion, acquisition at 18°C). The
lesion was marked andmeasured in the tile-scan image and cells
were quantified using the Cell Counter Plugin in FIJI. Cell den-
sity was calculated as number of cells per squaremillimeter. The
R index for quantification of clustering of cells per area was
calculated using the clarkevans.test R function (R package
spatstat; Baddeley et al., 2005). For evaluation of clustering, the
ratio of the observed average nearest-neighbor distance r (rA) to
the expected pattern for a Poisson point process of the same
intensity (rE): R=rArE. An R index of >1.0 indicates ordered spatial
distribution, R = 0 indicates even distribution, and R < 1.0 in-
dicates aggregation. Hypothesis testing was performed against
the null hypothesis, which is complete spatial randomness/a
uniform Poisson process. For every animal, the cell density and
R index were calculated and averaged among the three acquired
images. Whole-slice images were acquired using a 10× objective
(EC Plan-Neofluar 10×, NA = 0.3, air immersion, acquisition at
18°C) and high-resolution images were acquired using a 40×
objective (EC Plan-Neofluar 40×, NA = 1.3 oil differential inter-
ference contrast, oil immersion, acquisition at 18–20°C).
Patient characteristics for postmortem histological analyses
Ethical approval for the use of human postmortem material was
granted according to institutional ethics board protocol and
national regulations by the HungarianMedical Research Council
Scientific and Research Ethics Board (19312/2016/EKU) and the
University of Kentucky Medical Institutional Review Board (UK
IRB #44009), respectively. Clinical information was provided by
the respective brain bank (Table S1).
Histological and immunohistochemical staining of human
brain tissue samples
Histochemical and immunohistochemical staining was per-
formed on sections cut to 6 µm from paraffin-embedded tissue
blocks. Randomly chosen sections of every patient were depar-
affinated and rehydrated and subsequently stained with H&E.
Immunohistochemistry for CD3 (polyclonal rabbit anti-human
CD3, diluted 1:50, A0452; Dako) was performed on sections ad-
jacent to H&E-stained sections with the Ventana Benchmark GX
automated staining system using a CC1 (Roche) pretreatment
and the iView DAB Detection Kit (Roche). Sections were coun-
terstained with hematoxylin and coverslipped with Entellan
(Merck) as mounting medium. Age of infarcts was estimated by
two experienced and independent neuropathologists (T. Arzberger
and P.T. Nelson) on H&E sections according to published criteria
(Mena et al., 2004). CD3 stains were scanned with Zeiss Axio
Scan Z1 using a 20× objective. The infarct area was demarcated,
and the absolute numbers and coordinates of intra- and extra-
lesional CD3+ T cells were assessed manually using Qupath
(version 0.2.2). Cell density was calculated as number of cells per
cm2 of defined lesion area. The R index for quantification of cell
clustering per area was calculated as described above in R (ver-
sion 3.6.0). Intralesional cell density was correlated with time
after stroke onset for each sample.
Immunofluorescence staining of human brain tissue samples
Immunofluorescence staining was performed on sections cut to
6 µm from paraffin-embedded tissue blocks. Randomly selected
sections were deparaffinated and blocked in 3% H2O2. After
heat-induced antigen retrieval in Tris-buffered EDTA (pH 9.0)
for 30min at 95°C, sections were blocked with 5% donkey serum
for 4 h at room temperature. Then, sections were incubated in
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antibody staining solution (0.3% Triton X-100 and 20 mM so-
dium azide containing 0.05 M Tris-buffered saline [TBS], pH
7.4) overnight at 4°C (1:50, CD3, polyclonal rabbit anti-human,
reference A0452; and 1:100, Ki67, monoclonal mouse anti-
human, clone MIB-1, reference M7240; Dako). After washing
with 0.05 M TBS, secondary antibody staining was performed
with antibody staining solution (0.3% Triton X-100 and 20 mM
sodium azide containing 0.05 M TBS, pH 7.4) for 2.5 h at room
temperature in the dark (1:500, donkey anti-rabbit, Alexa Fluor 594,
reference 711–586-152; and 1:500, donkey anti-mouse, Alexa Fluor
488, reference 715–546-151; Jackson ImmunoResearch). For nuclear
staining, Hoechst 33334 (0.02mg/ml diluted in 0.05MTBS, pH 7.4,
reference 62249; Thermo Fisher Scientific) was applied for 30 min
at room temperature. After staining, an autofluorescence elimi-
nator reagent (reference 2160; EMD Millipore) was applied for
5 min before mounting the slides with Fluoromount-G (reference
0100–01; Southern Biotech). The images were acquired at 20×
magnification (objective: Plan Apo VC 20×, NA = 0.75, working
distance = 1 mm, field of view = 645.12 µm, calibration: 0.62 µm/
pixel orwith 5× optical zoom, calibration: 0.12 µm/pixel, acquisition
at 21°C) using a Nikon Ni C2 confocal microscope.
Statistics
To assess whether the lesion involution (number of auto-
fluorescent pixels), behavioral recovery (neuroscore and cylin-
der test) or FC (left intra-FC and overall homotopic FC) between
anti-CD49d–treated and control-treated animals were signifi-
cantly different, we performed linear-mixed models for cal-
culating group-by-time interaction in R (version 3.6.0). To test
for statistical difference in infarct volume between treatment
groups, we used one-way ANOVA and Tukey’s post-hoc test.
Next, we assessed the difference in dendritic spine numbers
between anti-CD49d–treated and control-treated animals using
the Wilcoxon rank-sum test with continuity correction and
Bonferroni post-hoc correction for multiple testing in R (Version
3.6.0). To test for significantly different numbers of infiltrating
T cells between anti-CD49d– and control-treated animals, we
used unpaired t tests and Holm–Sidak’s correction for multiple
testing. For determining significant differences in histologically
quantified T cells, we used an unpaired t test. To assess signif-
icant differences in the R index between treatment groups at
different time points, we used one-way ANOVA and Tukey’s test
for correction of multiple comparisons. We next quantified
significant differences between the number of EdU+ T cells in
different organs using one-way ANOVA and Tukey’s test for
correction of multiple comparisons. To test for significant dif-
ferences in the percentage of Ki67+ T cells between treatment
groups, we used an unpaired t test. We used linear regression
analysis to test for a correlation between the intralesional T cell
density in stroke patients and time after stroke onset. Unless
otherwise mentioned all analyses were performed in GraphPad
Prism (version 7.0a). For all analyses, an α level of adjusted P <
0.05 was considered statistically significant.
Online supplemental material
Fig. S1 provides pharmacokinetic analysis data for the rationale
of the treatment regimen with anti-CD49d and additional results
on infarct volumetry supporting the findings in the Fig. 1 in the
PT and dMCAo stroke model. Fig. S2 provides information on
the temporal dynamics of cerebral invasion on innate and
adaptive immune subpopulations over 1 mo after experimental
stroke. Fig. S3 shows comparable findings for chronic T cell
accumulation in female mice as shown in the main figures for
male mice. Additionally, this figure confirms chronic T cell ac-
cumulation and proliferation in the dMCAo stroke model. Table
S1 lists patient data.
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Figure S1. Rationale for anti-CD49d treatment regimen and infarct volumetric assessment. (A) Flow cytometric analysis of acute CD4+ and CD8+ T cell
infiltration into the ipsilateral hemisphere after photothrombosis; n (0 = sham) = 10, n (2 h) = 3, n (3 d) = 6, n (7 d) = 6, n (14 d) = 5. Data are shown asmean + SD;
ordinary one-way ANOVA + Dunnett’s post-hoc test. At least two independent experiments were performed per time point inWT animals. (B) Saturation levels
of anti-CD49d measured at 2 h and 7 and 14 d after i.p. injection of 300 µg anti-CD49d per animal; n = 3–4 per time point. Data are shown as mean + SD. Data
were acquired in at least two independent experiments in WT animals. (C) Quantification of anti-CD49d molecules bound per cell at 2 h and 7 and 14 d after
anti-CD49d treatment; n = 3–4 per time point. Data were acquired in at least two independent experiments in WT animals. (D)Mouse plasma concentration of
anti-rat IgG is shown at day 28 from mice receiving two injections of 300 µg anti-CD49d at 2 h and 14 d after stroke. Naive mouse plasma was spiked with
monoclonal anti-rat IgG as a positive control (spiked plasma); n = 3. (E) Correlation of lesion volume (histological analysis) and lesion size (autofluorescent
pixels). Pearson correlation n = 13. Data were acquired in two independent experiments in Thy1GCaMP6s animals. (F) Infarct volume 28 d after distal middle
cerebral occlusion; n (control) = 6, n (αCD49d) = 5. Data are shown as mean + SD. Unpaired t test. Data were acquired in three independent experiments in WT
animals. **, P < 0.01; ***, P < 0.001.
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Figure S2. Temporal dynamics of myeloid and lymphoid immune cell infiltration after stroke. (A–F) Absolute counts of monocytes (A), activated
monocytes (B), neutrophils (C), CD4+ T helper cells (D), CD8+ cytotoxic T cells (E), and CD19+ B cells (F) were assessed using flow cytometry at 2 h and 3–28 d
after stroke, as well as after sham surgery (day 0) in the ipsilateral hemisphere; n (sham) = 10, n (2 h) = 3, n (3 d) = 5–6, n (7 d) = 5–6, n (14 d) = 5, n (28 d) = 5.
Mean values are shown per time point. Ordinary one-way ANOVA + Dunnett’s post-hoc test. At least two independent experiments were performed per time
point in WT animals. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Heindl et al. Journal of Experimental Medicine S2
















Table S1 is provided online as a Word document and lists patient data.
Figure S3. Chronic T cell accumulation in female mice and after dMCAo. (A) Flow cytometric analysis of CD4+ and CD8+ T cells 28 d after stroke in female
mice; n = 7–8 per group, unpaired t test. Data are shown as mean + SD. (B) Evaluation of cell density and cell agglomeration of CD3+ intralesional T cells 28 d
after dMCAo; n = 5 per group, unpaired t test. Data are shown as mean + SD/median and interquartile range. (C) i.v. labeling of circulating CD45+ leukocytes
over 3 d before flow cytometric brain analysis 28 d after stroke reveals only a small fraction of brain-invading CD4+ and CD8+ T cells out of total cerebral T cells
in the ischemic hemisphere; n = 4. Data are shown as mean + SD. (D) Percentage of Ki67+ T cells 28 d after dMCAo; n = 5 per group, unpaired t test. Data are
shown as mean + SD. All data were generated in three independent experiments in WT animals. #, P < 0.05 for R < 1.0.
Heindl et al. Journal of Experimental Medicine S3















Table S1.  
Patient number Age (yr) Sex (F/M) Days after stroke Cardiovascular risk factors 
1 69 F 124 Hypertension 
2 78 F 20 Smoking 
3 80 F 10 Hypertension 
4 92 F 8 Hypertension 
5 85 F 1–4 — 
6 98 F 1 Smoking, hypertension, previous 
TIA 
F, female; M, male; TIA, transient ischemic attack. 
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Microglia monitor and protect neuronal function via specialized somatic pu-
rinergic junctions 
Short title: Microglia control neurons at somatic junctions  
 
One-sentence summary: Neuronal cell bodies possess specialized, pre-formed sites, 
through which microglia monitor their status and exert neuroprotection. 
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Microglia are the main immune cells in the brain with emerging roles in brain homeostasis 
and neurological diseases, while mechanisms underlying microglia-neuron communication 
remain elusive. Here, we identify a novel site of interaction between neuronal cell bodies 
and microglial processes in mouse and human brain. Somatic microglia-neuron junctions 
possess specialized nanoarchitecture optimized for purinergic signaling. Activity of neuronal 
mitochondria is linked with microglial junction formation, which is rapidly induced in 
response to neuronal activation and blocked by inhibition of P2Y12 receptors (P2Y12R). 
Brain injury-induced changes at somatic junctions trigger P2Y12R-dependent microglial 
neuroprotection, regulating neuronal calcium load and functional connectivity. Collectively, 
our results suggest that microglial processes at these junctions are in ideal position to monitor 
and protect neuronal functions in both the healthy and injured brain. 
  





Microglia are the main immunocompetent cells of the nervous system and their role 
in brain development and maintenance of proper neuronal function throughout life is widely 
recognized (1–3). Importantly, changes in microglial activity are linked with major human 
diseases including different forms of neurodegeneration, stroke, epilepsy and psychiatric 
disorders (4, 5), directing increased attention towards microglial research in recent years.  
Microglia perform dynamic surveillance of their microenvironment by motile micro-
glial processes including their constant interactions with neurons (6, 7), yet, the molecular 
mechanisms of bidirectional microglia-neuron communication have remained elusive. To 
date, the majority of studies have focused on the interactions between microglial processes 
and synaptic elements, including axonal boutons and dendritic spines, which have been com-
monly perceived as the main form of interaction between microglia and neurons (8, 9). How-
ever, neurons are extremely polarized cells with a high degree of functional independence 
concerning metabolism and signal integration in their dendritic and axonal compartments 
(10–12). In line with this, the large-scale structure of neurons (i.e. their cell body and ax-
onal/dendritic branches) in the brain is relatively stable under most conditions, unlike highly 
dynamic small synaptic structures, such as dendritic spines and axonal boutons (13), which 
are often distant from neuronal cell bodies. Thus, we argued that the interactions between 
microglia and synapses may not fully explain how microglia are capable of monitoring and 
influencing the activity of neurons via dynamic surveillance, or detecting early events of 
cellular injury in the perisomatic compartment. This may be particularly relevant for the 
migration and differentiation of neural precursors, cell survival and programmed cell death, 
adult neurogenesis and the phagocytosis of damaged neuronal cell bodies (14–17). In line 
with this, it is not understood how microglia could monitor neuronal status over years or 
even decades, and discriminate salvageable neurons from irreversibly injured cells mainly 




based on changes occurring at distant synaptic structures. For example, microglial TAM 
receptors, which control physiological microglial processes, neurogenesis and phagocytic 
clearance of apoptotic cells upon binding of their extracellular ligands (18), are likely to 
exert their complex actions via also interacting with different structures on neurons other 
than synapses. 
To understand the possible mechanisms of effective communication between micro-
glia and neuronal cell bodies, we tested the hypothesis that specialized junctions on neuronal 
somata may be present that support the dynamic monitoring and assistance of neuronal func-
tion by microglia. Here, using in vivo two-photon (2P) imaging, high-resolution light- and 
electron microscopy combined with advanced 3D-analysis we identified a novel type of 
morpho-functional communication site between microglial processes and neuronal cell bod-
ies in mice and human. Surprisingly, these somatic microglial junctions are present on the 
vast majority of neurons regardless of their cell type, and have specialized molecular com-
position and a unique nanoarchitecture linked to mitochondrial signaling. Furthermore, we 
provide direct in vivo evidence that these somatic junctions are essential for microglia-neu-
ron communication, and for the neuroprotective effects of microglia after acute brain injury. 
 
Results 
Microglial processes contact specialized areas of neuronal cell bodies in the mouse and 
human brain 
To visualize microglia together with cortical neurons and to study microglia-neuron interac-
tions in the intact brain in real-time, CX3CR1+/GFP microglia reporter mice were electro-
porated in utero with pCAG-IRES-tdTomato plasmid (Fig. S1a). In vivo 2P imaging revealed 
microglial processes contacting the cell bodies of cortical layer 2-3 neurons in the adult brain 
(Fig. 1a, b; Movie S1). To our surprise, microglial processes preferentially returned to the 




same areas on the neuronal soma (observed in the case of 23 neurons out of 28 from 3 mice). 
Furthermore, trajectory analysis revealed that the average lifetime of somatic microglia-neu-
ron contacts was 25 min (some contacts persisting for more than 1 hour, Fig. S1b), while 
dendritic contacts had a significantly shorter lifetime of 7.5 min (Fig. 1c, p=0.00035, n=26 
contacts from 3 mice), similar to what Wake et al. found for synaptic contacts (19). Post-hoc 
confocal laser scanning microscopy (CLSM) and electron microscopic analysis further val-
idated the direct interaction between microglial processes and the cell bodies of cortical py-
ramidal neurons (Fig. 1d; Fig. S1c), termed somatic microglial junctions. Similar interac-
tions were present on well-characterized interneuron populations, namely type 3 vesicular 
glutamate transporter positive (vGluT3+) and parvalbumin-expressing (PV+) cells in the ne-
ocortex and the hippocampus (Fig. 1e). Importantly, CLSM revealed the presence of somatic 
microglia-neuron junctions in the human neocortex as well (Fig. 1f). Quantitative 3D anal-
ysis of fully reconstructed neurons uncovered that somatic microglial junctions were present 
on 91% of cortical pyramidal cells, 96% of vGluT3+, and 87% of PV+ interneurons in mice 
(n=155 cells from 2 mice). Despite the well-established microglial regulation of neuronal 
synapses, only 9% of glutamatergic and 14% of GABAergic synapses were associated with 
microglial processes (Fig. 1g; Fig. S1d, n=800 synapses from 2 mice). Remarkably, 87% of 
neurons in the human neocortex were found to receive microglial contact onto their cell body 
(Fig. 1f-g, n=89 cells from 2 patients). We also tested the possible presence of somatic mi-
croglial junctions in subcortical areas, and found that 98% of neurons in the caudate puta-
men, 91% of neurons in the nucleus reticularis gigantocellularis and 96% of neurons in the 
medial septum were contacted by microglial processes (n=268 cells from 2 mice) confirming 
that this phenomenon is not only evolutionary conserved, but also broadly present in all main 
areas of the brain.  




Next, we argued that microglia at somatic junctions may sense changes in neuronal state via 
signals released by exocytosis, which requires a specific molecular machinery supporting 
membrane trafficking. In neurons, clustered Kv2.1 proteins are well known to provide exo-
cytotic surfaces via anchoring vesicle fusion molecules to the neuronal membrane (20, 21). 
Furthermore, both Kv2.1 and Kv2.2 proteins are involved in forming endoplasmic reticulum 
(ER)/plasma membrane (PM)-junctions (membrane trafficking hubs), and anchoring intra-
cellular organelles to the neuronal plasma membrane (22). We found that microglia con-
tacted neuronal somatic membranes at sites of Kv2.1/2.2 clustering (Fig. 1h). The integrated 
density of Kv2.1 signal at these sites was 96% higher, and the density of Kv2.2 signal was 
254% higher compared to those without microglial contacts (Fig. 1h, p<0.0001 in both cases, 
n=114 and 107 from 3 mice). More importantly, 87% of all microglia-neuron contacts ex-
pressed both types of clusters, 6.3% expressed only Kv2.1, 4.5% only Kv2.2 clusters, and 
only 1.8% of contacts were void of any Kv-clusters (Fig. 1i, n=111 contacts from 2 mice). 
Furthermore, 99% of neocortical and 94% of hippocampal CA1-region neurons coexpressed 
both Kv2.1 and Kv2.2 channels at the cellular level (Fig. S1i-k). The striking spatial associ-
ation between Kv2.1 clusters and microglial processes was also observed on human cortical 
neurons (Fig. S1e, f, n=21 cells). Since Kv2.1-clusters are implicated in a large number of 
cellular processes involved in cell-to-cell communication, we focused on Kv2.1 in our fur-
ther experiments. We found that these Kv2.1 hot spots are likely to define preformed neu-
ronal microdomains, because Kv2.1 clusters remained unaltered after selective elimination 
of microglia by PLX5622 (Fig. S1g, h, 4.71 cluster/cross section in control vs. 6.64 cluster/cs 
in depleted, n=59 cells from 4 mice), suggesting their neuron-intrinsic nature. To test the 
functional involvement of Kv2.1-clusters in the formation of somatic junctions, we devel-
oped a dominant-negative Kv2.1 mutant construct (DNKv2.1), which is not able to integrate 
into the plasma membrane and which blocks the forward trafficking of any endogenous Kv2 




proteins that may be expressed. We transfected HEK293-cells, which naturally lack Kv2.1 
and Kv2.2 proteins (23), with fluorescent protein-coupled Kv2.1 or DNKv2.1 constructs, 
and cocultured these with microglia. Strikingly, microglial processes contacted Kv2.1-trans-
fected HEK cells preferentially at Kv2.1 clusters, but not the DNKv2.1 transfected ones (Fig. 
1j, Movie S2). 84% of Kv2.1-transfected HEK cells received microglial process contacts 
(97% of these contacts arrived onto Kv2.1-clusters), while only 5.4% of DNKv2.1 trans-
fected HEK cells received process contacts (n=75 cells from 3 experiments). 
Because activity-dependent exocytotic ATP or ADP release is known to take place from 
neuronal cell bodies under physiological conditions (24, 25) and ATP (ADP) is a major 
chemoattractant for microglial processes via the microglial purinoceptor, P2Y12 receptor 
(P2Y12R, 6, 26), we next tested the hypothesis that signaling via P2Y12R is also essential 
for microglia-neuron interactions at these somatic junctions.  





Figure 1. Microglia contact specialized areas of neuronal cell bodies in the mouse and the human brain 
a) Single image plane (upper panel) and 3D reconstruction (lower panel) from an in vivo 2-photon (2P) Z-
stack shows a neocortical neuron (red) being contacted by microglial processes (green). b) In vivo 2P time-
lapse imaging shows temporal dynamics of microglia-neuron contacts. c) Analyzed trajectories of microglial 
processes contacting the neuron on B. The lifetime of somatic contacts was significantly longer than dendritic 
ones. (p<0.001, n=26 contacts from 3 mice.) d) 3D-reconstruction from high-resolution confocal laser 
scanning microscopy (CLSM) Z-stack shows that microglial processes (yellow) contact GABAergic (red) and 
glutamatergic (cyan) boutons as well as the neuronal cell body (Kv2.1 labeling, magenta). Inserts on the right 
show orthogonal projections of these contacts from the confocal Z-stack. e) CLSM image planes show yellow 




microglial processes touching cell bodies of hippocampal vGluT3+ and PV+ interneurons. f) CLSM images 
show P2Y12R+ microglial processes contacting SMI32+ neuronal cell bodies in human neocortex. g) 
Quantitative analysis of contact prevalence between microglial processes and different neuronal elements 
confirms that microglia contact the vast majority of neuronal cell bodies independently from neurochemical 
identity, while only a small fraction of synapses receive microglial contact. (n=155 neurons and 800 synapses 
in mice, and 89 neurons in human). h) CLSM image shows a neuronal cell body contacted by a microglial 
process at a Kv2.1-2.2-cluster. The integrated fluorescent density of both Kv2.1 and Kv2.2 signal is 
significantly higher within the contact site than elsewhere (p<0.001 in both cases, n=114 and 107 ROIs). i) 
The vast majority of microglia-neuron junctions expressed both Kv2.1 and 2.2 clusters (n=111 junctions). j) 
Microglial processes contact Kv2.1-transfected HEK-cells at the clusters, but not those transfected with a 
dominant-negative mutant (n=50 cells). k) Overlaid images show microglial P2Y12R (green for CLSM and 
cyan for STORM) and neuronal Kv2.1 (red and yellow) clusters overlapping. Arrows show borders of Kv2.1 
clusters. j) P2Y12R clustering depends on the contact with neuronal cell body. Bar graphs show STORM 
localization point (LP) density (top) and density of identified P2Y12R clusters (bottom) on different parts of 
microglia (for statistics, see Table S1). Scale bars: 5 µm on b, 1 µm on d and k, 2 µm on h and j, 15 µm on e, 
20 µm on f. Median values and interquartile ranges are plotted on c and h, mean and range on g and i, 
mean+SEM on l. 
 
In fact, all microglia – but no other cells in the brain, including perivascular macrophages – 
were found to be P2Y12R-positive (Fig. S3), including their processes recruited to somatic 
junctions (Fig. S3b). The restriction of P2Y12R expression to microglia within the brain is 
in perfect agreement with results of earlier single-cell transcriptomics studies (27, 28). 
To investigate the nanoscale architecture of P2Y12R at somatic microglia-neuron junctions, 
we used correlated CLSM and STORM superresolution microscopy, which enables the 
precise assessment of P2Y12R and Kv2.1 clusters at 20 nm lateral resolution (29). We found 
that P2Y12R forms dense clusters on microglial processes at somatic junctions, directly fac-
ing neuronal Kv2.1 clusters (Fig. 1k). Importantly, unbiased cluster analysis revealed that 
P2Y12R localization point (LP) density and cluster density were both significantly higher 




on microglial processes inside the junctions than on processes outside the junctions or on the 
whole microglial cell (Fig. 1l; Fig. S2a; for detailed statistics and numbers see Table S1). 
Furthermore, somatic contact-dependent clustering of P2Y12R was found to be a general 
phenomenon occurring on both pyramidal cells and interneurons (Fig. S2b; for detailed sta-
tistics and numbers see Table S1). Contact-dependent molecular clustering, however, could 
not be observed in the case of the microglial calcium-binding protein, Iba1 (Fig. S2c). EM 
analysis also confirmed, that contact-dependent P2Y12R clustering is specific to somatic 
junctions, and immunogold density is 62% lower on microglial membranes contacting bou-
tons than on ones contacting somata (p=0.0002, n=26 contacts from 3 mice). All these data 
suggest the presence of a functionally specialized, yet ubiquitous communication site be-
tween P2Y12R-positive microglial processes and neuronal cell bodies. 
 
Somatic microglia-neuron junctions possess a unique nanoarchitecture and molecular 
fingerprints, suggesting mitochondrion-related purinergic cell-to-cell communication  
To further investigate the ultrastructural features of somatic microglia-neuron junctions, we 
performed transmission electron microscopy and high-resolution electron tomography with 
3D reconstruction. P2Y12R immunogold labeling confirmed the formation of direct junc-
tions between microglial processes and neuronal somata both in mice (Fig. 2a) and in post-
mortem human brain tissue (Fig. S4a). Surprisingly, we found that microglia-neuron junc-
tions possess a unique ultrastructure within the neuronal cell body composed of closely ap-
posed mitochondria, reticular membrane structures, intracellular tethers and associated ves-
icle-like membrane structures (Fig. 2a). 3D electron tomography confirmed this nano-archi-
tecture in neurons (Fig. 2b; Movie S3-4). These morphological features could not be ob-
served in perisomatic boutons contacted by microglia, confirming the specific association of 
these structures with somatic microglial junctions. Furthermore, automated 3D analysis of 




tomographic volumes showed that P2Y12R density negatively correlated with the distance 
between microglial and neuronal membranes within the junctions (Fig. 2c, d; Fig. S4c, 
p<0.001, n=13055 points from 3 contacts), supporting the contact-dependent enrichment of 
P2Y12Rs on microglial processes. We also compared P2Y12R density between microglial 
membrane surfaces establishing junctions with neuronal somata and adjacent surfaces 
(within a few µm-s), that contacted boutons or other neuronal elements. We could detect a 
significantly higher P2Y12R density at microglial membranes directly contacting neuronal 
cell bodies (Fig. 2e; Movie S5, p=0.00115, n=24 surfaces), suggesting an important role for 
purinergic signaling in the formation of somatic microglia-neuron junctions.  
Taking advantage of the ultra-high isotropic resolution provided by electron tomography, 
we could also observe discrete intercellular structures in the extracellular space resembling 
cell adhesion molecules, connecting the membranes of microglia and neuronal cell bodies 
(average length 23.5±3.1 nm, n=89 from 3 mice, Fig. S4b). This falls in the range of the size 
of integrins expressed by microglia (30, 31) or the width of immunological synapses between 
peripheral immune cells (32). Mitochondria-associated membranes (MAM, average dis-
tance: 19.5 nm; n=104 from 3 mice, Fig. S4b) (33), and discrete tethers could also be ob-
served between mitochondria and MAM (Movie S4). 
We hypothesized that mitochondrial ATP-production and changes in neuronal activity could 
trigger microglial process recruitment, therefore we investigated the possible enrichment of 
neuronal mitochondria at microglial junctions on a large sample size, using an unbiased, 
semi-automatic analysis of TOM20 expression, which is the main element of the transport 
protein complex in the outer mitochondrial membrane (34). TOM20 immunofluorescent in-
tensity was 420% higher at somatic junctions compared to adjacent areas (Fig. 2f, g, 
p<0.001, n=14 contacts from 2 mice), confirming the strong accumulation of neuronal mi-
tochondria at the somatic junctions.  





Figure 2. Microglia-neuron junctions possess a specialized nano-architecture and molecular machinery 
optimized for purinergic cell-to-cell communication  
a) Transmission electron micrograph shows the area of the neuronal cell body (neu.) contacted by a P2Y12R-
immunogold (black grains) labeled microglial process (mic.). The junction possesses a unique ultrastructure 
with closely apposed mitochondria (mito., cyan), reticular membrane structures (green), intracellular tethers 
(red). A mitochondria-associated vesicle (blue, marked by white arrowhead) is also visible. The nucleus (n) of 




the neuron is purple. b) 0.5 nm thick virtual section of an electron tomographic volume (left) and 3D model 
(right) shows the special nano-architecture of a somatic microglia-neuron junction (colors represent the same 
structures, as in panel a). Note the specific enrichment of P2Y12R labeling at the core of the junction. c-d) 
P2Y12R density negatively correlates with the distance between microglial and neuronal membranes within 
the junctions. c) Side- and face (90 degrees rotated) view of the 3D model of a contact site. Immunogold density 
is the highest where the intercellular distance is the smallest. d) Density versus distance analysis performed 
on 3D models of contact sites confirms that the density of P2Y12R-immunogold particles within the junction is 
significantly higher where the distance between neuronal and microglial membrane is smaller than 13 nm 
(p<0.001, n=13055 points from 3 neocortical contacts, 3 mice). e) P2Y12R density is highest at those surfaces 
of microglial processes that are in direct contact with the neuronal cell bodies. Different views of the 3D 
models of two junctions illustrate that P2Y12R-immunogold density shows an uneven distribution along 
microglial membranes, being strongly and selectively enriched where the processes are in direct contact with 
neuronal somata (mitochondria – mito., neuron – neu., microglia – mic., bouton – b., microglial membrane 
contacting neuronal cell body – „Somatic”, microglial membrane contacting profiles other than neuronal 
somata – „Non-somatic”). (p<0.001, n=24 surfaces, neocortex, 3 mice). f) CLSM maximal intensity projection 
(M.I.P.) shows microglial processes (yellow) contacting neuronal somata (magenta) with adjacent 
mitochondria (green). g) Neuronal mitochondria are enriched at microglial junction sites, as TOM20 
immunofluorescent intensity is significantly higher along neuronal membrane parts where microglial 
processes contact the somata. (p<0.001, n=14, 2 mice). h) Transmission electron micrographs show TOM20-
immunogold labeling in neocortical neurons. Immunogold labeling (black grains) is specifically associated 
with outer mitochondrial membranes, while TOM20-positive vesicles can also be observed (arrowheads). 
Some immunogold particles can be found on the plasma membrane of the neurons (arrows), suggesting the 
exocytosis of mitochondria-derived vesicles. i) vNUT immunofluorescent intensity is significantly higher in 
neurons where microglial processes contact the somata. (p=0.002, n=15, 2 mice). j) 3D reconstruction of high-
resolution confocal Z-stack shows parts of two neuronal cell bodies (magenta), both contacted by microglial 
processes (yellow). The vNUT signal (cyan) was concentrated between the junctions and closely positioned 
mitochondria (green). Scale bars: 500 nm on a, 100 nm on b, 5 µm on f, 2 µm on g, 300 nm on h and 3 µm on 
i. Median values and interquartile ranges are plotted on d, e, f and i. 
 




Immunoelectron microscopy demonstrated the presence of TOM20-containing vesicles be-
tween mitochondria and the neuronal membrane in addition to TOM20-negative vesicles, 
suggesting the trafficking and possible exocytosis of mitochondria-derived vesicles (35) at 
somatic microglial junctions (Fig. 2h; Fig. S4e, f). Mitochondria-derived vesicles (MDVs) 
often integrate into the endo-lysosomal pathway (35), and these vesicles are positive for the 
lysosomal marker LAMP1 (36). Therefore, we investigated the presence of this marker, and 
found that LAMP1-positive puncta were closely associated to 83.3% of all Kv2.1 clusters at 
somatic junctions (Fig. S4g, n=72 contacts from 2 mice), suggesting the release of MDVs 
and lysosomal content at these junctions. 
We also found that Kv2.1-immunogold clusters were tightly associated with the observed 
neuronal structures (i.e. closely apposed mitochondria, MAMs, ER, vesicle-like structures, 
cytoplasmatic densities) within these junctions (Fig. S4d). Similarly to our CLSM results 
(Fig. S1g), Kv2.1 nanoclustering was not affected by the absence of microglia (Fig. S4d), 
confirming the neuron-intrinsic nature of these morpho-functional units, and suggesting that 
they may function as mitochondria-related signaling hubs in neurons that microglia can spe-
cifically recognize. Vesicular release of mitochondria-derived ATP from neurons may occur 
in a vesicular nucleotide transporter (vNUT) dependent manner (37, 38). Indeed, we found 
that vNUT signal intensity was 2.5 times higher in the vicinity of the neuronal membranes 
at somatic microglia-neuron junctions than at areas outside the junctions (Fig. 2i, p=0.002, 
n=15 contacts from 2 mice). Neuronal vNUT labeling was concentrated between mitochon-
dria and the microglia-contacted neuronal membranes (Fig. 2j). 
Importantly, Kv2.1 or vNUT signal was not present in perisomatic axon terminals (GABAer-
gic synaptic boutons) including those contacted by microglial processes (Fig. S4h, i, n=220 
boutons for Kv2.1, n=194 boutons for vNUT, from 2 mice), confirming again that these 
molecular fingerprints are associated specifically with somatic microglia-neuron junctions. 





Physiological microglia-neuron communication at somatic junctions is P2Y12R-de-
pendent and is linked with neuronal mitochondrial activity 
Next, we aimed to test whether microglial process recruitment to somatic junctions is func-
tionally linked with the activity of mitochondria in neurons. To this end, CX3CR1+/GFP mice 
were electroporated in utero with the mitochondria-targeted CAG-Mito-R-Geco1 reporter 
construct (Fig. S5a), which further confirmed the involvement of somatic mitochondria in 
microglial junctions (Fig. 3a). In vivo 2P imaging was performed to monitor microglial pro-
cess recruitment to neuronal mitochondria in the cerebral cortex (Fig. 3b). In line with our 
histological data, our in vivo results show that recruited microglial processes came to close 
apposition with neuronal mitochondria. These processes stayed in the vicinity of neuronal 
mitochondria for around 29 minutes in vivo (Fig. 3b, Movie S6, n=25 contacts on 19 neurons 
from 3 mice, median value), which number closely matches the value measured in case of 
tdTomato electroporated mice (Fig. 1c). Next, to study the functional relationship between 
microglial junction formation and activity of neuronal mitochondria, we assessed intracellu-
lar changes of the metabolic electron carrier nicotinamide adenine dinucleotide (NADH) (39, 
40) in coronal slices of visual and somatosensory cortices from CX3CR1+/GFP mice. Intra-
cellular NADH fluorescence showed a granular pattern indicating mitochondrial NADH 
source. Indeed, the NADH signal perfectly co-localized with Mito-R-Geco1 signal, confirm-
ing its mitochondrial origin (Fig. 3c). To search for somatic junction formation, we per-
formed 2P imaging, which allowed us to track the movement of microglial processes and 
monitor cytosolic NADH in viable layer 2/3 neurons simultaneously (Fig. S5c). We could 
detect apparent increases in NADH intrinsic fluorescence (Fig. 3d, f, p=0.024, n=10 cells) 
parallel with the formation of somatic microglial junctions. In contrast, we found no changes 




in the mean intrinsic NADH fluorescence detected at neuronal somata contacted by micro-
glial processes in P2Y12R-/- tissue (Fig. 3e, f, p=0.3, n=11 cells). These data suggest that 
microglial process recruitment to somatic junctions is linked to the metabolic activity of 
neuronal mitochondria via a P2Y12R-dependent mechanism. 
 
Figure 3. Neuronal mitochondrial activity and purinergic signaling is involved in microglia-neuron com-
munication  




a) CLSM image shows a microglial process (green) contacting Kv2.1 clusters (magenta) on a neuronal soma 
in the vicinity of a mitochondrion (Mito-R-Geco1, red) in perfusion-fixed brain. b) In vivo 2P imaging of 
CX3CR1+/GFP mice in utero electroporated with CAG-Mito-R-Geco1 construct. Dashed line shows the outline 
of the neuron, green microglial processes touch neuronal cell body where somatic mitochondria are present. 
Contact lifetime was 29 min (median, 10-41 interquartile, n=25 contacts on 19 neurons from 3 mice). ROIs 1 
and 2 are enlarged to show the development of somatic junctions. c) Mito-R-Geco1 expression colocalizes with 
NADH intrinsic fluorescence. d-e) Representative samples from time-lapse imaging of microglia show pro-
cesses extending and contacting neuronal soma in CX3CR1+/GFP/P2Y12R+/+ (d) and CX3CR1+/GFP/P2Y12R-/- 
(e) mice. White arrow indicates the contact site of microglia. DIC images of the imaged neurons and the fluo-
rescence signal of GFP (green) and NADH (dark cyan) of red outlined areas are shown. f) Average of NADH 
intrinsic fluorescence of all neurons in P2Y12R+/+ (red, n=10) and P2Y12R-/- mice (black, n=11). g) CLSM 
image shows microglial process contacting a neuronal Kv2.1 cluster with closely apposed quinacrine-labeled 
ATP-containing vesicle and closely localized neuronal mitochondria. Quinacrine-labeling colocalizes with 
vNUT-signal. h) Images from CLSM in vitro time-lapse imaging show that quinacrine-labeled ATP-containing 
vesicles (green) are released (red arrows) from neuronal cell body (white dashed outline) after KCl-stimulation 
(M.I.P. of z-stack of 2.5 µm). i) Number of released quinacrine+ vesicles plotted as a function of time after 
KCl or vehicle treatment. j) Size distribution of quinacrine-labeled puncta. The measured diameter of the re-
leased puncta can correspond to sub-diffraction sized emitters because of the point-spread function size (~0.3-
0.4 µm at 488 nm), meaning that the size of the released vesicles can be as small as 40 nm. The smaller ones 
(vesicles) tend to be released, and the larger ones (mitochondria) are retained. k) KCl induces a robust ATP 
release in cultured neurons (p=0.0218, n=11), which could not be inhibited by a mixture of the synaptic cal-
cium-channel blockers ω-Agatoxin and ω-Conotoxin (SC, p=0.6532, n=11), but is almost completely inhibited 
by the L-type calcium channel blocker Nimodipine (NIM, p=0.0271, n=10), or the vNUT-inhibitor clodronate 
(CLO, p=0.0284, n=10). l) CLSM image shows robust NTPDase1 expression on microglial processes within 
the somatic junctions. Electron microscopic insert shows NTPDase1-labeled (dark precipitate) microglial pro-
cess contacting neuronal cell body. Neuronal mitochondria (m), vesicles and membrane structures (white ar-
rowheads) are closely apposed to the contact site (black arrows), where NTPDase1 is expressed on microglial 
membrane. Scale bars: 2 µm on a and l, 4 µm on b, 5 µm on c, 10 µm on d and e, 500 nm on g, 3 µm on h, and 
200 on the EM insert on l. Median values and interquartile ranges are plotted on j, mean+SD on f, mean+SEM 
on k. 





The molecular machinery and intercellular interactions identified above strongly suggested 
the involvement of purinergic signaling in these somatic junctions. To test whether neuronal 
somata could release ATP at these sites, we conducted a series of in vitro experiments. We 
found quinacrine labeled ATP-containing vesicles localized between neuronal mitochondria 
and neuronal membranes present at sites where microglial processes contacted neuronal 
Kv2.1 clusters in neuron-microglia cocultures (Fig. 3g). Quinacrine labeling also colocalized 
with vNUT signal (Fig. 3g), as previously demonstrated for neurons (37).  
Next, we tested whether neuronal activity could release ATP-containing vesicles from neu-
ronal cell bodies. 40 mM KCl-stimulation induced a rapid membrane depolarization and 
calcium influx in cultured neurons (Fig. S5d, n=23 cells for FluoVolt measurements, n=20 
cells for Rhod3 measurements). CLSM in vitro time-lapse imaging confirmed that quina-
crine-labeled (ATP-containing) vesicles are released from neuronal cell bodies after KCl-
stimulation (Fig. 3h, i, 880% increase in release events after KCl vs. 27% decrease after 
vehicle, n=13 cells). Size analysis confirmed that the smaller profiles were released (Fig. 3j, 
median diameter of released: 0.37 µm and retained: 0.59 µm, n=118 puncta, similarly to 
previous reports (37, 41)). The larger ones were identified as mitochondria by their uniform 
TOM20-labeling (Fig. 3j, median diameter of vesicle-labeling: 0.45 µm and mitochondrial-
labeling: 1.2 µm, n=83 puncta). 
Next, we applied high sensitivity HPLC to detect the levels of released ATP in the medium 
(Fig 3k). KCl induced a robust ATP release in cultured neurons (p=0.0218, n=11), which 
could not be significantly inhibited by a mixture of the synaptic calcium-channel blockers 
ω-Agatoxin and ω-Conotoxin (SC, p=0.6532, n=11), but was almost completely inhibited 
by the L-type calcium channel blocker Nimodipine (known to be important for somatic ve-
sicular release (42, 43); NIM, p=0.0271, n=10), or the vNUT-inhibitor clodronate (CLO, 




p=0.0284, n=10). These data confirmed the presence of an activity-dependent somatic ATP 
release from neurons. Since the main ligand for microglial P2Y12Rs is ADP, we tested the 
possible presence of nucleosidase expression at microglia-neuron contacts. Using CLSM 
and electron microscopy we found robust NTPDase1 expression on 99.6% of all microglial 
processes within the somatic junctions (Fig. 3l, n=275 contacts from 2 mice). Thus, neuron-
derived ATP can readily be converted into ADP, and sensed by microglia right within the 
somatic junctions.  
Because our data strongly suggest that microglial processes are in the perfect position at the 
somatic junctions to sense neuronal activity, we aimed to further explore the signaling mech-
anisms at these sites in vivo, by 2P imaging in CX3CR1+/GFP microglia reporter mice that 
were electroporated in utero with the neuronal reporter pCAG-IRES-tdTomato (Fig. 4a, b).  
Administration of the potent and selective P2Y12R-inhibitor PSB0739 (PSB) into the 
cisterna magna (i.c.m.) significantly reduced somatic junction lifetime by 45%, but did not 
affect the lifetime of dendritic microglia-neuron contacts (Fig. 4c, ctrl som. vs. PSB som. 
p=0.0331, n=40). We also tested synapse density after acute i.c.m. administration of vehicle 
(control) or PSB. PSB treatment did not alter neocortical synapse numbers (Fig. S6g, 0.353 
synapse/µm2 in control, and 0.352 synapse/µm2 in PSB-injected, n=423 appositions from 4 
animals). Since these data showed that the maintenance of somatic microglia-neuron 
junctions depends on physiological P2Y12R function, we aimed to test whether microglia 
would react directly to changes in neuronal activity. To this end, we induced neuronal 
activation by using the chemogenetic DREADD (Designer Receptor Exclusively Activated 
by Designer Drug) approach. pAAV carrying the hSyn-hM3D(Gq)-mCherry construct was 
injected into the cerebral cortex of P2Y12R+/+ and P2Y12R-/- mice that had been crossed 
with CX3CR1+/GFP mice to visualize microglial responses in the presence or absence of 
P2Y12R signaling (Fig. 4d, e). After intraperitoneal injection of clozapine-N-oxide (CNO) 




to induce hM3D(Gq)-DREADD activation, we observed a 234% increase in neuronal cFos 
signal compared to vehicle treatment (Fig. 4f, p<0.001, n=100), confirming a specific and 
robust neuronal activation.  
 
Figure 4. Physiological microglia-neuron communication at the somatic junction site is P2Y12R-dependent 
a) Outline of acute P2Y12R-blockade experiments. Baseline in vivo 2P imaging of cortical microglia-neuron 
contacts of tdTomato electroporated CX3CR1+/GFP mice was followed by administration of the P2Y12R-inhib-
itor PSB0739 (PSB) into the cisterna magna (i.c.m.) and a further imaging session. b) CLSM images show 
examples of the recorded microglia-neuron contacts. Empty arrowheads point to dendritic contacts, full ar-
rowheads mark somatic junctions. c) Acute i.c.m. administration of PSB significantly reduced somatic junction 
lifetime, but did not affect the lifetime of dendritic microglia-neuron contacts (ctrl som. vs. PSB som. p=0.0331, 
n=40). d) Outline of chemogenetic experiments. e) An example of an injection site. f) CNO administration 




induced a 2.3-fold increase in cFos mean fluorescent intensity value in DREADD expressing neurons 
(p<0.001, n=100). g) Neuronal activity induced a robust elevation of microglial process coverage of neuronal 
cell bodies in CNO-treated animals (p=0.0139, but not in DREADD+/cFos- cells, p=1, n=101 cells from 8 
mice). h) CNO-triggered neuronal activity could not induce an elevation of microglial process coverage of 
neuronal cell bodies in P2Y12R-/- mice (p=0.7497, n=85 cells from 6 mice). i) Outline of combined chemoge-
netic - acute P2Y12R-blockade experiments. j) Acute inhibition of microglial P2Y12Rs prevented neuronal-
activity induced increase of microglial process coverage (p<0.001, n=124 cells from 6 mice). Scale bars: 5 
µm on b and j, 20 µm on f, 8 µm on g and h. Median values and interquartile ranges are plotted. 
 
We found that chemogenetic neuronal activation resulted in an increased microglial process 
coverage of the soma of DREADD- and cFos-coexpressing neurons in P2Y12R+/+ mice (Fig. 
4g, 243% of control, p=0.0139, n=101 neurons from 8 mice), but not in P2Y12R-/- mice (Fig. 
4h, 133% of control, p=0.7497, n=85 neurons from 6 mice). We also tested the effect of 
acute central pharmacological blockade of microglial P2Y12Rs (Fig. 4i), and found that PSB 
injected i.c.m. completely abolished the neuronal activity-induced increase in microglial 
process coverage (Fig. 4j, 72.34% lower process coverage in CNO+PSB than in 
CNO+vehicle, p<0.001, n=124 neurons from 6 mice). Collectively, these results confirmed 
that microglia dynamically react to changes in neuronal activity at somatic microglia-neuron 
junctions in a P2Y12R-dependent manner, leading to a rapid increase of somatic coverage 
by microglial processes. 
 
Microglia protect neurons after acute brain injury in a P2Y12R-dependent manner via 
altered somatic junctions 
Since somatic microglia-neuron junctions were abundant in the healthy brain, we next ex-
amined how these morpho-functional communication sites are altered in response to brain 




injury. Microglia are known to rapidly respond to changes in neuronal activity in the bound-
ary zone of the infarct after stroke (44). Thus, we performed experimental stroke and delin-
eated the evolving penumbra based on the metabolic activity of the tissue as assessed by the 
redox indicator TTC (tetrazolium chloride) coregistered with the immunofluorescent signal 
for MAP2 and microglia (Fig. S6a). We observed the fragmentation of mitochondria (Fig. 
5a, 74% decrease of individual mitochondrial area, 46% decrease of mitochondrial major 
axis, p<0.001 for both, n=189 mitochondria) and an almost complete declustering of Kv2.1 
proteins (45, 46) in morphologically intact penumbral neurons (Fig. 5b; Fig. S6e, from 4 to 
0 median cluster/cross section and from 0.0947 to 0 cluster/µm in control and stroke, respec-
tively, p<0.001, n=58 cells). These morphological changes were accompanied by a robust 
increase in the microglial process coverage of neuronal cell bodies, originating from somatic 
microglia-neuron junctions in both mice and human post-mortem brain tissues (Fig. 5b-e, 
mouse: 3.8-fold increase, p<0.001, n=30 neurons; human: 1.5-fold increase, p=0.007, n=249 
neurons). Strikingly, acute i.c.m. administration of the P2Y12R-inhibitor PSB, or preventing 
mitochondrial injury by using the mitochondrial ATP-sensitive potassium (KATP) channel 
opener diazoxide (47, 48), completely abolished stroke-induced increases in microglial pro-
cess coverage around somatic junctions (Fig. 5d, ctrl vs. stroke: p<0.001, PSB ctrl vs. PSB 
stroke: p=0.792, diazo. ctrl vs. diazo. stroke: p=0.053, n=140 neurons). Viability of the ex-
amined neurons with increased microglial process coverage was confirmed by normal chro-
matin structure and membrane integrity (Fig. S6b, c). Transmission electron tomography 
also confirmed increased microglial process coverage and mitochondrial fragmentation of 
neurons (Fig. 5c).  
To test the impact of P2Y12R-dependent microglial functions on neuronal viability in vivo, 
we investigated pharmacological inhibition of P2Y12R by injection of PSB i.c.m. prior to 




middle cerebral artery occlusion (MCAo). Inhibition of microglial P2Y12R not only pre-
vented increases in microglial process coverage of neuronal cell bodies in the penumbra, but 
it also altered functional connectivity in the brain as assessed by a widefield imaging ap-
proach in Thy1-GCaMP6s mice (Fig. 5f, g,). In fact, an absence of P2Y12R signaling 
significantly increased the area of functional disconnection (global connectivity < 0.6) in the 
ipsilateral hemisphere during ischemia, accompanied by a trend towards elevated neuronal 
calcium-load (Fig. 5f; Fig. S6f, p=0.0439, n=17 mice). Seed-based connectivity analysis 
revealed a significant increase in the contralateral sensory hindlimb area after reperfusion 
in PSB treated animals. Moreover, connectivity analysis of 14 functional areas revealed a 
substantial and widespread increase in connectivity strength in the absence of microglial 
P2Y12R signaling (Fig. 5g, p=0.0077, n=7 mice ). 





Figure 5. Microglia protect neurons after acute brain injury in a P2Y12R-dependent manner via altered 
somatic junctions 
a) CLSM images show that stroke induces the fragmentation of mitochondria (magenta) in neuronal cell bodies 
(Kv2.1 labeling, cyan) in the penumbra. Mitochondrial area and mitochondrial major axis are both 
significantly decreased (p<0.001, n=189 mitochondria). b) CLSM images of cortical neurons show that in 
parallel with the declustering of Kv2.1-channels (cyan) microglial coverage (yellow) is significantly increased 
after stroke in the penumbra (p<0.001, n=30 neurons). c) 3D reconstruction from electron tomographic 
volume shows elevated microglial coverage and fragmentation of neuronal mitochondria. d) Microglial 
coverage of neuronal cell bodies is robustly increased after stroke, while acute central blockade of P2Y12Rs 




or activation of mitochondrial ATP-sensitive potassium (KATP) channels completely abolishes the stroke-
induced increase of coverage (ctrl vs. stroke: p<0.001, PSB ctrl vs. PSB stroke: p=0.792, diazo. ctrl vs. diazo. 
stroke: p=0.053, n=140 neurons). e) Stroke induces a 1.5-fold increase in somatic microglia coverage of 
human cortical neurons (p=0.007, n=249 neurons). f) Topographical maps show the area of pixels with a 
global connectivity (GC) score less than 0.6 after ischemia. The sum of outlined pixels revealed higher 
dropdown of GC in PSB treated animals after stroke (p=0.0439, n=17 mice). g) Left panel: Topographical 
maps show increased ROI-to-GC of the contralateral HLs in PSB-treated mice 120 min after stroke. Individual 
ROI-to-GC scores were normalized to baseline and quantified for group comparison (p=0.0077, n=7 mice). 
Right panel: Seed-to-seed connectivity is increased in PSB-treated animals after stroke. h) In vivo 2P calcium 
imaging reveals a significant increase of neuronal calcium load during reperfusion after acute P2Y12R 
inhibition with PSB (p<0.0001, n=96 neurons from 3 mice). i) Infarct volume is increased after acute central 
P2Y12R-inhibition (stroke: 14.96±0.95 mm3; stroke+PSB: 23.06±2.519 mm3, p=0.008, n=20 mice), which is 
accompanied by a significantly worse neurological outcome. Scale bars: 4 µm on a, 2 µm on b, 8 µm on e, 20 
µm on h. Median values and interquartile ranges are plotted on a, b, d and e, mean+SEM on f, g, h and i. 
 
To examine the effect of P2Y12R inhibition at the single neuron level in the evolving is-
chemic penumbra in vivo, we investigated GCaMP6f-injected mice with 2P microscopy. In 
control mice, neuronal GCaMP6f signal remained unchanged for the first 90 minutes of 
reperfusion, while blockade of microglial P2Y12Rs with PSB resulted in a strong elevation 
in neuronal calcium load (Fig. 5h, p<0.0001, n=96 neurons, 3 mice), corroborating the find-
ings obtained from the widefield imaging approach also at the cellular level. Most im-
portantly, P2Y12R inhibition significantly increased lesion volume at 24 h reperfusion (Fig. 
5i, stroke: 14.96±0.95 mm3 /mean±SEM/; stroke+PSB: 23.06±2.519 mm3, p=0.008) and re-
sulted in worse neurological outcome (Fig. 5i, Bederson score, stroke: 1.7±0.26; 
stroke+PSB: 2.5±0.224, p=0.033, n=20 mice). 
To investigate the duration of PSB effect in vivo, two-hour long imaging sessions were per-
formed with 2P microscopy 1-3 hours and 24-26 hours after i.c.m. PSB-injection (n=173 




contacts analyzed, from 3 mice). The lifetime of somatic junctions was significantly reduced 
up to 3 hours following PSB administration (56.3% of lifetime under baseline conditions, 
p=0.0139), while there was no effect observed one day later (93.8% of lifetime under base-
line conditions, p=1), suggesting an acute effect of i.c.m. PSB (Fig. S6h, i). The acute effect 
of PSB is also confirmed by the histological measurements performed 4 hours after MCAo 
(Fig. 5d). To verify that i.c.m. injected PSB only inhibited microglial P2Y12Rs but not those 
expressed by circulating platelets, we measured ADP-induced platelet activation in plasma 
samples 1h after MCAo, when BBB injury is apparent (44, 49, 50). ADP-induced increases 
in platelet CD62P were not altered in mice treated with i.c.m. PSB compared to vehicle-
treated animals (Fig. S5f). We also attempted to study whether genetic deletion of P2Y12R 
has similarly detrimental effect on neuronal injury after MCAo as seen after i.c.m. PSB ad-
ministration. However, P2Y12R-/- mice displayed over 50% mortality after MCAo, therefore 
this study was discontinued due to ethical considerations (data not shown). 
Taken together, the above data collectively show that disintegration of somatic microglia-
neuron junctions after neuronal injury triggers increased microglial process coverage of the 
cell bodies of compromised but potentially viable neurons via P2Y12R and mitochondrial 
signaling, allowing the initiation of protective microglial responses that limit brain injury. 
 
Discussion 
Here we identify a novel form of interaction between microglia and neurons. We 
show that under physiological conditions, somatic microglia-neuron junctions are present on 
the majority of neurons in both mice and humans, function as major communication sites 
and are rapidly altered in response to brain injury. We propose that microglia constantly 
monitor neuronal status via these newly identified somatic junctions, allowing neuroprotec-
tive actions to take place in a targeted manner.  




Our in vivo 2P imaging, CLSM and electron microscopic studies showed that sites 
of somatic junctions in neurons are preferentially and repeatedly contacted by microglia and 
such interactions have profoundly increased lifetime compared to the microglial contacts 
targeting dendrites. In previous studies, the proximity between microglial cell bodies or pro-
cesses with neuronal somata has been observed in zebrafish and mice (51, 52). However, the 
formation of direct membrane-to-membrane junctions, the molecular identity of neuronal 
membranes contacted, activity-dependent recruitment of microglial processes to neuronal 
cell bodies, the mechanisms of junction formation, and the function of somatic microglia-
neuron interactions have not been experimentally addressed. Thus, we took advantage of 
cutting edge neuroanatomical approaches that have not been previously used to study mi-
croglia-neuron interactions, and discovered that somatic microglia-neuron junctions are 
characterized by unique ultrastructural and molecular composition. These morphological 
and molecular features are absent in perisomatic boutons contacted by microglia, suggesting 
that the main form of neuronal quality control by microglial processes is not mediated by 
interactions between microglia and perisomatic axon terminals. 
Mitochondria are the primary energy generators in cells, playing fundamental roles 
in calcium homeostasis, intracellular signaling (53–55), neuronal quality control (56), and 
in determining cellular fate (57, 58). While neuronal mitochondria are also considered as 
“immunometabolic hubs” involved in antigen presentation and the regulation of innate im-
mune responses (59, 60), changes in mitochondrial function due to metabolic imbalance, 
oxidative stress, inflammation, cellular injury or cell death occur in most neuropathological 
states (61). Mitochondria-associated membranes (MAM) are also considered to be key inte-
grators of metabolic and immunological signals, playing a central role in neurodegeneration 
and cell-fate decisions (33, 62–64). Thus, somatic mitochondria and MAMs are ideally po-
sitioned to report neuronal status to microglia and to mediate neuronal quality control. In 




line with this, we show that the recruitment of microglial processes to somatic junctions in 
the vicinity of neuronal mitochondria is linked with mitochondrial activity (NADH fluores-
cence). This may indicate rapid sensing of mitochondrial activity-associated changes of neu-
rons by microglial processes via the release of ATP and other mediators, or the impact of 
microglia-derived substances on neuronal activity and/or mitochondrial function at somatic 
junctions. Since potential shifts in the fluorescence of NADH indicates both oxidative and 
glycolytic metabolism (65), the precise molecular interactions involved need to be investi-
gated in future studies. Neurons can execute somatic ATP release via pannexin hemichan-
nels, voltage-dependent anion channels or through activity-dependent vesicle exocytosis 
(24, 25, 42). Vesicular nucleotide transporter (vNUT) is known to be responsible for somatic 
vesicular ATP-release in neurons (38). In fact, we demonstrated the enrichment of vNUT 
between neuronal mitochondria and the somatic membranes contacted by microglia, and 
using time-lapse imaging and HPLC measurements, we confirmed the presence of activity-
dependent somatic ATP release from neurons that was blocked by vNUT inhibition. 
TOM20-positive mitochondria-derived vesicles and other vesicles were also observed 
within the neuronal cytoplasm at somatic microglia-neuron junctions, together with the en-
richment of LAMP1-positive lysosomes, which could – together with the released ATP – 
provide a constant readout of neuronal activity and mitochondrial function as seen in neurons 
and other cells (35, 66, 67). The strong enrichment of vNUT in these contacts (Fig. 2i, j), the 
existence of an activity- and vNUT-dependent somatic ATP-release (Fig. 3h-k), the presence 
of filamentous cytoplasmatic structures connecting vesicles to the core of the junction (Fig. 
2a, b), the presence of TOM20 immunogold positive vesicles within the contacts attached to 
the neuronal plasma membrane (Fig. 2h), close association of neuronal lysosomes (Fig. S4g), 




and the massive accumulation and nanoscale clustering of exocytosis-promoting Kv2.1-pro-
teins within these contact sites (Fig. 1k) collectively indicate the convergence of multiple 
parallel vesicular exocytotic pathways at microglia-neuron junctions. 
Kv2.1 channels are major regulators of neuronal potassium levels. However, they 
tend to assemble into discrete clusters on the surface of neurons, where they do not function 
as ion channels, but provide sites for intensive membrane trafficking as exo- and endocytotic 
hubs (20, 68–70). Furthermore, Kv2.1 clusters are known to induce stable ER-plasma mem-
brane junctions (69), anchoring MAMs and mitochondria into these morpho-functional 
units, providing an ideal site for release of mitochondria-associated messenger molecules 
(35). The functional importance of these interactions is confirmed by our results showing 
that Kv2.1-clusters on transfected HEK-cells readily induced the formation of microglial 
process-contacts to these clusters, which could not be observed on HEK-cells transfected 
with the dominant-negative mutant Kv2.1. Furthermore, using STORM super-resolution im-
aging, we found that microglial P2Y12R clusters are precisely aligned with neuronal Kv2.1 
clusters at somatic junctions (Fig. 1k).  
Interestingly, the activation of P2Y12Rs was mainly associated with injury or patho-
logical states in previous studies, and was considered negligible for physiological microglial 
surveillance, based on ex vivo studies (71). Compared to normal extracellular ATP levels in 
the brain, high levels of ATP (1 mM) were shown to induce P2Y12R-dependent microglial 
recruitment, similarly to that seen during microglial phagocytosis or in models of synaptic 
plasticity, while microglial surveillance is considered to be P2Y12R-independent (71–74). 
Our in vivo results refine this view and highlight the importance of compartment-dependent 
effects of P2Y12R on microglial process responses: PSB0739 significantly reduced somatic 
junction lifetime but did not affect the lifetime of dendritic microglia-neuron contacts, while 
abolished microglial reactions to altered neuronal activity, confirming P2Y12R-dependence 




of microglial actions under physiological conditions. Furthermore, neuronal mitochondrial 
activity was also linked with physiological microglial P2Y12R activity at these junctions. 
Based on our data, it is also possible that P2Y12R-mediated actions are more important for 
the sustainment than for the formation of somatic junctions during the communication be-
tween neuronal somata and microglial processes. The contact-dependent clustering of 
P2Y12 receptors further confirms their involvement in physiological microglia-neuron in-
teractions at somatic junctions. Interestingly, blockade of microglial P2Y12R left cortical 
synapse numbers completely unchanged (Fig. S6g) and contact-dependent nano-clustering 
of microglial P2Y12Rs was not seen when microglia contacted synaptic boutons. The above 
structural and functional data in addition to the markedly longer lifetime of these somatic 
junctions in vivo collectively suggest that microglia-neuron interactions at these sites are not 
only P2Y12R-dependent, but are fundamentally different from those seen at synapses.  
The failure of most neuroprotection trials in stroke and other brain diseases strongly 
indicates the importance of understanding the complexity of pathophysiological processes, 
including microglial actions. In fact, potentially salvageable neurons around the infarct core 
may show metabolic activity up to 6-17 hours following stroke in patients and experimental 
animals (75–77). Concerning the fate of these neurons, both the detrimental role of inflam-
matory mechanisms and the protective nature of microglial actions have been previously 
demonstrated (44, 78, 79). We found that Kv2.1 declustering takes place in compromised 
neurons of the penumbra as early as 4 hours after brain injury that paralleled mitochondrial 
fragmentation in neurons, and increased microglial process coverage around somatic micro-
glia-neuron junctions. Our results reveal that P2Y12R-dependent microglial actions protect 
neurons, while blockade of microglial P2Y12R signaling alone impairs cortical network 
function, increases calcium load, and the area of ischemia-induced disconnection within two 




hours following stroke (a clinically relevant time window), leading to augmented brain in-
jury, similarly to that seen after the complete and selective elimination of microglia (44). We 
also show that these protective microglia- and P2Y12R-mediated effects are linked with mi-
tochondrial actions initiated upon neuronal injury, since the KATP channel opener diazoxide 
abolished the increases in microglial process coverage of neurons after stroke, similarly to 
the blockade of P2Y12R signaling. All these results unequivocally indicate that microglia 
continuously monitor neuronal status via these newly described somatic junctions, rapidly 
respond to neuronal changes and initiate neuroprotective actions. 
Clinical significance 
Genome-wide association studies, clinical data and experimental research collec-
tively identify both microglia and neuronal mitochondria as key effectors in common neu-
rological diseases including dementia and other psychiatric disorders, acute brain injury and 
different forms of neurodegeneration (4, 5, 61, 80). The exact mechanisms underlying these 
conditions are currently unclear and effective therapies are lacking, despite all research ef-
forts and numerous clinical trials performed to protect injured neurons in the brain. Based 
on the available data, microglia-mediated effects in health and disease cannot be explained 
merely by microglia-synapse interactions that often occur at a great distance from injured 
neuronal somata, where the majority of mitochondria critical for cell fate decisions are lo-
calized (57, 81). To resolve these controversies, we describe a novel form of intercellular 
interaction through which microglia recognize neuron-intrinsic somatic signaling hubs, dy-
namically monitor neuronal state and mitochondrial function, respond to changes in neuronal 
activity through increased coverage of neuronal cell bodies and influence neuronal fate in a 
P2Y12R-dependent manner. These unique somatic microglia-neuron junctions exist in both 
mice and human in the majority of neurons and are altered in response to brain injury, sug-
gesting their importance. These structures are likely to accommodate presently unexplored 




molecular fingerprints and signaling pathways involved in intercellular communication, in 
addition to recently described cell surface signals and intercellular communication pathways 
(2, 4, 18, 82). We propose that healthy neurons may constitutively release ATP and other 
signaling molecules at these junctions, reflecting their “well-being“ towards microglia. In 
turn, disintegration of these specialized morpho-functional hubs due to excitotoxicity, en-
ergy depletion or other noxious stimuli may trigger rapid and inherently protective micro-
glial responses, leading to the restoration of neuronal function or isolation and phagocytosis 
of dying neurons, in case terminal neuronal injury occurs (74). Along with P2Y12R-medi-
ated microglial process recruitment, it is likely that a broad range of signals is integrated at 
somatic microglial junctions through which microglia may sense products of neuronal exo-
cytosis, changes in the cell membrane (e.g. apoptotic signals), and alter the duration of phys-
ical contact or initiate phagocytosis. The most important open questions include the clarifi-
cation of additional signaling mechanisms (vesicular and non-vesicular) involved in neuron-
to-microglia communication at these junctions, and the mechanisms of microglial neuropro-
tection (e.g. regulation of neuronal ion-fluxes, neuronal calcium dynamics (83) or the me-
tabolism of neuronal mitochondria). Since the role of microglia-neuron somatic junctions in 
most brain diseases is completely unknown, we assume that microglia-neuron interactions 
through these sites markedly differ in different forms of acute and chronic neuropathologies 
and have enormous therapeutic potential. 
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All experiments were performed in accordance with the Institutional Ethical Codex and the 
Hungarian Act of Animal Care and Experimentation guidelines (40/2013, II.14), which are 
in concert with the European Communities Council Directive of September 22, 2010 
(2010/63/EU). The Animal Care and Experimentation Committee of the Institute of Exper-
imental Medicine and the Animal Health and Food Control Station, Budapest, have also 
approved the experiments under the number PE/EA/1021-7/2019, PE/EA/673-7/2019. Con-
trol human brain tissue was obtained from two female (59- and 60-years-old) and one male 
(73-years-old) subjects who died from causes not linked to brain diseases, and did not have 
a history of neurological disorders (ethical approval ETT TUKEB 31443/2011/EKU 
[518/PI/11]). Tissues from patients who died after ischemic stroke affecting the MCA area 
were obtained from two female (77- and 78-years-old) and one male (66-years-old) subjects 
(ethical approval ETT-TUKEB 62031/2015/EKU, 34/2016 and 31443/2011/EKU 
(518/PI/11)) See Supplementary Table 2. Informed consent was obtained for the use of brain 
tissue and for access to medical records for research purposes. Tissue was obtained and used 
in a manner compliant with the Declaration of Helsinki.  
Post-mortem human brain tissues 
Brains of patients who died in non-neurological diseases were removed 3-5 h after death. 
The internal carotid and the vertebral arteries were cannulated, and the brains were perfused 
first with physiological saline (using a volume of 1.5 l in 30 min) containing heparin (5 ml), 
followed by a fixative solution containing 4% paraformaldehyde, 0.05% glutaraldehyde and 
0.2% picric acid (vol/vol) in 0.1 M PB, pH 7.4 (4–5 l in 1.5–2 h). The cortical and hippo-
campal samples were removed from the brains after perfusion, and were postfixed overnight 
in the same fixative solution, except for glutaraldehyde, which was excluded. Blocks were 




dissected, and 50 µm thick sections were prepared on a vibratome (VT1200S, Leica, Ger-
many). Brains of stroke patients were removed after 10-15 h after death and immersion fixed 
in 4% paraformaldehyde. Small regions from the affected cerebral cortex were dissected, 
embedded into paraffin both from the ipsilateral and contralateral hemisphere and 6-8 µm 
thick sections were cut on a sledge microtome. 
Animals 
Experiments were carried out on 12-18 weeks old C57BL/6 (RRID:IMSR_JAX:000664), 
CAMK2 GFP, PVA GFP, GAD65 GFP, CX3CR1+/GFP (IMSR_JAX:005582), 
CX3CR1+/GFP/P2Y12−/− and C57BL/6J-Tg(Thy1-GCaMP6s)GP4.12Dkim/J mice (26, 84–
87). Mice were bred and genotyped at the SPF unit of the Animal Care Unit of the Institute 
of Experimental Medicine (IEM, Budapest, Hungary) as described earlier (44). Mice had 
free access to food and water and were housed under light-, humidity- and temperature-
controlled conditions. All experimental procedures were in accordance with the guidelines 
set by the European Communities Council Directive (86/609 EEC) and the Hungarian Act 
of Animal Care and Experimentation (1998; XXVIII, section 243/1998), approved by the 
Animal Care and Use Committee of the IEM. All experiments were performed in accordance 
with ARRIVE guidelines. 
In vivo pharmacological treatments and chemogenetics 
To study the effect of P2Y12 receptor (P2Y12R) antagonists in healthy mice or after exper-
imental stroke, either a single dose of PSB0739 (Tocris, R&D Systems, Minneapolis, USA, 
15 µg dissolved in saline), or vehicle was administered to the cisterna magna in 5 µl final 
volume using a glass capillary. The diffusion of materials injected i.c.m. was controlled with 
i.c.m. dye injections (Fig. S5e). For experiments aiming to assess the effect of microglial 
P2Y12R blockade on infarct size and neurological outcome, PSB0739 was administered at 
reperfusion after 30 min MCAo. For technical reasons, mice subjected to in vivo widefield 




calcium imaging and two-photon imaging received i.c.m. PSB0739 60 min prior to MCAo. 
Brains were harvested 24 hours later for histology. Diazoxide (#D9035, Sigma, Merck 
KGaA, Darmstadt, Germany) dissolved in 0.4% DMSO and 0.01 M NaOH was administered 
in a single dose of 10 mg/kg intraperitoneally, immediately before reperfusion of the MCAo 
took place during the stroke surgeries. Brains were prepared 4 hours later for histological 
assessment. For selective microglia elimination, C57BL/6J mice were fed a chow diet con-
taining the CSF1 receptor antagonist, PLX5622 (Plexxikon Inc., 1200 mg PLX5622 in 1 kg 
chow) for 3 weeks to eliminate microglia from the brain (and another group of C57BL/6J 
mice were fed control chow diet). For the chemogenetic activation of neurons 0.1 µl of 
AVV8-pAAV-hSyn-HA-hM3D(Gq)-MCherry (RRID: Addgene_50474, Addgene, USA) 
was injected into the neocortex of CX3CR1+/GFP mice. After 3 weeks of incubation, mice 
received saline or clozapine-N-oxide (0.1 mg/ml) intraperitoneally to induce DREADD ac-
tivation. Animals were perfused 1 hour after the injections, and processed for histology. For 
in vivo calcium imaging C57BL/6 mice were used. 200 nl concentrated 
AAV1.Syn.GCaMP6f.WPRE.SV40 (RRID:Addgene_100837, Penn Vector Core) was in-
jected into the cortex 200-300 µm below the surface with glass capillary. The injection co-
ordinates were 1.5 mm lateral from midline, 1.2 mm posterior from bregma. Cranial window 
surgery and two-photon (2P) resonant imaging were performed 2 weeks after injection. 
Experimental stroke 
MCAo was performed using the intraluminal filament technique as described earlier (88). In 
brief, animals were anaesthetized with isoflurane and a silicone-coated monofilament (210-
230 µm tip diameter, Doccol, Sharon, US) was introduced into the left external carotid artery 
and advanced along the internal carotid artery to occlude the MCA for 30 or 45 min. Occlu-
sion was confirmed by a laser Doppler (Moor Instruments, UK). During surgery, core tem-
perature was maintained at 37±0.5°C. The following exclusion criteria were set up: animals 




having less than 70% relative reduction in blood flow, either having haemorrhage or having 
shorter survival than 24 h were excluded from any further analysis pre hoc. In total 2 animals 
(one control and one PSB treated) were excluded post hoc due to intracerebral haemorrhage, 
1 PSB treated animal died before 24 h. Altogether 3 out of 36 animals were excluded 
(28.26%) from the analysis, and total mortality was 2.77%. 
Functional outcome of mice was assessed 24 h after MCAo using the corner test (89) and 
the 5-point Bederson’s sensory-motor deficit scoring system (90). Briefly, the following 
scores were given: a 0, no motor deficit; 1, flexion of torso and contralateral forelimb when 
mouse was lifted by the tail; 2, circling to the contralateral side when mouse is held by the 
tail on a flat surface, but normal posture at rest; 3, leaning to the contralateral side at rest, 4, 
no spontaneous motor activity, 5, early death due to stroke. 
Infarct size was calculated based on cresyl-violet stained coronal sections as described pre-
viously in (44, 91, 92). In brief, lesion volume at 24 h reperfusion was calculated by integra-
tion of areas of damage measured at eight neuro-anatomically defined coronal levels (be-
tween 2.9 mm rostral and 4.9 mm caudal to bregma) followed by correction for oedema.  
To delineate the ischemic penumbra, unfixed 1 mm thick brain slices were incubated in 1% 
TTC (2,3,5-Triphenyltetrazolium chloride, Sigma) dissolved in PBS at 37°C for 20 minutes. 
Slices were then postfixed with 4% PFA in PB for 24 hours at 4°C, resectioned and processed 
for immunostaining. 
Perfusion, tissue processing for histology 
Adult mice were anesthetized by intraperitoneal injection of 0.15-0.25 ml of an anaesthetic 
mixture (containing 20 mg/ml ketamine, 4 mg/ml xylazine-hydrochloride). Animals were 
perfused transcardially with 0.9% NaCl solution for 1 minute, followed by 4% freshly de-
polymerized paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) pH 7.4 for 40 minutes, 
and finally with 0.1 M PB for 10 minutes to wash the fixative out. Blocks containing the 




primary somatosensory cortex and dorsal hippocampi were dissected and coronal sections 
were prepared on a vibratome (VT1200S, Leica, Germany) at 20 µm thickness for STORM 
experiments, 50 µm thickness for immunofluorescent experiments and electron micros-
copy/electron tomography. 
Cloning 
CAG-IRES-tDTomato (pCAG-IRES-tDTomato): The GFP-polyA part of the pCAGIG plas-
mid (a gift from Connie Cepko, Addgene plasmid #11159, RRID:Addgene_11159 (93)) was 
replaced with tDTomato-pA (a gift from Gyula Balla, IEM, Hungary) using blunt-end clon-
ing (pCAGIG:PstI-BstXI, pcDNA3-tDTomato: HindIII-PvuII), fragments were blunted via 
Klenow chewback/fill-in respectively.  
CAG-Mito-R-Geco: CMV-Mito-R-Geco1 (a gift from Robert Campbell; Addgene plasmid 
#46021, RRID:Addgene_46021 (94)) was digested PmeI and the mito-R-Geco fragment 
then subcloned into EcoRV-digested pBSKII SK+ (Stratagene). Orientation was checked 
with restriction analysis. Then pBSKII-Mito-R-Geco was cut with Acc65I-NotI and cloned 
into pCAG-GFP (a gift from Connie Cepko (Addgene plasmid #11150, 
RRID:Addgene_11150 (93)) digested with Acc65I-NotI.  
Kv2.1-EGFP: CMV-hKv2.1-pEGFP-C1 was a gift from Federico Sesti (Addgene plasmid 
#111538; http://n2t.net/addgene:111538 ; RRID:Addgene_111538) 
Kv2.1-ruby: CMV-Kv2.1-Ruby2 encoding plasmid was constructed by removing the NheI-
GFP-EcoRI fragment in pEGFPC1-rKv2.1 (described earlier (69)) and replacing it with an 
in frame NheI-Ruby2-EcoRI fragment. 
DNKv2.1-YFP (CMV-DNKv2.1-YFP): A YFP and myc epitope tagged Kv2.1 dominant neg-
ative construct was assembled using standard PCR-based cloning methods to insert the de-
sired nucleotide sequences. Rat Kv2.1 cDNA fragment corresponding to amino acids 1-218 
and encoding the N-terminus and first transmembrane domain was amplified and tagged 




with the myc epitope on the 3’ end. This fragment was then inserted into the BamHI-XbaI 
sites of the pEYFP-C1 polylinker. The resulting construct expresses the Kv2.1 peptide with 
YFP on the N-terminus and the myc epitope on the C-terminus. 
In utero electroporation: 
Timed-pregnant C57Bl/6J (Jackson) females bred with homozygous CX3CR1GFP/GFP trans-
genic animals were anesthetized by isoflurane vaporization at embryonic day 14.5. Ab-
dominal cavity was opened longitudinally and uterine horns were exposed. Approximately 
1µl of expression vector (1 µg/µl all of the constructs) in endotoxin-free water containing 
Fast Green dye (Roth 1:10000 dilution) was injected into the embryonic lateral ventricles, 
using glass capillary and mouth pipette. Electroporation was performed with tweezer elec-
trodes, 5x50 V pulses of 50 millisecond duration were applied with 950 millisecond intervals 
using the In Utero Electroporator SP-3c (Supertech). After the electroporation, uterine horns 
were returned into the abdominal cavity, the muscle wall and skin were sutured, and embryos 
were allowed to continue their normal development. All the littermates were CX3CR1+/GFP 
heterozygous and were born naturally.  
Mito-R-Geco1 in vitro transfection into HEK-cells 
HEK-293 cells were cultured in Dulbecco's Modified Eagle Medium (4.5 g/L glucose, L-
glutamine & sodium pyruvate; Corning) with 10% heat-inactivated Fetal Bovine Serum (Bi-
osera) and incubated at 37 °C in 5% CO2 in air. On the day of transfection, cells were plated 
on poly-D-lysine (Sigma) coated 18 mm coverslips in 12-well cell culture plates. For trans-
fection 2 µl Lipofectamine® 2000 Reagent (Thermo Fisher Sc.) were mixed with 2 µg Mito-
R-Geco1 in Gibco® Opti-MEM™ Media (Thermo Fisher Sc.) and stored in the hood ap-
proximately half an hour. Transfection solution was mixed with the culturing media and cells 
were incubated overnight. Next day, cells were fixed with 4% PFA for 10 minutes, then 
washed with PBS. Permeabilization and blocking steps were performed by 0.1% TritonX 




and 5% NDS (Normal Donkey Serum; Sigma)/PBS solution for 30 mins. TOM20 antibody 
(1:1000) was applied in PBS for 90 mins. After several PBS washes cell were treated with 
secondary antibodies/PBS solution for an hour. Finally coverslips were washed in PBS and 
mounted with VECTASHIELD® HardSet™ mounting medium and sealed with nail polish. 
Confocal images were taken with 60X objective by Nikon A1R confocal system guide by 
NIS-Elements Microscope Imaging Software. 
Isolation of microglial cells 
Primary microglial cells were isolated from astroglia/microglia mixed cell cultures, as de-
scribed earlier (74). In brief, meninges were removed and tissue pieces were subjected to 
enzymatic dissociation, using 0.05% w/v trypsin and 0.05% w/v DNase for 10 minutes at 
room temperature. The cells were plated onto poly-L-lysine coated plastic dishes and were 
grown in Minimal Essential Medium (MEM, ThermoFisher Sc. 21090-055) supplemented 
with 10% fetal bovine serum (FBS, Thermofisher 16000044), glutamine (4 mM; Sigma-
Aldrich G3126), gentamycin (40 µg/ml; Gentamicin Sandoz, 80 mg/ml injection) and am-
photericin B (2.5 µg/ml; Sigma-Aldrich A2411) in humidified air atmosphere containing 5% 
CO2, at 37oC. The culture medium was changed on the first two days and every third day 
afterwards. Microglial cells were isolated from 21-28 day old mixed cultures by mild tryp-
sinization. In some experiments, microglia were isolated from P8 mice using anti-CD11b 
conjugated magnetic microbeads (Miltenyi Biotec 130-093-634) and magnetic-activated cell 
sorting (MACS), according to the manufacturer’s protocol. The P8-derived cells were main-
tained in the presence of 10 nM Macrophage Colony-Stimulating Factor (M-CSF; Ther-
mofisher PMC2044) until use. 
HEK-microglia co-cultures and Kv2.1 construct transfections 
In co-cultures used for transfection HEK293 cells were plated at 2.5 × 104 cell/cm2 density 
and microglial cells were seeded on top of HEK293 cell cultures in 2.5 × 104 cell/cm2 density 




a day prior to transfection. The cells were transfected with 1 µg Kv2.1-GFP, Kv2.1-Ruby2 
or DNKv2.1-YFP plasmid DNA. Transfection was carried out using LipofectamineTM 3000 
Transfection Reagent (ThermoFisher Sc. L3000001) and Opti-MEM™ Media (Ther-
moFisher Sc. 31985-062), according to the manufacturer’s instructions. In brief, 1.5 µl 
LipofectamineTM 3000 reagent was mixed with 25 µl Opti-MEM ™ and 1 µg DNA was 
mixed with 1 µl P-3000 reagent and 25 µl Opti-MEM™. The two solutions were combined, 
incubated for 20 min at room temperature and the mix was added to the cells. Gene expres-
sion was evaluated the day after transfection. To label microglia, isolectin B4–Alexa 488 or 
594 (Isolectin GS-IB4 From Griffonia simplicifolia, Alexa Fluor™ 488 or 594 Conjugate, 
ThermoFisher Sc. I21411 and I21413) was applied in 5 µg/ml during imaging sessions. Live 
imaging was performed in HEPES buffered ACSF (NaCl 124.5 mM, KCl 2.5 mM, glucose 
10 mM, MgCl2 2 mM, CaCl2 2 mM, NaHCO3 8 mM, HEPES 20 mM) at room temperature 
on a Nikon A1R confocal microscope at 60× magnification (Plan Apo VC NA=1.2 
WD=0.31-0.28mm FOV=215.04um). Images were analyzed using the NIS-Elements AR 
software. 
Neuronal cultures  
Primary cultures of embryonic hippocampal cells were prepared from C57Bl/6 mice on em-
bryonic day 18, as described earlier (74). Briefly, cells were seeded onto poly-L-lysine 
coated tissue culture plates or laminin coated glass coverslips at 1×105 cells/cm2 density and 
grown in NeuroBasal medium (ThermoFisher Sc. 21103-049) supplemented with 5% FBS 
(ThermoFisher Sc. 16000044), B-27TM Supplement (50×) (ThermoFisher Sc. 17504-044), 
GlutaMaxTM Supplement (0.5 mM; ThermoFisher Sc. 35050061), gentamicin (40 µg/ml; 
Gentamicin Sandoz, 80 mg/ml injection), amphotericin B (2.5 µg/ml; Sigma-Aldrich 
A2411). Cytosine-arabinofuranoside (CAR, 10 µM; Sigma-Aldrich C1768) was added to 
the cultures 24-120 h after plating to limit glia growth. 48 h after CAR treatment half of the 




culture medium was changed to BrainPhys-SM1 medium (BrainPhys™ Neuronal Medium 
and SM1 Kit, Stemcell Technologies 05792) without FBS. Medium change was repeated 
every 3-4 days thereafter. Media of cultures treated with CAR as early as DIV1 were sup-
plemented with astroglial conditioned media (1:1) collected from 1-2 week old primary as-
trocytic cultures after 72 h incubation. Primary neuronal cultures were cultivated for 7-14 
days at 37 °C in 5% CO2, 95% air atmosphere. 
In vitro quinacrine experiments 
To monitor vesicular ATP release, neuronal cultures were incubated with 20 µM quinacrine-
dihydrochloride (Sigma-Aldrich Q3251) for 20 min at 37 oC. Live imaging was performed 
in HEPES buffered ACSF (NaCl 124.5 mM, KCl 2.5 mM, glucose 10 mM, MgCl2 2 mM, 
CaCl2 2 mM, NaHCO3 8 mM, HEPES 20 mM) at room temperature on a Nikon A1R con-
focal microscope at 60× magnification (Plan Apo VC NA=1.2 WD=0.31-0.28mm 
FOV=215.04 µm). Images were analyzed using the NIS-Elements AR software. For neuron-
microglia cocultures microglial cells were seeded on top of primary neuronal cultures in 2.5 
× 104 cell/cm2 density a day prior to quinacrine-loading and imaging. 
Quantification of ATP 
The levels of ATP was determined in culture media by using HPLC method. The primary 
cultures were highly 
enriched in neurons, as non-neuronal cell proliferation was blocked by CAR as early as 
DIV1, as described above. Cell culture supernatants were collected at DIV7, 5 min after 40 
mM KCl treatment, preceded by a 20 min incubation period with combinations of the fol-
lowing drugs: Nimodipine (20 µM; Alomone Labs N-150), Clodronate disodium (10 µM; 
Sigma Aldrich D4434), Omega-Agatoxin IVA (100 nM; Alomone Labs STA-500), Omega-
Conotoxin GVIA (1 µM; Alomone Labs SNX-124). Media (400 µl/well) were separated into 
a cold Eppendorf tube which contained 50 µl of homogenization solution (0.1 M perchloric 




acid containing theophylline as an internal standard at 10 µM concentration). Perchloric an-
ion from the supernatant was precipitated by 1 M potassium hydroxide, the precipitate was 
then removed by centrifugation. The extracted purines were kept at -20oC until analysis. The 
adenine nucleotides and adenosine in culture media were determined by online column 
switching separation using Discovery HS C18 50 x 2 mm and 150 x 2 mm columns. The 
flow rate of the mobile phases [“A” 10 mM potassium phosphate, 0.25 mM EDTA “B” with 
0.45 mM octane sulphonyl acid sodium salt, 8% acetonitrile (v/v), 2% methanol (v/v), pH 
5.2] was 350 or 450 µl/min, respectively, in a step gradient application. The enrichment and 
stripping flow rate of buffer [10 mM potassium phosphate, pH 5.2] was during 4 min and 
the total runtime was 55 min. The HPLC system used was a Shimadzu LC-20 AD Analytical 
& Measuring Instruments System, with an Agilent 1100 Series Variable Wavelength Detec-
tor set at 253 nm. Concentrations were calculated by a two-point calibration curve using 
internal standard method. 
Platelet aggregation in response to P2Y12 receptor inhibition after stroke 
12-14 weeks old male C57BL/6J mice were subjected to 30 min MCA occlusion and imme-
diately after the induction of reperfusion a specific P2Y12 receptor inhibitor (PSB0739, 
#3983 Tocris, 15 µg in 5µl volume) or vehicle (PBS) was administered to the cisterna magna. 
1 h later mice were sacrificed and venipuncture was performed from the vena cava inferior. 
Platelet-rich plasma samples from anticoagulated (3.8% Sodium citrate) blood samples were 
isolated by centrifugation (100 x g, 10 min), were plated (30 µl/ well in a 24-well plate) and 
incubated at 37°C for 30 min before treatment with 0.5 mM ADP for 1 h at 37°C. ADP-
induced platelet activation was measured by FACS based on CD62-P and CD42d fluores-
cence intensity, as described earlier in (50, 95). After 10 min antibody staining (CD62-P-
APC, 1:400, #17-0626-80 eBioScience, CD42d-PE, 1:400, #12-0421-80 eBioScience) sam-
ples were lysed to remove any red blood cell contamination (BD FACS Lysing Solution), 




acquired with a BD FACSVerse instrument, and analyzed with BD FACSSuite software (BD 
Biosciences). Changes in CD62P mean fluorescence intensity values were determined on 
CD42d-positive platelets. 
In vivo two-photon imaging 
Animals were anaesthetized using fentanyl (100-200 µl). Cranial window (3 mm diameter) 
was opened on the left hemisphere above the primary somatosensory area and supplementary 
somatosensory area border (centered 3 mm lateral and 2 mm posterior to bregma) without 
hurting the dura mater. After removal of the skull bone a 3 mm and 5 mm double glass 
coverslip construct was fixed with 3M™ Vetbond™ tissue glue on top of the dura mater. 
Then a custom made metal headpiece (Femtonics Ltd., Budapest, Hungary) was fixed with 
dental cement on the surface of the skull. All experiments were performed on a Femto2D-
DualScanhead microscope (Femtonics Ltd., Budapest, Hungary) coupled with a Chameleon 
Discovery laser (Coherent, Santa Clara, USA). For tDTomato electroporated animals the 
wavelength of the laser was set to 920 nm to measure the tdTomato and GFP signals simul-
taneously. For Mito-R-Geco1 mitochondrial electroporated animals the wavelength was set 
to 1000 nm. Following excitation the fluorescent signal was collected using a Nikon 18X 
water immersion objective. Data acquisition was performed by MES software (Femtonics 
Ltd.). Since it has recently been shown that volatile anesthetics such as isoflurane may in-
fluence microglial process motility (71), we used fentanyl anaesthesia for these studies, 
which did not block microglial responses. (Fig. S5b; median process motility observed: 
isoflurane 0.6 µm/min, 0.3-0.83 interquartile; fentanyl 0.6 µm/min, 0.42-0.78; urethane 0.48 
µm/min, 0.36-0.84; n=153 processes from 9 animals). 
To analyze contacts established by microglial processes on neuronal cell bodies and proxi-
mal dendrites, we used in utero tdTomato electroporated CX3CR1+/GFP mice. To visualize 
microglial processes and neuronal mitochondria simultaneously, we used Mito-R-Geco1 




electroporated CX3CR1+/GFP mice. Galvano Z-stacks of 7 images (820x820 pixels, 5 µm 
step size, range=200-225 µm from pial surface) were made at every 2 or 2.5 minutes. Two-
photon image sequences were exported from MES and analyzed using FIJI. Dual colour 
images were analyzed with the Manual Tracking plugin of FIJI. We applied a local maxi-
mum centring correction method with a search square of 5 pixels. Pixel size was 167 nm/px.  
Microglial process velocity was measured on time-series images acquired with 2P micros-
copy. Following motion correction, monocolour images from the same region of 
CX3CR1+/GFP mice taken 135 seconds apart were analyzed with the Manual Tracking plugin 
of FIJI. We applied a local maximum centring correction method with a search square of 5 
pixels. Pixel size was 167 nm/px. Processes were included in the measurement, when they 
were clearly traceable for at least 10 minutes. The GCaMPf signal was imaged with the laser 
wavelength set to 920 nm, using the resonant scanner at 32.75 Hz. Image size was 512x488 
pixels. 
Immunofluorescent labeling and confocal laser scanning microscopy (CLSM) 
Before the immunofluorescent staining, the 50 µm thick sections were washed in PB and 
Tris-buffered saline (TBS). This was followed by blocking for 1 hour in 1% human serum 
albumin (HSA; Sigma-Aldrich) and 0.1% Triton X-100 dissolved in TBS. After this, sec-
tions were incubated in mixtures of primary antibodies overnight at room temperature. After 
incubation, sections were washed in TBS and were incubated overnight at 4°C in the mixture 
of, all diluted in TBS. Secondary antibody incubation was followed by washes in TBS, PB, 
the sections were mounted on glass slides, and coverslipped with Aqua-Poly/Mount (Pol-
ysciences). Immunofluorescence was analyzed using a Nikon Eclipse Ti-E inverted micro-
scope (Nikon Instruments Europe B.V., Amsterdam, The Netherlands), with a CFI Plan Ap-
ochromat VC 60X oil immersion objective (numerical aperture: 1.4) and an A1R laser con-
focal system. We used 405, 488, 561 and 647 nm lasers (CVI Melles Griot), and scanning 




was done in line serial mode. Image stacks were obtained with NIS-Elements AR software 
and deconvolved using Huygens Professional software (www.svi.nl). For primary and sec-
ondary antibodies used in this study, please see Supplementary Table 3. 
Quantitative analysis of CLSM data 
Quantitative analysis of each dataset was performed by at least two observers, who were 
blinded to the origin of the samples, the experiments and did not know of each other’s results. 
For the analysis of somatic junction prevalence, confocal stacks with double immunofluo-
rescent labeling (cell type-marker and microglia) were acquired from at least three different 
regions of mouse cortex. All labeled and identified cells were counted, when the whole cell 
body was located within the Z-stack. A somata was considered to be contacted by microglia, 
when a microglial process clearly touched it.  
For the analysis of synaptic contact prevalence, confocal stacks with triple immunofluores-
cent labeling (pre- and postsynaptic markers and microglia) were analyzed in an unbiased, 
semi-automatic method. First, the two channels representing the pre- and postsynaptic mark-
ers were exported from a single image plane. The channels were thresholded automatically 
in FIJI, the „fill in holes” and „erode” binary processes applied. After automatic particle 
tracking, synapses were identified where presynaptic puncta touched postsynaptic ones. 
From these identified points we selected 200/animal in a systematic random manner. After 
this, the corresponding synapses were found again in the original Z-stacks. A synapse was 
considered to be contacted by microglia, when a microglial process was closer than 200 nm 
(4 pixels on the images).  
To measure the distribution of Kv2.1 and Kv2.1 labeling relative to microglial processes, 
confocal stacks were exported into single-channel TIFF-series. Identical measuring frames 
(1.32 µm2) were placed randomly along the surface of pyramidal cells and integrated Kv2.1 




fluorescent density was measured in each frame in FIJI. Afterwards, frames containing mi-
croglial contacts were identified (“contact” group) and compared with frames not containing 
microglial processes (“non-contact” group).  
For the measurements of mitochondrial fragmentation, we used tissue from mice that were 
sacrificed 4 hours after a one hour-long unilateral MCAo. Confocal stacks with double im-
munofluorescent labeling (Kv2.1 and TOM20) were taken from the penumbra and the cor-
responding contralateral region. We used the Kv2.1 labeling to trace neuronal cell bodies as 
regions of interest (ROI). Every cell was counted once using the confocal plane containing 
its largest cross-section. Within the ROIs TOM20 labeling was investigated with FIJI: after 
automatic thresholding, we ran the ‘Analyze Particles’ command to obtain the area and the 
major axis of individual somatic mitochondria. 
For the analysis of Kv2.1 clusters, individual cells were measured by using the confocal Z-
plane containing the largest cross-section of the cell body. The intensity profile of Kv2.1 
labeling was plotted using FIJI. A cluster was identified when at least three adjacent pixels’ 
intensity was more than 25 grayscale values (10% of an 8-bit image) larger than the average 
fluorescent intensity of that particular cells Kv2.1 labeling. 
Microglial process coverage was measured on CLSM Z-stacks acquired with a step size of 
300 nm. On single-channel images, Kv2.1-positive cells were selected randomly, the cell 
bodies of which were fully included in the captured volume. The surface of these cells was 
calculated by measuring the circumference of the soma on every section multiplied by sec-
tion thickness. The length of microglial process contacts was measured likewise. 
TOM20 and vesicular nucleotide transporter (vNUT) fluorescent intensity profiles were an-
alyzed using a semi-automatic method. Confocal stacks with triple immunofluorescent la-
beling (microglia, Kv2.1 and TOM20/vNUT) were collected. The section containing the 
largest cross-section of a pyramidal cell was used to trace the cell membrane according to 




Kv2.1-labeling. This contour was then expanded and narrowed by 0.5 µm to get an extracel-
lular and an intracellular line, respectively. The intensity of fluorescent labeling was ana-
lyzed along these lines. After normalizing and scaling, microglial contact was identified 
where microglial fluorescent intensity was over 20% of total, for at least 500 nm. Then the 
contact area was extended 500-500 nm on both sides, and TOM20/vNUT fluorescent inten-
sity within these areas was measured for “contact” value. 
3-dimensional reconstruction of CLSM and 2P imaging stacks was performed using the 
IMOD software package (96). 
STORM super-resolution imaging 
Free-floating brain sections were blocked with 2% normal donkey serum followed by im-
munostaining with rabbit anti-P2Y12R and mouse anti-Kv2.1 antibodies, followed by anti-
rabbit Alexa 647 and anti-mouse Alexa 594 secondary antibodies. Sections were mounted 
onto #1.5 borosilicate coverslips and covered with imaging medium containing 5% glucose, 
0.1 M mercaptoethylamine, 1 mg/ml glucose oxidase, and catalase (Sigma, 1500 U/ml) in 
Dulbecco’s PBS (Sigma), immediately before imaging (97). STORM imaging was per-
formed for P2Y12R (stimulated by a 647 nm laser) by using a Nikon N-STORM C2+ super-
resolution system that combines ‘Stochastic Optical Reconstruction Microscopy’ technology 
and Nikon’s Eclipse Ti research inverted microscope to reach a lateral resolution of 20 nm 
and axial resolution of 50 nm (29, 98). Imaging was performed using the NIS-Elements AR 
4.3 with N-STORM 3.4 software, and we used VividSTORM open-source software (98). 
Molecule lists were exported from NIS in txt format, and the three image planes of the ics-
ids file pairs from the deconvolved confocal stacks matching the STORM volume were con-
verted to the ome-tiff format using FIJI software. Confocal and corresponding STORM im-
ages were fitted in VividSTORM. Localization points exceeding a photon count of 2000 




were counted as specific superresolution localization points. Local density filter (10 neigh-
bours within 150 nm for P2Y12R and Iba1, and 5 neighbours within 150 nm for Kv2.1) and 
Z-filter (±300 nm from focal plane) was applied to the localization points.  
Pre-embedding immunoelectron microscopy  
After extensive washes in PB and 0.05 M TBS sections were blocked in 1% HSA in TBS. 
Then, they were incubated in primary antibodies (Supplementary Table 3) diluted in TBS 
containing 0.05% sodium azide for 2-3 days. After repeated washes in TBS, the sections 
were incubated in blocking solution (Gel-BS) containing 0.2% cold water fish skin gelatine 
and 0.5% HSA in TBS for 1 h. Next, sections were incubated in gold-conjugated or bioti-
nylated secondary antibodies (Supplementary Table 3) diluted in Gel-BS overnight. After 
extensive washes in TBS the sections were treated with 2% glutaraldehyde in 0.1 M PB for 
15 min to fix the gold particles into the tissue. This was occasionally followed by incubation 
in avidin–biotinylated horseradish peroxidase complex (Elite ABC; 1:300; Vector Labora-
tories) diluted in TBS for 3 h at room temperature or overnight at 4°C. The immunoperoxi-
dase reaction was developed using 3,3-diaminobenzidine (DAB; Sigma-Aldrich) as chro-
mogen. To enlarge immunogold particles, sections were incubated in silver enhancement 
solution (SE-EM; Aurion) for 40-60 min at room temperature. The sections were then treated 
with 1% (for electron tomography) or 0.5% OsO4 in 0.1 M PB, at room temperature (for 
electron tomography) or on ice, dehydrated in ascending alcohol series and in acetonitrile 
and embedded in Durcupan (ACM; Fluka). During dehydration, the sections were treated 
with 1% uranyl acetate in 70% ethanol for 20 min. For electron microscopic analysis, tissue 
samples from the CA1 area of dorsal hippocampus/somatosensory cortex (S1) were glued 
onto Durcupan blocks. Consecutive 70 nm thick (for conventional electron microscopic 
analysis) or 150 nm thick (for electron tomography) sections were cut using an ultramicro-
tome (Leica EM UC6) and picked up on Formvar-coated single-slot grids. Ultrathin sections 




for conventional electron microscopic analysis were examined in a Hitachi 7100 electron 
microscope equipped with a Veleta CCD camera (Olympus Soft Imaging Solutions, Ger-
many). 150 nm thick electron tomography sections were examined in FEI Tecnai Spirit G2 
BioTwin TEM equipped with an Eagle 4k HS camera. 
Electron tomography 
For the electron tomographic investigation, we used 150 nm thick sections from the hippo-
campal CA1 region from the anti-P2Y12R immunogold stained material (see: “Pre-embed-
ding immunoelectron-microscopy”). Before electron tomography, serial sections on single-
slot copper grids were photographed with a Hitachi H-7100 electron microscope and a Veleta 
CCD camera. After this, grids were put on drops of 10% HSA in TBS for 10 minutes, dipped 
in distilled water (DW), put on drops of 10 nm gold conjugated Protein-A (Cytodiagnostics 
#AC-10-05) in DW (1:3), and washed in DW. Finally, we deposited 5 nm thick layers of 
carbon on both sides of the grids. Electron tomography was performed using a Tecnai T12 
BioTwin electron microscope equipped with a computer-controlled precision stage (Com-
puStage, FEI). Acquisition was controlled via the Xplore3D software (FEI). Regions of in-
terest were pre-illuminated for 4-6 minutes to prevent further shrinkage. Dual-axis tilt series 
were collected at 2 degree increment steps between -65 and +65 degrees at 120 kV acceler-
ation voltage and 23000x magnification with -1.6 – -2 µm objective lens defocus. Recon-
struction was performed using the IMOD software package (96). Isotropic voxel size was 
0.49 nm in the reconstructed volumes. After combining the reconstructed tomograms from 
the two axes, the nonlinear anisotropic diffusion filtering algorithm was applied to the vol-
umes. Segmentation of different profiles has been performed on the virtual sections using 
the 3Dmod software, and measurements were done on the scaled 3D models. 




Analysis of the connection between membrane distance and P2Y12R density was carried 
out by investigating all points of the microglial membrane facing neuronal soma, using re-
constructed 3D models. Coordinates of the points of neuronal membrane, soma-facing mi-
croglial membrane and P2Y12R labeling gold particles were exported using IMOD. For 
every single point of microglial membrane, the lowest distance to the neuronal membrane 
and the number of P2Y12R labeling gold particles within 40 nm was calculated with a unique 
algorithm running in program R (The R Foundation). Since neuronal junctions established 
by microglial processes are dynamic, a strong linear correlation can not be expected, there-
fore statistical analysis was carried out by dividing data into two groups. In the analyzed 
tomograms the average distance between neuronal somatic membranes and facing microglial 
membranes was 13.06 nm, which we used as demarcation point. 
Analysis of P2Y12R density along different surfaces of microglial processes was done using 
reconstructed 3D models. We identified segments of microglial membranes facing (running 
parallel with) different neuronal membranes. These segments were grouped depending on 
opposing neuronal profiles (e.g neuronal soma or other neuronal parts). Using IMOD, the 
surfaces of microglial profiles were measured and gold particles were assigned to the closest 
membrane part. Due to different labeling density and penetration differences, we only per-
formed pairwise comparisons between ‘somatic’ and ‘non-somatic’ microglial membranes 
within the same microglial processes. Only those gold particles were counted that localized 
within 40 nm of the microglial membrane.  
In vitro nicotinamide adenine dinucleotide (NADH) imaging 
Mice were anaesthetized by inhalation of halothane, and following decapitation 200 µm 
thick coronal slices were prepared from the somatosensory and visual cortex with a vibrating 
blade microtome (Microm HM 650 V) immersed in slicing solution containing (in mM): 130 
NaCl, 3.5 KCl, 1 NaH2PO4, 24 NaHCO3, 1 CaCl2, 3 MgSO4, 10 D(+)-glucose, saturated 




with 95% O2 and 5% CO2. The solution used during experiments was identical to the slicing 
solution, except it contained 3 mM CaCl2 and 1.5 mM MgSO4. Experiments were carried 
out less than 4 hours after slicing. During image acquisition slices were kept at ~36˚C. Im-
aging with multiphoton excitation was performed using a Zeiss LSM 7MP scanning micro-
scope (Carl Zeiss, Germany) through a 40X water-immersion objective (W-Plan, NA 1.0, 
Carl Zeiss). To acquire simultaneous excitation of GFP and NADH autofluorescence of 
acute brain slices we used two single wavelength mode-locked Ti:sapphire lasers the beams 
of which were coupled to each other by a dichroic beam splitter (t810lpxr, Chroma Technol-
ogy Corp, USA). One of our lasers (MaiTai DeepSee, Spectra-Physics, Santa Clara, USA) 
exciting GFP operated at 885 nm, while our second laser (FemtoRose 100 TUN, R&D Ul-
trafast Lasers, Hungary) exciting NADH had an operation wavelength of 750 nm. Both laser 
systems delivered ~100 fs pulses at ~80 MHz and ~76 MHz repetition rate, respectively. A 
total average laser power of 16-18 mW was measured after the objective during imaging. 
Time-lapse images (1024x1024 pixels) were collected continuously for up to 55 minutes 
with 30.98 seconds frame scan time. Emission filters were chosen to separate intrinsic 
NADH fluorescence (ET460/50m, Chroma Technology Corp, USA) from GFP fluorescence 
(ET525/50m, Chroma Technology Corp, USA). Time lapse images were processed and an-
alyzed in FIJI (ImageJ, NIH) software. As a first step images were spatial filtered (mean 
filter smooth with 1 pixel diameter) and corrected for contrast. To remove jitter in image 
series stabilization was applied with a FIJI plugin (K. Li, "The image stabilizer plugin for 
ImageJ," http://www.cs.cmu.edu/ ~kangli/code/Image_Stabilizer.html, February, 2008). 
Analysis and quantification of NADH fluorescence was carried out in manually selected 
areas of compartments of cell bodies at microglial contact site. 
 
 




In vivo widefield calcium imaging  
In vivo widefield calcium imaging was performed as previously described in detail (99). In 
brief, as an optogenetic calcium-reporter mouse strain, C57BL/6J-Tg(Thy1-
GCaMP6s)GP4.12Dkim/J (87) heterozygous mice were bred at the Institute for Stroke and 
Dementia Research, Munich. The skin covering the skull and the underlying connective tis-
sue were removed in head-fixed mice and a layer of transparent dental cement was distrib-
uted on the window area and covered with a coverslip. Afterwards, the mice were allowed 
to recover from the surgery for more than 48 h before the first image acquisition. For image 
acquisition, mice were injected with 0.05 mg/kg bodyweight of medetomidine intraperito-
neally 5 minutes prior to inducing inhalation anesthesia with a mixture of 5% isoflurane in 
70% nitrous oxide and 30% oxygen. After 70 seconds, the animals were fixed in a stereo-
tactic frame, the dose of isoflurane was decreased to 1.5% for 140 seconds and finally de-
creased to 0.75% for 4 minutes to maintain steady-state before data-acquisition. In vivo wide-
field calcium imaging was performed on a custom-built imaging setup described in (99). 
This setup allowed widefield imaging through the chronic window on top of the skull into 
the cortex of both forebrain hemispheres by covering a field-of-view of 12x12 mm, corre-
sponding to an image matrix of 330x330 pixels. Image acquisition was conducted for 29 
minutes (44 x 1000 frames, immediately after MCAo induction, starting 60 min after injec-
tion of PSB) or 4 minutes (6 x 1000 frames, baseline acquisition, starting 60 min after injec-
tion of PSB and after 120 min reperfusion, respectively). After the imaging session, anes-
thesia was terminated by intraperitoneally injecting the mice with 0.1 mg/kg bodyweight 
Atipamezole. During all anesthetized procedures body temperature was maintained using a 
feedback-controlled heating system. After end of surgeries animals were put in a heating 




chamber until they had recovered from anesthesia. Post-surgery analgesia and sedation pro-
tocols were conducted in accordance with approved protocols by the governmental commit-
tee.  
Images of every acquisition were masked in a two-step procedure. First, a general mask was 
applied to exclude lateral cortical areas, which were out of focus due to the curvature of the 
cortical surface as described in (99). Second, an individual mask was computed to exclude 
all pixels, in which the calcium signal was saturated due to autofluorescence, as occurring 
in areas affected by the infarct (99). Both, the general and the individual masks were com-
bined for every acquisition. 
To characterize changes in the cortical network after stroke, functional connectivity was 
computed between pairs of ROIs, representing functional cortical areas, previously defined 
(99). Functional connectivity was calculated as the Fisher z-transformed Pearson-moment 
correlation between the ROI signal time-courses. The average connectivity scores were cal-
culated within each group (PSB-treated and control group), and the difference between 
groups was depicted for all ROI pairs in a heatmap.  
For seed-based functional connectivity analysis, connectivity scores were calculated in the 
same way but between a selected ROI in the right hindlimb sensory area (rHLs) and the 
signal time series of all pixels on the cortical surface included in the combined general and 
individual masks. In order to quantify connectivity change of the rHLs after stroke, the con-
nectivity scores were normalized by dividing through the connectivity scores resulting in the 
baseline condition. Results were visualized as topographical maps of all brain pixel.  
Overall functional connectivity alterations due to treatment of the mice with PSB(naïve and 
stroke) were assessed by computing the global connectivity (GC) (100, 101) for each pixel 
inside the combined general and individual mask. For a given pixel, GC was calculated by 
calculating the functional connectivity with each other pixel inside the mask, followed by 




averaging across the resulting connectivity scores. In order to assess treatment effects, GC 
scores were averaged pixel-wise within group (PSB and control group). The difference be-
tween groups was then visualized as topographical map of all brain pixels.  
To compare the extent of GC dropdown between PSB and control treated animals after 
stroke, the sum of all pixels with a moderate GC (i.e. global connectivity less than 0.6 ac-
cording to (102)) was calculated for every mouse. The mean area of each group was con-
toured within the GC map and the area was assessed quantitatively per animal and compared 
between the groups. 
To represent the non-functionality of cortical tissue during the occlusion of the middle cer-
ebral artery, the number of saturated pixels during the occlusion was calculated. During the 
occlusion, cortical spreading depressions (CSDs) appeared. Given the high degree of neu-
ronal activation within areas covered by these waves, the high amplitude of the Ca2+ derived 
signal caused saturation in these areas. Therefore, we quantified the spatial extent of CSDs 
by counting the saturated pixels during these waves. The start- and end-time of every cortical 
wave were defined as first appearance of saturated pixels and the full disappearance of sat-
urated pixels. The absolute maximum spatial extent of every cortical wave was identified 
and used to align the individual cortical waves of all animals. The area of saturated pixels 
was then acquired for every CSD wave for every animal atthe endpoint of the shortest wave 
(which ended 37 seconds after the aligned absolute maximum). The area of saturated pixels 
was groupwise depicted as overlay of the area of every CSD wave upon the general mask. 
Statistical analysis 
All quantitative assessment was performed in a blinded manner and based on power calcu-
lation wherever it was possible. Based on the type and distribution of data populations (ex-
amined with Shapiro-Wilks W test) we applied appropriate statistical tests: in case of two 
independent groups of data unpaired t-test or Mann Whitney U-test, for two dependent 




groups of data Wilcoxon signed-rank test, for multiple comparisons one-way ANOVA (with 
Tukey’s test) or Kruskal-Wallis test was used. Statistical analysis was performed with the 
Statistica 13.4.0.14 package (TIBCO), differences with p<0.05 were considered significant 
throughout this study. 
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animal category mean S.E.M. n comparison (Tukey's multiple comparisons test) p-value
contact 136.8 10.02 12 contact vs. non-contact <0,0001
non-contact 60.42 7.719 12 contact vs. whole microglia <0,0001
whole microglia 76.8 5.128 12 whole microglia vs. non-contact 0.3179
contact 142.6 17.17 18 contact vs. non-contact <0,0001
non-contact 52.2 10.08 17 contact vs. whole microglia 0.0008
whole microglia 76.47 6.054 18 whole microglia vs. non-contact 0.3423
contact 81.05 15.37 11 contact vs. non-contact 0.0116
non-contact 38.62 4.892 13 contact vs. whole microglia 0.0197
whole microglia 41.58 7.661 13 whole microglia vs. non-contact 0.973
contact 93.75 21.59 10 contact vs. non-contact 0.0009
non-contact 20.03 2.746 10 contact vs. whole microglia 0.003
whole microglia 31.17 5.736 12 whole microglia vs. non-contact 0.7957
animal category mean S.E.M. n comparison (Tukey's multiple comparisons test) p-value
contact 0.9705 0.084 12 contact vs. non-contact <0,0001
non-contact 0.4451 0.071 12 contact vs. whole microglia 0.0004
whole microglia 0.5401 0.055 12 whole microglia vs. non-contact 0.6164
contact 0.6089 0.069 18 contact vs. non-contact 0.0002
non-contact 0.3111 0.046 18 contact vs. whole microglia 0.0031
whole microglia 0.3673 0.02 18 whole microglia vs. non-contact 0.7007
contact 0.368 0.072 9 contact vs. non-contact 0.4608
non-contact 0.2659 0.052 13 contact vs. whole microglia 0.4681
whole microglia 0.2684 0.051 14 whole microglia vs. non-contact 0.9994
contact 0.3726 0.062 10 contact vs. non-contact 0.0107
non-contact 0.1839 0.024 11 contact vs. whole microglia 0.0553
























































host source catalog nr. RRID 
CB1 goat MyBioSource MBS422809 n.a. 
CytC mouse BioLegend 612302 RRID:AB_315774 
c-fos guinea-pig Synaptic Sys-
tems 
226 004 RRID:AB_2619946 
CD206 rat BioRad MCA2235 RRID:AB_324622 
CD42d armenian 
hamster 
eBioScience 12-0421-80 RRID:AB_10804037 
CD62-P-
APC 
mouse eBioScience 17-0626-80 RRID:AB_11218294 
Gephyrin mous  Synaptic Sys-
tems 
147 021 RRID:AB_2232546 
GFAP chicken Synaptic Sys-
tems 
173 006 RRID:AB_2619873  
GFP chicken Invitrogen A10262 RRID:AB_2534023 
Homer1 chicken Synaptic Sys-
tems 
160 006 RRID:AB_2631222 
Iba1 goat Novusbio NB100-1028 RRID:AB_521594 
Iba1 rabbit Wako Chemi-
cals 
019-19741 RRID:AB_839504 
Kv2.1 mouse NeuroMab 75-014 RRID:AB_10673392 
Kv2.1 rabbit Synaptic Sys-
tems 
231 002 RRID:AB_2131650 
Kv2.2 rabbit Synaptic Sys-
tems 
231 103 RRID:AB_10805652 
Lamp1 rabbit Abcam ab24170 RRID:AB_775978 
MAP2 guniea-pig Synaptic Sys-
tems 
188 004 RRID:AB_2138181 
NTPDase1 rabbit Labome rN1-6L n.a. 
P2Y12R rabbit Anaspec AS-55042A RRID:AB_2267540 
P2Y12R rabbit Anaspec AS-55043A RRID:AB_2298886 
Parvalbumin goat Swant PVG 213 RRID:AB_2721207 
PDGFRB goat R and D Sys-
tems 
AF1042 RRID:AB_2162633 
Pecam1 rat BioLegend 102501 RRID:AB_312908 
RFP rat Chro oTek 5f8-100 RRID:AB_2336064 
SMA mouse Abcam ab7817 RRID:AB_262054 
SMI32 mouse Covance SMI-32P RRID:AB_10719742 
TOM20 rabbit Santa Cruz sc-11415 RRID:AB_2207533 




vGAT guinea pig Synaptic Sys-
tems 
131 004 RRID:AB_887873 
vGluT1 guinea pig Millipore AB5905 RRID:AB_2301751 
vGLuT3 guinea pig Synaptic Sys-
tems 
135 204 RRID:AB_2619825 
vNUT guinea pig Millipore ABN83 n.a. 
     
Secondary 
antibodies 
    
biotinylated 
anti-rabbit 
donkey BioRad 644008 RRID:AB_619842 
DyLight 405 
anti-mouse 
donkey  Jackson 715-475-150 RRID:AB_2340839 
Alexa 405 
anti-rabbit 
donkey Jackson 711-475-152 RRID:AB_2340616 
Alexa 488 
anti-chicken 
donkey Jackson 703-546-155 RRID:AB_2340376 
Alexa 488 
anti-goat 
donkey Jackson 705-546-147 RRID:AB_2340430 
Alexa 488 
anti-rabbit 
donkey Jackson 711-546-152 RRID:AB_2340619 
CF568 anti-
mouse 
donkey Biotium 20802 RRID:AB_10853136 
Alexa 594 
anti-goat 




goat LifeTech A11076 RRID:AB_141930 
Alexa 594 
anti-mouse 
donkey LifeTech A21203 RRID:AB_141633 
Alexa 594 
anti-rabbit 
donkey LifeTech A21207 RRID:AB_141637 
Alexa 594 
anti-rat 
donkey Jackson 712-585-150 RRID:AB_2340688 
Alexa 647 
anti-goat 




donkey Jackson 706-606-148 RRID:AB_2340477 
Alexa 647 
anti-mouse 
donkey Jackson 715-605-150 RRID:AB_2340866 
Alexa 647 
anti-rabbit 
donkey Jackson 711-605-152 RRID:AB_2492288 
 
  






Figure S1. a) Result of CX3CR1+/GFP mouse in utero electroporation with pCAG-IRES-tdTomato. Lower left 
panel shows the outspread of tdTomato-positive neurons in red. Middle and right panels show the non-
overlapping staining of electroporated neurons (red) and microglia (green). Cell nuclei are visible in blue. b) 
Distribution of microglial contact lifetimes. c) Electron microscopic images showing microglial processes (m) 
establishing direct contact with neuronal cell body (left, neur.), dendritic shaft (right, d) and presynaptic 




bouton (b) in mice. Microglia are visualized by immunoperoxidase reaction against Iba1. Pseudocoloring 
shows microglia in yellow, neuronal cell body and dendritic processes in magenta, presynaptic bouton in cyan 
and nucleus (nucl.) in purple. Arrow points at a dendritic spine receiving asymmetric synaptic contact. d) 
Microglial processes contacting cortical inhibitory and excitatory synapses. Presynaptic terminals are visible 
by stainings against vesicular GABA transporter (vGAT, red) and type 1 vesicular glutamate transporter 
(vGlut1, cyan), while postsynaptic side is characterized by stainings against gephyrin (blue) and Homer1 
(magenta). White arrowheads point at colocalization of pre- and postsynaptic markers. Microglial contacts in 
white circles are enlarged in the panels right, with the previous and following Z-planes from the stack (Z-step 
= 250 nm). Empty arrowheads point at the presynaptic marker, white arrows point at the postsynaptic side. e) 
Heatmap shows Kv2.1 clusters of a human cortical neuron. f) CLSM image shows that a P2Y12R-labeled 
microglial process contacts a human cortical neuron exactly at the spot where a Kv2.1 cluster is located. g) 
Heatmap shows that Kv2.1-clustering of mouse cortical neurons is not affected by microglia depletion. h) 
CLSM images show that 3 week PLX5622-diet almost completely depleted microglia from the brain. i) CLSM 
images show labeling patterns of Kv2.1 and Kv2.2 in the neocortex. j) CLSM images show labeling patterns of 
Kv2.1 and Kv2.2 in the hippocampus. k) Percentages of neurons expressing Kv-channels in the neocortex and 
hippocampus. Scale bars: 500 µm on a, 50 µm on left panel of b and on h, 25 µm on right panel of b, 1 µm on 
c, 2 µm on d and f, 100 µm on i and j. 
 
Figure S2. a) P2Y12R clustering differs depending on location. Microglial processes were classified 
depending on neuronal contacts established: contact processes are pale magenta, non-contact processes are 
pale green on bottom panel. b) Analysis of P2Y12R cluster and LP density on different microglial processes 




contacting distinct cell populations. Microglial contact processes on CamK2a (red) and PVA-positive cells 
(orange) possess significantly higher cluster density, than non-contact segments, while there is a similar trend 
observable in the case of GAD65-positive cells (yellow, for detailed results see Supplementary Table 1.). 
Contact processes had significantly higher number of P2Y12R LPs in all populations. Anti-PV and vGluT3 
labelings were used to confirm cell specificity. c) Superresolution imaging of microglial Iba1 shows no clus-
tering at somatic junctions. CLSM images show neuronal Kv2.1 (green) and a contacting microglial process 
made visible by Iba1-labeling (red). Iba1 (yellow) STORM-signal is overlaid and shown individually in the 
middle panel. Lower panel shows a homogenous distribution of Iba1 LPs using DBScan analysis. Scale bars: 
1 µm on a and c, 10 µm on b. Mean+SEM is plotted. 
 




Figure S3. a) CLSM images show triple immunolabeling for GFP, Iba1 and P2Y12R in CX3CR1+/GFP and 
CX3CR1+/GFP –P2Y12R-/- animals. b) CX3CR1-GFP and P2Y12R double positive microglial processes touch 
Kv2.1 clusters on neuronal somatic membrane. c) P2Y12R-positive microglial processes contact cells of the 
neurovascular unit. d) Transmission electron micrographs show P2Y12R-immunogold labeled microglial 
processes touching vascular endothelial cell. P2Y12R expression is clearly restricted to microglia. e) P2Y12R-
labeled microglial processes are contacting CD206-positive perivascular macrophages (PVM). PVMs do not 
express P2Y12Rs. f) P2Y12R-labeled microglial processes are contacting PDGFRβ-positive pericytes. 
Pericytes are not expressing P2Y12Rs. Scale bars: 20 µm on a, 4 µm on b, 10 µm on c, 1 µm on d, 5 µm on e, 
3 µm on f. 





Figure S4. a) Electron microscopic image shows a microglial process (m) establishing direct contact with 
neuronal cell body (n) in human tissue. Microglia is visualized by immunogold-labeling against P2Y12R. 
Arrowheads point at accumulation of gold particles at contact sites. b) Single virtual plane of an electron 
tomographic volume (thickness: 0.49 nm) showing a P2Y12R-positive (black immunogold particles) microglial 
process (yellow) contacting a neuronal cell body (magenta). Mitochondria (blue), mitochondria-associated 




membranes (MAM, green), vesicles (purple) and intracellular densities (red) are commonly visible in the vi-
cinity of these junctions. In some cases, intercellular linking structures (cyan) can be seen within the cleft. 
Right: distribution of measured distances between mitochondria and MAM (upper chart, n=105) and measured 
length of intercellular tethers (lower chart, n=89). c) Schematic illustration showing the principles of P2Y12R 
density and membrane distance measurements using electron tomography (Fig. 2c, d). Single points of the 
microglial membrane were divided into two groups based on their closest distance from the neuronal mem-
brane: closer than the average distance of 13 nm (red) or farther (green). For every observed point, P2Y12R 
labeling gold particles were counted within a radius of 40 nm. In the bottom right corner, the distribution of 
measured points is shown in the case of a representative junction. d) Transmission electron micrographs show 
Kv2.1 clusters on cortical neuronal cell bodies (arrowheads). Kv2.1-clustering and the association of the clus-
ter with neuronal organelles is not affected by microglia depletion. e) Transmission electron micrographs show 
TOM20-immunogold labeling in neocortical neurons. Immunogold labeling (black grains) is specifically as-
sociated with outer mitochondrial membranes, while TOM20-positive vesicles can also be observed (arrow-
heads). Some immunogold particles can be found on the plasma membrane of the neurons (arrows), suggesting 
the exocytosis of mitochondria-derived vesicles. Nucleus is blue, neuronal cytoplasm is magenta. Left and 
middle panel is the same as on Fig. 2h, f) Electron micrographs from TOM20-Iba1 combined immunogold-
immunoperoxidase reaction. Right upper panel is taken from a consecutive serial section and corresponds to 
the dashed area on the left panel. Right lower panel is enlarged from the right upper. Iba1-positive (dark DAB 
precipitate) microglial process contacts the cell body of a cortical pyramidal cell. TOM20-immunogold signal 
decorates the outer mitochondrial membrane, while arrows point to smaller membrane structures (putative 
MDVs), also positive for TOM20. Note the presence of a TOM20 positive vesicle attached to the neuronal 
plasmamembrane within the somatic junction on the right lower panel. g) CLSM images show Lamp1-positive 
neuronal lysosomes closely apposed to neuronal Kv2.1-clusters. Right panel shows a microglial process touch-
ing a neuronal Kv2.1-cluster with closely located/attached Lamp1-positive lysosomes. h) Kv2.1 accumulation 
does not overlap with somatic inhibitory terminals. CLSM images show perisomatic terminals stained with 
antibodies against PV and CB1 (red) and neuronal Kv2.1 (magenta). Panels on the right show the area in 
white rectangle on the first image. Dashed lines mark clear separation between perisomatic boutons and 
Kv2.1-signal, n=220 perisomatic boutons tested for Kv2.1 from two mice. i) Neuronal vNUT signal (cyan) is 
not present in perisomatic inhibitory terminals (red), n=194 perisomatic boutons tested for vNUT from two 




mice. Scale bars: 300 nm on a (400 for right bottom panel), 50 nm on b, 300 nm on d and e, 300 nm on f, 1 µm 
on g (2 µm for left panel), 2 µm on h and i. 
 
Figure S5. a) Neuronal cell culture transfected with CMV-Mito-R-Geco1 and counterstained with TOM20 and 
DAPI. Scale bar is 10 µm. b) Effects of different anaesthetics on microglial process motility. Median process 
motility observed: isoflurane 0.6 µm/min, 0.3-0.83 interquartile; fentanyl 0.6 µm/min, 0.42-0.78; urethane 0.48 
µm/min, 0.36-0.84; n=153 processes from 9 animals). c) Representative NADH intrinsic fluorescence image 
of a pyramidal cell. Left: Sample image of NADH fluorescence of neuronal somata. Middle: DIC image of the 
same region with whole cell patch clamp electrode. Right: Electrophysiological recordings of membrane 
potential response to -100 and +160 pA current injections. Scales: 20 mV and 100 ms. d) 40 mM KCl induces 
rapid membrane depolarization and calcium influx in cultured neurons in vitro. e) Mixture of carboxyfluores-
cein succinimidyl ester (CFSE) and Hoechst injected into the cisterna magna (i.c.m.) rapidly diffuses to all 




layers of neocortex and hippocampus. f) Central blockade of microglial P2Y12R with PSB does not alter ADP-
induced platelet activation. Platelet rich plasma samples were collected from mice 1h after 30min MCAo and 
stimulated ex vivo with 0.5mM ADP for 1.5h at 37 °C. Platelets shown on SSC x FSC dot blots were labeled 
with CD49d and CD62P. ADP-induced increases in platelet CD62P were not altered in mice treated with 
i.c.m. PSB compared to vehicle-treated animals. Unpaired t-test, n.s. – not significant. Median and 










Figure S6. a) Outline of middle cerebral artery occlusion (MCAo) experiment and delineation of 
core/penumbra regions of stroke affected brain. 1 hour MCAo was followed by 4 hours of reperfusion. 
Delineation was performed with the use of TTC staining and immunofluorescent labeling of MAP2 and 
microglia. b) DAPI staining pattern reveals that neurons with increased microglial coverage (white 




arrowheads) in the penumbra region possess normal chromatin structure, confirming their viability. Empty 
arrowheads point to pycnotic nuclei. c) Transmission electron micrograph shows a P2Y12R-immunogold 
particle labeled microglial process covering a neuron in the penumbra region. Note the increased coverage, 
the disappearance of cytoplasmatic structures like closely apposed mitochondria and MAM. Neuronal 
membrane integrity and chromatin structure are sustained. d) Delineation of core/penumbra border in 
postmortem human cortical tissue. Neurons and nuclei are visualized by Nissl-staining (blue), microglia is 
labeled by anti-P2Y12R DAB-Ni immunoperoxidase reaction (dark brown precipitate). e) Heatmaps of Kv2.1 
immunostaining reveal that Kv2.1 clusters disappear after stroke in the penumbra. f) The saturated calcium 
signal after experimental stroke (left MCAo in every experiment) corresponds to the dysfunctional tissue during 
the occlusion. The maps show an overlay of the area of saturated pixels (pink) of every animal in the two 
groups. g) CLSM images show type 1 vesicular glutamate transporter (vGlut1) and Homer1 immunolabeling 
after acute i.c.m. administration of vehicle (control) or PSB. The closely apposed vGluT1 and Homer1 puncta 
represent glutamatergic synaptic contacts. PSB-treatment did not alter neocortical synapse numbers (0.353 
synapse/µm2 in control, and 0.352 synapse/µm2 in PSB-injected, n=423 appositions from 4 animals). h) 
Schematic outline of repeated 2P imaging of PSB effects. Vehicle was administered i.c.m., and baseline 
imaging performed between the 1st and 3rd hours after injection. The imaging session was repeated after 24h 
(24h baseline). After 3-5 days, PSB was injected i.c.m., and imaging performed between the 1st and 3rd hours 
after injection (PSB). The imaging session was repeated after 24h (24h PSB). i) Acute central PSB 
administration decreased the contact lifetime to 56% of control, but this effect could not be observed after 24 
hours (68.8-143.8% baseline interquartile range, 112.5% (81.3-175) 24h baseline, 56.3% (50-118.8) after 
PSB, 93.8 (68.8-112.5) 24h after PSB; p=0.0139, n=173 contacts from 3 mice). Scale bars: 100 µm on a, 10 
µm on b, 300 nm on c, 12 µm on d, 2 µm on g. Mean+SEM is plotted.  
 
 
Supplementary Movie legends 
Movie S1. In vivo 2P time-lapse imaging shows temporal dynamics of microglia-neuron contacts. A tdTomato 
expressing neocortical neuron (red) is being contacted by processes of a microglial cell (green) in 
CX3CR1+/GFP mouse electroporated in utero with pCAG-IRES-tdTomato. The analyzed trajectories of micro-
glial processes contacting the neuron are shown on the right panel, warm colors label trajectories of somatic 




contacts, while cold colors label trajectories of microglial processes contacting neuronal dendrites. The middle 
panel shows the trajectories overlaid on the recording.  
Movie S2. In vitro CLSM time-lapse imaging of cocultured HEK293 and microglial cells. HEK cells were 
transfected with GFP-coupled control Kv2.1 construct on the left panel, and with YFP-coupled dominant-
negative (DN) Kv2.1 construct on the right panel. Microglia is visualised by Alexa594-conjugated Lectin (red). 
Microglial processes contact Kv2.1-transfected HEK-cells at the clusters, but not those transfected with a 
dominant-negative mutant. 
Movie S3. Left: stack of electron tomographic 0.5 nm thick virtual sections shows the special nano-architecture 
of a somatic microglia-neuron junction with closely apposed mitochondria, mitochondria-associated mem-
branes (MAMs) and cytoplasmatic structures. The silver-intensified P2Y12R-immunogold grains are clearly 
visible at the cytoplasmatic surface of microglial membrane. Note that large number of gold particles are 
clustered exactly where the neuronal cytoplasmatic structure is anchored. Right: 3D model of the same tomo-
graphic volume, neuronal membrane is magenta, microglial membrane is green, immunogold particles white, 
mitochondria light blue, MAM light green, cytoplasmatic densities red, vesicle-like structures blue and micro-
glial reticular membrane structures darker green. Note the specific enrichment of P2Y12R labeling at the core 
of the junction. 
Movie S4. Stack of electron tomographic virtual sections shows the special nano-architecture of the core of a 
somatic microglia-neuron junction. The silver-intensified P2Y12R-immunogold grains are clearly visible at 
the cytoplasmatic surface of microglial membrane. The tethers between the anchored mitochondria and MAM 
are clearly visible. The neuronal cytoplasmatic structure (mitochondria, MAM) is anchored to a membrane 
segment that is precisely facing the high density of P2Y12Rs on the microglial membrane. Note that distance 
between the neuronal and microglial membrane is the smallest exactly here, and intercellular tethers are also 
clearly visible. 
Movie S5. Left: stack of electron tomographic virtual sections shows the special nano-architecture of a somatic 
microglia-neuron junction with closely apposed mitochondria, MAMs and cytoplasmatic structures. The silver-
intensified P2Y12R-immunogold grains are clearly visible at the cytoplasmatic surface of microglial mem-
brane that touches the neuronal cell body, but are present only at a lower density at membrane segments, 
where the microglia touches a perisomatic bouton. Right: 3D model of the same tomographic volume, neuronal 
membrane is magenta, microglial membrane is ocker, immunogold particles white, mitochondria light blue, 
MAM light green, bouton membrane vivid green. 




Movie S6. In vivo 2P imaging of CX3CR1+/GFP mice in utero electroporated with CAG-Mito-R-Geco1 con-
struct. Dashed lines show the outline of a neuron, green microglial processes touch neuronal cell body where 
somatic mitochondria are present. White arrow indicates the contact site of microglia. 
Movie S7. In vitro CLSM time-lapse imaging of KCl-stimulation of quinacrine-loaded cultured neuron. Left 
panel shows transmitted channel and superimposed green channel (quinacrine-labeled ATP-containing vesi-
cles), right panel shows the green channel and the outline of the neuron (white dashed line). White arrows 
point to vesicles that are released spontaneously, red arrows point to vesicles that are released after 40 mM 
KCl stimulation. MIP of z-stack (z-range: 2.5 µm), frame dimension: 12.3 x 22.2 µm. 
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  Neurobiology of Disease
Short-Chain Fatty Acids Improve Poststroke Recovery via
Immunological Mechanisms
Rebecca Sadler,1,2 Julia V. Cramer,1 Steffanie Heindl,1 Sarantos Kostidis,3 Dene Betz,4 XKielen R. Zuurbier,4
X Bernd H. Northoff,5 Marieke Heijink,3 Mark P. Goldberg,4 Erik J. Plautz,4 X Stefan Roth,1 Rainer Malik,1
X Martin Dichgans,1,2 Lesca M. Holdt,5 Corinne Benakis,1 Martin Giera,3 Ann M. Stowe,4,6 and Arthur Liesz1,2
1Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-University LMU, 81377, Munich, Germany, 2Munich Cluster for
Systems Neurology (SyNergy), 81377, Munich, Germany, 3Leiden University Medical Center, Center for Proteomics & Metabolomics, 2300 RC Leiden, The
Netherlands, 4Department of Neurology and Neurotherapeutics, Peter O’Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center,
Dallas, Texas 75390, 5Institute of Laboratory Medicine, University Hospital, Ludwig-Maximilians-University LMU, 81377, Munich, Germany,
and 6Department of Neurology, University of Kentucky, Lexington, Kentucky 40508
Recovery after stroke is a multicellular process encompassing neurons, resident immune cells, and brain-invading cells. Stroke alters the
gut microbiome, which in turn has considerable impact on stroke outcome. However, the mechanisms underlying gut– brain interaction
and implications for long-term recovery are largely elusive. Here, we tested the hypothesis that short-chain fatty acids (SCFAs), key
bioactive microbial metabolites, are the missing link along the gut– brain axis and might be able to modulate recovery after experimental
stroke. SCFA supplementation in the drinking water of male mice significantly improved recovery of affected limb motor function. Using
in vivo wide-field calcium imaging, we observed that SCFAs induced altered contralesional cortex connectivity. This was associated with
SCFA-dependent changes in spine and synapse densities. RNA sequencing of the forebrain cortex indicated a potential involvement of
microglial cells in contributing to the structural and functional remodeling. Further analyses confirmed a substantial impact of SCFAs on
microglial activation, which depended on the recruitment of T cells to the infarcted brain. Our findings identified that microbiota-derived
SCFAs modulate poststroke recovery via effects on systemic and brain resident immune cells.
Key words: microbiome; neuroinflammation; plasticity; stroke models
Introduction
Stroke induces a multiphasic pathophysiological cascade, which
consists of an initial excitotoxicity followed by a longer neuroin-
flammatory phase within the brain (Dirnagl et al., 1999; Iadecola
and Anrather, 2011). Moreover, stroke can be regarded as a sys-
temic disease affecting also remote organ function, including the
lung (Austin et al., 2019), heart (Bieber et al., 2017 ), and immune
system and intestinal function (Singh et al., 2016 ). Recently, it has
been shown that a dysbiotic gut microbiota is correlated with a
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Significance Statement
Previous studies have shown a bidirectional communication along the gut– brain axis after stroke. Stroke alters the gut microbiota
composition, and in turn, microbiota dysbiosis has a substantial impact on stroke outcome by modulating the immune response.
However, until now, the mediators derived from the gut microbiome affecting the gut-immune-brain axis and the molecular
mechanisms involved in this process were unknown. Here, we demonstrate that short-chain fatty acids, fermentation products of
the gut microbiome, are potent and proregenerative modulators of poststroke neuronal plasticity at various structural levels. We
identified that this effect was mediated via circulating lymphocytes on microglial activation. These results identify short-chain
fatty acids as a missing link along the gut– brain axis and as a potential therapeutic to improve recovery after stroke.




worsened outcome in patients (Xia et al., 2019), and that these
changes are evident up until 3 weeks after hospitalization (Swidsin-
ski et al., 2012). We have previously demonstrated an important role
of the gut microbiome on stroke outcome in proof-of-principle
experiments using germ-free and recolonized mice (Singh et al.,
2018). Further experimental studies in rodent stroke models have
identified a key role for the immune system, particularly brain-
invading lymphocytes originating from the intestinal immune
compartment, in mediating along the gut– brain axis (Benakis et
al., 2016; Singh et al., 2016).
The gut microbiome produces a large number of bioactive
metabolites which may affect brain function via modulating the
immune system or afferent neuronal pathways (Kau et al., 2011;
Cryan and Dinan, 2012). In particular, the metabolite group of
short-chain fatty acids (SCFAs) acetate, butyrate, and propionate
have been shown to readily cross the blood– brain barrier (Frost
et al., 2014; Morrison and Preston, 2016) and affect brain func-
tion in development, health, and disease. For example, SCFA
treatment improved the disease course in experimental autoim-
mune encephalitis by promoting anti-inflammatory mechanisms
and reducing axonal damage (Haghikia et al., 2015). In mouse
models of chronic stress, mice that received SCFA treatment
exhibited significant improvements in antidepressant and anxi-
olytic behaviors, which was accompanied by reduced plasma cor-
ticosterone levels and differential gene regulation (van de Wouw
et al., 2018).
More recently, the role of SCFAs in modulating the immune
system has been studied in great detail. Through these investiga-
tions, they have been shown to play a role in the polarization of
T cells in the intestinal immune compartment and inducing anti-
inflammatory T-cell subset (Smith et al., 2013; Tan et al., 2016).
Other studies have shown a critical role for microbiota-derived
SCFAs in the maturation of microglial cells, the brain’s resident
immune cells (Erny et al., 2015). However, SCFAs can have far-
reaching pleiotropic effects also beyond the immune system, in-
cluding a direct effect on neuronal function through their potent
function as histone deacetylase inhibitors (Bourassa et al., 2016).
Accordingly, the importance of SCFA function has been impli-
cated in neurodegenerative diseases and even in postischemic
neurogenesis (Chuang et al., 2009; Kim et al., 2009).
Despite the key contribution of the gut microbiome to stroke
outcome and the identification of SCFA as one of the micro-
biome’s primary bioactive mediators, the role of SCFAs and their
potential therapeutic use for poststroke recovery in the chronic
phase after brain ischemia have not yet been investigated. In this
study, we comprehensively investigated the effect of SCFA ad-
ministration on poststroke recovery using advanced behavior
analyses, in vivo wide-field calcium imaging, transcriptomic studies,
and histological analyses to study and link SCFA-mediated recovery
mechanisms from the molecular level up to behavior.
Materials and Methods
Animals and treatment. All experimental protocols were approved by the
responsible governmental committees (Regierung von Oberbayern,
Munich, Germany and Institutional Animal Care and Use Committee,
University of Texas Southwestern, Dallas). Specific pathogen-free
C57BL/6J female and male mice were purchased from Charles River
Laboratories or The Jackson Laboratory. On the day of arrival, mice were
6 – 8 weeks of age. Male mice were used for all experiments, except for
analysis of dendritic spine densities (see Fig. 2A–F ), in which female mice
were used. Mice were given SCFAs (25.9 mM sodium propionate, 40 mM
sodium butyrate, and 67.5 mM sodium acetate) or salt-matched control
(133.4 mM sodium chloride) (9265.1, ROTH) in drinking water ad libi-
tum for 4 weeks as previously reported (Smith et al., 2013; Erny et al.,
2015). Mice were continuously given supplemented water until the end
of the experiment. For antibiotic treatment, mice received metronidazol
0.5 mg/ml (Millipore Sigma, #46461), neomycin 0.5 mg/ml (Millipore
Sigma, # N1142), ampicillin 0.5 mg/ml (Millipore Sigma, #31591), and
vancomycin 0.5 mg/ml (Millipore Sigma, #V8138) and with 5% sucrose
in drinking water. All drinking water solutions were prepared and
changed twice a week and blinded for experimenters.
Experimental stroke model. For the photothrombotic stroke model
(PT), mice were anesthetized with isoflurane, delivered in a mixture of
30% O2 and 70% N2O. Mice were placed into a stereotactic frame; and
throughout the surgical procedure, body temperature was maintained at
37°C with a mouse warming pad. Dexpanthenol eye ointment was ap-
plied to both eyes. A skin incision was used to expose the skull. Bregma
was located and using the laser the lesion location was marked in the left
hemisphere (1.5 mm lateral and 1.0 mm rostral to bregma). Mice were
then injected intraperitoneally with Rosa Bengal (Millipore Sigma,
#198250). Shielding was placed on the skull, allowing a 2-mm-diameter
circular exposure over the lesion area. After 10 min, the laser (Cobolt Jive,
561 nm, 25 mV output power with fiber collimation at f ! 7.66 mm) was
applied to the lesion area for 17 min.
For the distal, permanent occlusion of the middle cerebral artery
(dMCAo), the distal middle cerebral artery (MCA) was permanently
electrocoagulated as previously described (Llovera et al., 2014). In brief,
under isoflurane anesthesia, mice were placed in the lateral position. A
skin incision was made to expose the skull. Using a drill, a burr hole into
the skull revealed the bifurcated MCA. Using electric forceps, the artery
was occluded and checked for no blood flow. Mice were then sutured
across the skull incision.
For the filament, transient occlusion of the MCA (fMCAo), the inter-
nal carotid artery was transiently occluded for 60 min as previously
described (Singh et al., 2016). In brief, mice were anesthetized with iso-
flurane, and an incision was made to expose the temporal bone. A laser
doppler probe was affixed to the MCA territory to determine blood flow.
Mice were included when a "80% cerebral blood flow drop was induced.
At the neck, an incision to the skin exposed the common carotid and
external carotid artery, which were ligated. The filament was inserted
into the internal carotid artery for 60 min, and the MCA was occluded.
Mice were sutured across the neckline. In total, 13 mice per group were
used. In the control group, 8 mice died. In the SCFA-supplemented
group, 3 mice died and 3 mice had no quantifiable infarct.
After all surgeries, mice were recovered in a nursing box at 37°C for
15 min and then returned to home cages.
Wide-field calcium imaging. In vivo wide-field calcium imaging was
performed as previously published (Cramer et al., 2019). Briefly, we used
Thy1GCaMP6s heterozygous reporter mice. Mice were scalped, and
transparent dental cement was placed upon the intact skull at least 3 d
before the start of the experiment. Resting-state in vivo imaging was
performed under mild anesthesia (0.5 mg/kg body weight of medetomi-
din with 0.75% isoflurane inhalation). Mice were placed in a stereotactic
frame below a customized macroscopic imaging setup, and the mouse
cortex was illuminated with 450 nm blue LED light. We recorded for 4
min in resting state with a CCD camera at 25 Hz frame rate. Functional
connectivity was computed for seed-based analysis with a seed pixel time
series centered in the right caudal forelimb cortex, contralesional to the
infarcted cortex. Pearson’s correlation between the time course of this
seed, and any other signal time course within the masked area was
computed; then Fisher’s z-transformed and topographically displayed.
Analogous functional connectivity between seed pairs was calculated as
correlation between signal time courses of two seeds within the sensori-
motor cortex. Seeds were defined as previously described (Cramer et al.,
2019). Mean correlation per group was calculated for each time point. We
used two-sample t test and Bonferroni correction for statistical testing.
Automated skilled reaching. Behavioral training and assessments were
measured using an automated reach task previously described (Becker et
al., 2016). Mice are trained to pull an isometric lever using the contral-
esional forelimb, with each successful application of force criteria re-
warded by a drop of peanut oil. For the first week, mice were trained in
groups of 23 littermates for 6 h. During this time, spontaneous peanut oil
deliveries occurred at randomly spaced time intervals ranging from 30 s




to 5 min. Additionally, the isometric handle was positioned !0.5 cm
from the inner edge of the chamber during these 6 h sessions. The force
criterion necessary to trigger a 4 !l peanut oil droplet was set just above
electrical noise so that any slight touch could trigger peanut oil disper-
sion. For the next 3 weeks, mice were trained individually for 2 h sessions.
The handle was positioned further back at 1 cm from the inner edge of the
chamber. The criterion for success during training sessions was changed
based on a customized, adaptive MATLAB program. The adaptive pro-
gram initially set the criterion for success at a specified value of at least 1 g.
After the first 15 pulls, the criterion was adjusted to the median force
value. The adjustments continued for the duration of the session unless
the median reached the maximum force requirement of 20 g. Finally, we
fixed the criterion at 20 g to measure baseline motor function for three
consecutive sessions. After stroke, assessments of reaching behaviors
were measured weekly for 6 weeks.
SCFA quantification. Mice were saline perfused, and organs extracted.
For feces, colon content was collected; and for plasma, cardiac puncture
blood was centrifuged at 4°C at 3000 rpm and the plasma removed. All
samples were frozen immediately on dry ice. SCFAs (acetic, propionic,
and butyric acid) were determined according to published protocols,
using gas chromatography-mass spectrometry (Hoving et al., 2018).
Briefly, for plasma, 10 !l was used and feces were homogenized with
LC-MS grade water in a bead beater. Samples were spiked with deu-
terated internal standards for each SCFA. Subsequently, SCFAs were
derivatized using pentafluorobenzyl bromide and analyzed using gas
chromatography-electron capture negative ionization in single ion mon-
itoring mode. Quantification was performed against external calibration
lines.
Infarct volumetry. After saline perfusion, the brain was removed from
the skull and placed immediately on dry ice. Microscopy slides were
mounted with 20-!m-thick coronal cryosections cut at 400 !m intervals
for dMCAo and fMCAo lesions, and at 120 !m intervals for PT lesions.
Sections were then stained with cresyl violet solution. For the infarct
volume, all slides were scanned using 600 dpi. The area of infarct tissue
was measured using the ImageJ software (National Institutes of Health)
and integrated for calculation of infarct volume.
Spine density analysis. Following saline perfusion, mice were perfused
with aldehyde fixative solution (Bioenno, #003780). Brains were then
carefully removed and placed in fixative solution at 4°C overnight. Brains
were then sliced at 100-!m-thick vibratome sections and immersed in
impregnation solution (Bioenno, sliceGolgi Kit, #003760) for 5 d. Fur-
ther staining was performed as described by the manufacturer (Bio-
enno). Images of dendrites were obtained at the same anatomical level for
all brains, 400 !m from the lesion perimeter in cortical layer 2/3. In total,
5 dendrites from 5 neurons each in both hemispheres were imaged
(100" brightfield). Dendrites from the images were then reconstructed
using Imaris "64 (version 8.4.0, Bitplane).
Immunohistochemistry. Mice were perfused with saline and then 4%
PFA. Brains were removed and postfixed in 4% PFA at 4°C overnight.
Brains were then dehydrated in 30% sucrose in 1" PBS. Microglia stain-
ing was performed on 100-!m-thick sections using rabbit anti-iba1 (1:
200, Wako, #019-19741), and then goat anti-rabbit 594 (1:200, Thermo
Fisher Scientific, #A-11012). Automated analysis of microglial cell
counts and morphology was performed using a MATLAB-automated
morphology protocol as previously described (Heindl et al., 2018). For
microglial costaining, we used anti-CD68 (1:300, Bio-Rad, #MCA1957GA),
anti-inducible nitric oxide synthases (iNOS) (1:300, Thermo Fisher Sci-
entific, #MA5-17139), and anti-Arginase1 (1:300, Novus Biologicals,
#NB100-59740SS), and the corresponding secondary antibodies. Cover-
age analysis was performed using ImageJ software. Quantification was
done for overlapping activation markers with Iba-1 from the maximum
intensity projections generated from z stacks of the ipsilateral cortex. For
synaptic staining, sections were incubated with guinea pig anti-VGlut1
(1:1000, Millipore, #AB5905) and chicken anti-Homer1 (1:2000, Synap-
tic Systems, #160006) for 3 d at 4°C, and then counterstained with goat
anti-guinea pig 488 (1:500, Invitrogen, #A11073) and goat anti-chicken
647 (1:500, Invitrogen, #A21449) for 18 h at room temperature. For
synaptic puncta analysis, a z stack of 3 slices at 0.33 !m was used as
previously described (Ippolito and Eroglu, 2010) using FIJI with the
SynapseCounter plugin (Schindelin et al., 2012).
Flow cytometric analysis. Following saline perfusion in deep anesthesia,
the entire spleen and both brain hemispheres were dissected. Spleens
were immediately placed on ice-cold 1" PBS, passed through a 40 !m
cell strainer, and treated with red blood cell lysis buffer. Cell surface
markers were stained using the following antibodies: anti-CD3 FITC
(clone 17A2) and anti-CD45 eFluor450 (clone 30-F11). Stained cells
were analyzed on a BD FACSVerse flow cytometer (BD Biosciences) and
analysis performed by FlowJo software (version 10.0). For brain, hemi-
spheres were isolated and cells isolated by mechanical dissociation.
Mononuclear cells were enriched using discontinuous Percoll gradient
centrifugation by standard protocols and then with 30 !m cell strainer,
as described previously (Benakis et al., 2016). Cell staining for flow cy-
tometry was performed by first preincubation of cells with Fc receptor
blocker (1:100, Invitrogen, 14 –91-61–73) for 10 min and then staining
with the following monoclonal antibodies: anti-CD3 FITC (clone 17A2),
anti-CD45 eFluor450 (clone 30-F11), and anti-CD11b Pe-Cy7 (clone
M1/70). Stained cells were analyzed on a BD FACSVerse flow cytometer
(BD Biosciences) and analysis performed by FlowJo software (version
10.0).
RNA sequencing and data analysis. Fourteen days after stroke, brains
were extracted from the skulls and placed into a stainless-steel brain
matrix. Brains were sliced coronally at 2 mm distance caudally and ros-
trally away from the lesion. The cortex was removed, frozen on dry ice,
and the mRNA isolated using the RNeasy Mini Kit (QIAGEN, #74109).
For library preparation, 100 ng of total RNA was fragmented and
processed using the Ovation Human FFPE RNA-Seq Library Systems
(Nugen) according to the instructions of the manufacturer.
Barcoded libraries were quantified using the Library Quantification
Kit-Illumina/Universal (KAPA Biosystems). Cluster generation was per-
formed with a concentration of 10 nM using a cBot (Illumina). Sequenc-
ing of 2" 100 bp paired-end reads was performed with a HiScanSQ
sequencing platform (Illumina) using version 3 chemistry at the se-
quencing core facility of the IZKF Leipzig (Faculty of Medicine, Univer-
sity Leipzig, Leipzig, Germany). Raw reads were mapped to the reference
genome mm10 using split-read mapping algorithm implemented in
segemehl (Hoffmann et al., 2009). Mapped reads were counted using
feature Counts (Liao et al., 2014) according to RefSeq annotation. Dif-
ferential expression was computed using DESeq2 algorithm (Love et al.,
2014). Raw data have been deposited at Gene Expression Omnibus da-
tabase (Accession number GSE131788).
RT-PCR. mRNA from brain tissue around the lesion was isolated as
described above and transcribed using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, #4368814) with Rnasin Plus
RNase Inhibitor (Promega, #N2611). The following primers were used:
BDNF (forward: CGGCGCCCATGAAAGAAGTA; reverse: AGACCT
CTCGAACCTGCCCT), TrkB (forward: ACTTCGCCAGCAGTAG-
CAG; reverse: ACCTCAGGGCTGGGGAG), synaptophysin (forward:
AGTACCCATTCAGGCTGCAC; reverse: CCGAGGAGGAGTAGTCA
CCA), EphrinA5 (forward: CTGGTGCTCTGGATGTGTGT; reverse:
CCCTCTGGAATCTGGGGTTG), PPIA (forward: ACACGCCATAATG
GCACTGG; reverse: ATTTGCCATGGACAAGATGCC), Claudin-5
(forward: GTTAAGGCACGGGTAGCACT; reverse: TACTTCTGTG
ACACCGGCAC), ICAM-1 (forward: CAATTTCTCATGCCGCACAG;
reverse: AGCTGGAAGATCGAAAGTCCG), and VCAM-1 (forward:
TGAACCCAAACAGAGGCAGAG; reverse: GGTATCCCATCACTTG
AGCAGG). The QuantiNova SYBR Green PCR Kit (QIAGEN, #208052)
was used with a LightCycler 480 II (Roche Diagnostics). All gene expres-
sion was expressed relative to the PPIA housekeeping gene and calculated
using the relative standard curve method.
Experimental design and statistical analysis. All statistical analyses were
performed using Prism software (GraphPad, version 6.0). Sample size
was chosen based on comparable experiments from previous experi-
ments (Singh et al., 2016). For experimental design details on sample size,
see Results and figure legends. A p value of #0.05 was regarded as statis-
tically significant.





SCFA supplementation improves recovery and cortical
reorganization after stroke
We previously showed that stroke induces dysbiosis of the gut
microbiome with the hallmark of reduced bacterial diversity
(Singh et al., 2016). To test the impact of poststroke gut dysbiosis
on the metabolic function of the microbiome, we performed tar-
geted analysis of plasma samples for SCFA concentrations after
fMCAo stroke and sham surgery in mice by mass spectrometry.
This analysis revealed significantly reduced plasma SCFA con-
centrations 3 d after fMCAo stroke surgery compared with sham-
operated mice (Fig. 1-1A, available at https://doi.org/10.1523/
JNEUROSCI.1359-19.2019.f1-1). Therefore, we hypothesized
that supplementation of SCFA would increase circulating SCFA
concentrations and potentially induce therapeutic effects within
the chronic poststroke recovery period. To test this hypothesis,
we supplemented mice for 4 weeks with drinking water contain-
ing either a mix of acetate, butyrate, and propionate (for details,
see Materials and Methods) or control drinking water with matched
sodium chloride concentration. SCFA supplementation did not
affect body weight (Fig. 1-1B, available at https://doi.org/
10.1523/JNEUROSCI.1359-19.2019.f1-1) or overt behavior of
the animals. We performed PT stroke surgery after 4 weeks of
SCFA supplementation and assessed poststroke motor deficits
of the affected forelimb with an automated lever pull test while
animals received further SCFA supplementation during the
complete survival period (Fig. 1A,B). Mice receiving SCFA sup-
plementation performed significantly better compared with
control-treated animals (Fig. 1B). A two-way ANOVA for re-
peated measurements revealed an overall p value of 0.01 for the
treatment effect, and a significant difference (after correction for
multiple comparisons) between treatment groups at 56 d after
stroke (Fig. 1B). To analyze cortical network plasticity as the
morphological surrogate of behavioral recovery, we used Thy1-
GCaMP6s mice and performed resting-state in vivo calcium to
record cortical wide-field fluorescence from a neuronal based
calcium reporter. Using the homotypical contralesional region of
the cortex, we performed seed-based correlation analysis, indi-
cating the connectivity strength (z score) of this area to every
other pixel in the cortex (Fig. 1C). Previous research using fMRI
in stroke patients has indicated that the homotypical contral-
esional region receives less neuronal inhibition from the stroked
hemisphere, leading to disinhibition of the contralesional hemi-
sphere (Rehme and Grefkes, 2013). To analyze the size of highly
connected homotypical contralesional regions (i.e., the contral-
esional motor cortex), we measured the area of pixels with a z
score ! 2.25 (Fig. 1D). We observed a significantly reduced area
of the contralesional motor cortex in SCFA- compared with
control-treated mice at D21 and D42 (Fig. 1E). In contrast, SCFA
treatment did not significantly affect the primary infarct area by
in vivo imaging (Fig. 1-1C, available at https://doi.org/10.1523/
JNEUROSCI.1359-19.2019.f1-1) and histological analyses with in-
farct volumetry in three different focal stroke models after stroke
(Fig. 2-1A-E, available at https://doi.org/10.1523/JNEUROSCI.
1359-19.2019.f2-1). These results indicated that, while SCFA
supplementation did not affect the initial lesion development,
SCFAs improved behavioral stroke outcome and modulated cor-
tical network plasticity at later stages after stroke.
Figure 1. SCFA supplementation improves recovery after stroke. A, Schematic diagram illustrating the timeline of SCFA supplementation and analysis time points. BL, Baseline; D, day (after
stroke). See Figure 1-1 (available at https://doi.org/10.1523/JNEUROSCI.1359-19.2019.f1-1). B, Representative images obtained during the lever pull test of trained mouse successfully reaching for
the lever (left, above) and obtaining the peanut oil reward (left, below). Right, Normalized success rate for lever pulls by the affected (contralesional) forelimb. Relative values are shown per time
point normalized to the mean of the control group. N " 8 per group. Horizontal line indicates mean. Two-way repeated measure ANOVA with Holm–Sidak’s post hoc test. C, Topographic depiction
of seed-based functional connectivity of both hemispheres at indicated time points of SCFAs and control-treated mice. Seed is placed in the homotypic contralesional region to the ipsilesional lesion
area (i.e., the contralesional motor cortex). Color code represents Fisher’s z correlation between the seed and every other pixel in the cortex. D, Enlarged images of the contralesional motor cortex
(region homotypic to the infarct lesion). Area highlighted with dotted line represents the highly connected functional motor cortex area (pixels with Fisher’s z values ! 2.25). E, Quantification of
highly correlated (Fisher’s z ! 2.25) area of the contralesional motor cortex in control (open bars) and SCFA-treated mice (gray bars). N " 15 per group. Multiple t tests per time point with
Holm–Sidak’s correction for multiple testing.




SCFA supplementation modulates poststroke
synaptic plasticity
After an ischemic brain injury, the entire cortex undergoes rapid
functional and morphological reorganization, including neuro-
nal dendritic plasticity, which allows adult neurons to form new
connections. This process is correlated with improved functional
connectivity after a cortical lesion (Jones and Schallert, 1994;
Biernaskie et al., 2004). To analyze underlying morphological
plasticity of the observed functional recovery in behavior and
cortical connectivity, we performed Golgi-Cox staining of brain
sections to investigate the effects of SCFA supplementation on
dendritic spine density of pyramidal cells (Fig. 2A,B). We ini-
tially performed this analysis in the brains of naive animals that
received either SCFA or control treatment, which revealed a
higher pyramidal cortical spine density in the SCFA-treated mice
(Fig. 2C). Next, we quantified brains at 14 d after PT stroke to
capture a time period before the behavioral and cortical connec-
tivity improvements were evident. Correspondingly, we observed
Figure 2. Poststroke neuronal plasticity is altered by SCFA treatment. A, Representative images of Golgi-Cox stained brain sections 14 d after PT stroke (Figure 2-1 A–E, available at https://
doi.org/10.1523/JNEUROSCI.1359-19.2019.f2-1). Dotted area in overview image represents perilesional cortical area used for spine analysis. Magnifications show representative pyramidal neuron
and high-magnification image as used for spine analysis. Top right, Cortical pyramidal neuron. Bottom right, Example of spines identified on dendrite. Scale bar, 10 !m. B, 3D reconstruction for a
dendrite section with spines as used for further quantification of spine densities and lengths. Scale bar, 2 !m. C, Quantification of pyramidal spine density per 10 !m of dendrite in the cortex of
control and SCFA-treated naive mice (no stroke induction). Each color represents a different mouse, and each dot indicates a different dendrite. Five neurons per hemisphere analyzed in total for 4
or 5 mice per group (Mann–Whitney U test). D, Quantification of spine density per 10 !m of dendrite in the perilesional and contralesional cortex at 14 d after stroke (Kruskal–Wallis test with Dunn’s
correction for multiple comparisons). E, Histogram of the relative frequency (fraction) of spines found at different lengths 14 d after PT lesion in the perilesional cortex. Bin width is 0.2 !m (Figure
2-1 F, G, available at https://doi.org/10.1523/JNEUROSCI.1359-19.2019.f2-1). F, Quantification of short (0.2 !m) and long (1.4 !m) spines in control (open bars) and SCFA (gray bars) treated mice.
N ! 4 or 5 per group. Mann–Whitney U test. G, Representative particle images of presynaptic terminals by VGlut1 (green), postsynaptic densities by Homer1 (red), and nuclei with DAPI (blue) of
the cortex from control and SCFA-treated mice, as used for quantification of colocalized presynaptic and postsynaptic particles (puncta). Scale bar, 20 !m. Arrowheads indicate colocalized (yellow)
puncta. H, Synapse counts were quantified as colocalized VGlut1 and Homer1 puncta (Figure 2-1 H, available at https://doi.org/10.1523/JNEUROSCI.1359-19.2019.f2-1). Quantification for colocal-
ization (left) and for single markers (middle and right) revealed significantly changed synapse counts as a result of the reduced number of VGlut1 " terminals in the perilesional cortex. contra,
Contralesional hemisphere; ipsi, ipsilesional hemisphere. N ! 3 or 4 mice (3 sections per mouse). Statistical analysis was performed with Kruskal–Wallis test with Dunn’s multiple comparison
correction. I, Relative expression (RE) of mRNA for key molecules involved in synaptic plasticity (left), synaptophysin (left middle), TrkB (right middle), and EphA5 (right) BDNF from the perilesional
cortex in control (open bars) and SCFA (gray bars) treated mice. N ! 7 per group. Mann–Whitney U test.




that, after stroke, SCFA supplementation was associated with a
significantly higher spine density in the homotypic contralesional
region; however, these differences were not observed in the ip-
silesional hemisphere (Fig. 2D) and were independent of infarct
volume (Fig. 2-1, available at https://doi.org/10.1523/JNEUROSCI.
1359-19.2019.f2-1). Moreover, the analysis of spine length distri-
bution revealed that SCFA treatment induced a shift toward
shorter spine lengths, specifically in the ipsilateral, but not
contralesional, hemisphere (Fig. 2 E, F; Fig. 2-1 F, G, available
at https://doi.org/10.1523/JNEUROSCI.1359-19.2019.f2-1). To
further investigate synaptic plasticity under control of SCFA sup-
plementation, we assessed synaptic density using costaining for
VGlut1 (presynaptic) and Homer1 (postsynaptic) (Fig. 2G). We
detected a significant reduction of the number of synapses (i.e.,
colocalized VGlut1 and Homer1 puncta) in the perilesional cor-
tex of SCFA-supplemented mice (Fig. 2H). Interestingly, the dif-
ference in synapse counts was exclusively driven by the number of
presynaptic VGlut1 puncta while Homer1-positive puncta re-
mained unaffected.
Additionally, this pattern was also mirrored in the mean size
of VGlut1 and Homer1 puncta (Fig. 2-1H, available at https://
doi.org/10.1523/JNEUROSCI.1359-19.2019.f2-1). Finally, we
analyzed the transcriptional regulation of key factors involved in
synaptic plasticity (Fig. 2I). We observed that SCFAs significantly
increased the expression of the presynaptic vesicle molecule syn-
aptophysin and the BDNF receptor TrkB. BDNF itself, or the
receptor tyrosine kinase EphA2, was not affected by SCFA sup-
plementation. These results indicate effects of SCFA on morpho-
logical, synaptic plasticity, which could potentially precede the
effects observed on functional recovery at later time points after
stroke.
Brain transcriptomic analysis indicates microglia as the main
cellular target of SCFA
To determine whether the observed effects of SCFA were either
directly mediated on neuronal function or affecting other cere-
bral cell populations, we took an unbiased approach to investi-
gate the effects of SCFA on gene expression in the peri-infarct
cortex. For this, we first depleted the gut microbiome of mice as
the main SCFA source by administration of antibiotics, followed by
supplementation of SCFA (Fig. 3A). Plasma gas chromatography-
mass spectrometry quantification confirmed an increase of SCFA
Figure 3. SCFA supplementation affects microglial gene signature after stroke. A, Schematic diagram illustrating antibiotic (ABX) treatment regimen and followed by supplementation with
SCFAs or control saline in drinking water (Figure 3-1, available at https://doi.org/10.1523/JNEUROSCI.1359-19.2019.f3-1). Delineated area on histological image represents perilesional cortex
isolated for mRNA sequencing. B, Volcano plot of regulated transcripts (SCFAs/control) in the perilesional cortex 14 d after PT stroke; n ! 3 per group. Black represents gene transcripts. Orange
represents gene transcripts with fold change (log2) " 1 and #log10-adjusted p $ 0.1. C, Heatmap of fold change (log2) for significantly regulated genes with an adjusted p $ 0.1. Each column
represents 1 individual mouse. D, FPKN abundance and association per cerebral cell type of all significantly regulated genes (C) were performed as detailed in Materials and Methods, revealing the
strongest association of the significantly regulated genes with microglial cells. E, Ingenuity pathway analysis showing the top networks regulated by SCFA supplementation compared with control
treatment.




after supplementation in drinking water (Fig. 3-1, available at
https://doi.org/10.1523/JNEUROSCI.1359-19.2019.f3-1). Four-
teen days after surgery, the infarct and peri-infarct regions were
isolated for RNA sequencing, identifying 18 upregulated and 20
downregulated genes in SCFA supplemented mice (Fig. 3B,C).
The list of the top upregulated genes (Fig. 3C) hinted at a role
for microglia as we found numerous genes that have previously
been reported to be involved in microglial function and/or acti-
vation, such as Ctsd, various complement molecules, Tyrobp and
Laptm5 (Zhong et al., 2018; Q. Li et al., 2019). To ascertain which
cell type SCFA supplementation was mainly regulating in the
brain, we took the 38 differentially regulated genes and compared
them with an existing RNA-Seq database, which lists the frag-
ments per kilobase of exon model per million reads found in astro-
cytes, neurons, oligodendrocytes, microglia, and endothelial cells
(www.brainrnaseq.org) (Zhang et al., 2014). From the total number
of fragments per kilobase of exon model per million read values of
the 38 differentially regulated genes (Table 1-1, available at https://
doi.org/10.1523/JNEUROSCI.1359-19.2019.t1-1), we discovered
that the vast majority of gene reads from the significantly regu-
lated genes were associated with microglial cells (Fig. 3D). Addi-
tionally, we performed an ingenuity pathway analysis on the 38
differentially regulated genes and found that the complement
system was the top pathway and highly upregulated in mice sup-
plemented with SCFA (Fig. 3E). Within the brain, the comple-
ment pathway is critical for microglia activation and has been
associated with synaptic pruning by microglia (Schafer et al.,
2012; Stephan et al., 2012; Wu et al., 2015).
SCFAs modulate microglial activation and immune
cell composition
Based on the transcriptomic data’s indication that microglia are
the effector of SCFA-mediated poststroke recovery, we performed
more in-depth analyses of microglial activation and the inflamma-
tory response to stroke. As a surrogate of microglia activation, we
performed Iba-1 immunohistochemistry of the cortex (Fig. 4A)
and assessed microglia morphology using automated analysis
(Heindl et al., 2018). Fourteen days after stroke, cortical micro-
glia from SCFA-supplemented mice displayed a significantly
more ramified and less spherical (i.e., less activated) morphology
compared with controls (Fig. 4B). Additionally, the total number
of microglia were significantly reduced in SCFA- compared with
control-treated mice (Fig. 4C). These results indicate a modula-
tion of the microglial response to stroke by SCFAs. Therefore, we
further explored microglial function by assessing classical histo-
logical markers for microglial activation and polarization. We
observed a significant reduction of CD68 expression in Iba-1!
microglia (Fig. 4D), whereas Arginase-1 and iNOS were not sig-
nificantly regulated by SCFA supplementation (Fig. 4E). Aside
from evoking a microglial response, stroke induces invasion of
peripheral immune cells into the brain parenchyma, which can
deteriorate stroke outcome (Iadecola and Anrather, 2011; Liesz et
al., 2015; Neumann et al., 2015; Selvaraj and Stowe, 2017). In
particular, lymphocyte counts in brains after photothrombosis
are still elevated 14 d after surgery (Feng et al., 2017). Addition-
ally, cytokines secreted by brain-invading lymphocytes can mod-
ulate microglial activation (Liesz et al., 2009; Meng et al., 2019).
Therefore, we performed flow cytometry of brain homogenates
(Fig. 4F) and observed a significant reduction in cerebral lym-
phocyte invasion in SCFA-treated animals compared with con-
trols (Fig. 4G).
The invasion of peripheral lymphocytes to the ischemic brain
depends on the number of circulating lymphocytes, the expres-
sion of cerebral endothelial adhesion molecules, and the chemo-
kine gradient derived from the injured brain tissue (Ransohoff
and Engelhardt, 2012). In accordance with our nontargeted tran-
scriptomic analysis (for results, see Fig. 3), which did not reveal
significant regulation of chemokines or adhesion molecules by
SCFAs, also a targeted PCR analysis of key adhesion molecules
and tight junction proteins involved in poststroke lymphocyte
recruitment at the blood– brain barrier did not show a significant
regulation by SCFA (Fig. 4-1, available at https://doi.org/10.1523/
JNEUROSCI.1359-19.2019.f4-1). In contrast, we detected a signif-
icant reduction of systemic T-cell counts by SCFA supplementation
in the spleen (Fig. 4H), a secondary lymphatic organ that well
characterizes the systemic immune response after stroke (Offner
et al., 2006; Liesz et al., 2013; Roth et al., 2018).
These findings suggest that SCFAs may primarily affect lympho-
cytes already in the peripheral immune compartments, which then
might secondarily mediate changes in the cerebral immune milieu
after brain invasion. Therefore, we next aimed to test this hypoth-
esis by investigating the effects of SCFA on microglia in the ab-
sence of lymphocytes. For this, we used lymphocyte-deficient
Rag1"/" mice, which were given SCFA supplementation or con-
trol drinking water. In contrast to lymphocyte-competent WT
mice, SCFA supplementation in Rag1"/" did neither affect mi-
croglia morphology, nor did it reduce microglial cell counts (Fig.
4 I, J), indicating a key role of lymphocytes for mediating the
SCFA effects on microglia.
Discussion
This study demonstrates that SCFAs, critical metabolites derived
from the gut microbiome, are capable of improving poststroke
recovery via the modulating effects of brain-invading lympho-
cytes on microglial function. Results from our study support this
conclusion through several key findings. First, stroke lowers blood
SCFA concentrations. Second, SCFA supplementation combats the
deleterious effects of this poststroke response, which we demon-
strated by associated SCFA supplementation with improved
behavioral recovery, changes in cortical network connectivity,
which are generally associated with improved stroke outcomes,
and changes in histological markers of synaptic plasticity. Third,
we indicated a potential mechanism for the observed improve-
ments in the recovery of SCFA-treated animals by finding changes in
microglial function, which were dependent on circulating lym-
phocytes. Consequently, these findings indicate that SCFAs affect
peripheral lymphocytes, maturation, or egress from primary
lymphatic tissue, and lymphocytes then indirectly mediate the
SCFA effects on the brain micromilieu either by their overall
reduction in cerebral invasion or polarization of the secreted cy-
tokine profile.
These novel findings introduce SCFA as the most likely miss-
ing link in the pathophysiological function of the gut– brain axis
in stroke and poststroke recovery, for which the microbiota-
derived effector molecules were so far unknown (Benakis et al.,
2016; Houlden et al., 2016; Singh et al., 2016). Our use of a novel
imaging modality, in vivo wide-field calcium imaging, provided a
highly sensitive tool for assessing cortical network plasticity after
stroke (Cramer et al., 2019). This tool allowed us to perform
analyses of network plasticity by comparable analytical ap-
proaches to fMRI in patients, with the exception of using a genet-
ically encoded reporter for direct neuronal activation instead of
the blood flow surrogate marker (BOLD) used in MRI (Cramer et
al., 2019). The analysis of connectivity within the cortical net-
work provides information about the dynamic changes in de-
fined cortical areas under resting-state conditions, which gave us




a unique ability to measure even the more subtle effects of SCFA
supplementation on poststroke plasticity.
In human stroke patients, interhemispheric resting-state con-
nectivity is significantly weakened following stroke. Specifically,
it is thought that inhibitory projections from the lesioned hemi-
sphere to the homotypic contralesional hemisphere are attenu-
ated, leading to a disinhibition of the homotypic area in the
contralesional hemisphere (Rehme and Grefkes, 2013). We con-
firmed this effect with our optogenetic imaging approach, by
observing an increase in the contralesional motor cortex area
as an indicator of reduced transhemispheric inhibition. This
“blooming” effect of the contralesional motor cortex was signif-
icantly ameliorated by the SCFA treatment at chronic time points
after stroke, which could indicate an improvement of interhemi-
spheric connectivity and thereby reestablish inhibition of the
contralesional hemisphere. However, the further in-depth explo-
ration of such interhemispheric inhibition is impeded by several
technical limitations of our imaging tool, such as autofluorescent
artifacts in the perilesional territory and the lack of directional
information of the interhemispheric connections. This would re-
quire in vivo electrophysiological studies on connectivity between
the recovering perilesional tissue and the homotypic contral-
esional brain area, which are currently not yet established in
stroke research. The functional relevance for the changes within
connectivity was ultimately confirmed by the corresponding ben-
eficial effects of SCFAs on recovery of motor functions. Behav-
ioral recovery was assessed in a highly sensitive, rater-blinded,
and high-throughput automated test, specifically analyzing mo-
Figure 4. Modulation of poststroke neuroinflammation by SCFA depends on peripheral lymphocytes. A, Representative maximum intensity projections of microglial staining using Iba-1 (red) and
DAPI (blue) in the ipsilesional hemisphere 14 d after PT stroke with either control (left) or SCFA (right) supplementation. B, Microglial morphology was analyzed in 3D using an automated analysis
algorithm in the ipsilesional cortex of mice 14 d after stroke, which revealed significantly reduced sphericity (left) and increased number of branch nodes (right) as markers of reduced microglial
activation by SCFA compared with control treatment. Each symbol represents one microglia. Different colors group together microglia from the same mouse. C, Number of microglia found per 1
high-power (40!) FOV in the perilesional cortex. D, Coexpression coverage analysis in the ipsilateral hemispheric cortex for CD68 and Iba-1 expressed as percentage of Iba-1 from a maximum
intensity projection. Representative immunofluorescence image (red represents microglia; green represents CD68) (left) and quantification (right). E, Coexpression coverage analysis in the
ipsilateral hemispheric cortex for iNOS and Arginase1 (Arg1) with Iba-1 expressed as percentage of Iba-1 coverage area from a maximum intensity projection. Representative immunofluorescence
image (red represents microglia; green represents Arg1; cyan represents iNOS) (left) and quantification (right). N " 3 mice per group and 3 images per hemisphere. In contrast to the effects of SCFA
on microglia function, endothelial cells were unaffected by the SCFA treatment (Figure 4-1, available at https://doi.org/10.1523/JNEUROSCI.1359-19.2019.f4-1). F, Representative gating strategy
for flow cytometric analysis of T cells (CD45 #CD3 #). SCFA supplementation significantly decreased the frequency of T cells in (G) brains and (H ) spleens 14 d after stroke. N " 9 per group.
Quantification of (I ) sphericity (left) and ramification index (right) and (J ) absolute cell counts of microglia 14 d after stroke in the perilesional cortex of Rag1 $/$ mice. In contrast to WT
mice (compare with B,C), SCFA treatment did not affect microglia activation in lymphocyte-deficient Rag1 $/$ mice. All statistical analyses in this figure were performed using the
Mann–Whitney U test.




tor deficits of the affected forelimb, hence providing a reliable
readout for poststroke recovery, even in the chronic phase, some-
thing that most conventional behavior tests lose their test sensi-
tivity toward (Zausinger et al., 2000; X. Li et al., 2004; Manwani et
al., 2011; Rosell et al., 2013).
As an independent line of evidence for the effects of SCFA on
poststroke recovery, we detected significant changes in dendritic
spine densities and synaptic counts based on histological analysis.
Previous studies have demonstrated changes in dendritic spine
density of the perilesional cortex as well as contralateral hemi-
sphere and have been identified as a hallmark of poststroke tissue
remodeling and marker of synaptic plasticity (Brown et al., 2008;
Huang et al., 2018). After stroke, it has been shown that there is a
gradual increase of spine density in the contralateral cortex (Huang
et al., 2018), whereas spine density in the peri-infarct region is re-
duced by!38% within the acute phase (Brown et al., 2008). Accord-
ingly, we observed significantly increased spine densities in the
contralateral motor cortex of SCFA-supplemented mice, suggesting
that these microbial metabolites could aid recovery by promoting
dendritic spine plasticity.
A key limitation of the various analysis readouts used in this
study (calcium imaging, spine density, synapse count) is their
exclusive reflection of processes in excitatory neurons. The ex-
pression of GCamp in Thy1-positive neurons, analysis of den-
dritic spines on pyramidal neurons, and the synapse count of
VGlut1-positive (glutamatergic) synapses all limit the analysis to
the excitatory system of the forebrain cortex and do not account
for potential alterations in subcortical structures or the complex
integration of information by (inhibitory) interneurons within
the cortex (Markram et al., 2004). However, the focus on the
excitatory cortical system across the different methodological ap-
proaches allowed us to thoroughly investigate the impact of
SCFAs from a global network perspective (wide-field imaging) to
synaptic (sub)structures within the same system. This approach
revealed a striking alignment of results across different functional
levels from synapse to network plasticity and behavior that strongly
support the impact of SCFAs on poststroke recovery. Despite this,
future studies need to address the intricate regulation of cortical
microcircuits underlying this effect and particularly the role of
the various interneuron types. Another relevant limitation is the
use only of male mice for most of the experiments (except den-
dritic spine analysis). Considering recent evidence for sex-
specific effects along the gut– brain axis and particularly on
microglial activation (Thion et al., 2018; Villa et al., 2018), we
cannot exclude a differential effect of the observed pathway in the
female sex.
The transcriptomic analysis performed in this study indicated
several genes which have previously been associated with micro-
glial activity and phagocytic function to be regulated by SCFAs in
the poststroke recovery phase. In contrast, only a very low amount of
significantly regulated genes by the SCFA supplementation were
enriched for other cell population marker genes, such as neurons
or endothelial cells. Therefore, we hypothesized that the SCFA
effect on poststroke recovery and neuronal plasticity might be
indirectly mediated via microglial activity. Indeed, microglia are
key players involved in synaptic pruning and dendritic remodel-
ing (Salter and Stevens, 2017). Upon proinflammatory stimuli,
microglial activation is associated with a change in cell morphol-
ogy. While homeostatic microglia are highly ramified, activated
cells acquire a more ameboid shape. We observed after stroke an
increase in cell ramification by the SCFA supplementation, indi-
cating a reduced microglial activation state. Interestingly, micro-
glial activation after stroke has previously been associated with
reduced phagocytic capacities (Faustino et al., 2011). Hence,
modification of microglial activation by SCFA could have an im-
pact on synapse elimination and thereby microglia-dependent
synaptic plasticity (Salter and Stevens, 2017). However, micro-
glial elimination (“pruning”) of dendritic synapses is vice versa
associated with synaptic activity (i.e., less active presynaptic in-
puts are more likely to be phagocytosed). Reduced synaptic ac-
tivity in the perilesional cortex due to the tissue injury or in the
contralesional cortex due to loss of transcallosal innervation from
the injured cortex could both induce excessive (pathological)
dendrite pruning (Brown et al., 2008; Riccomagno and Kolodkin,
2015; Salter and Stevens, 2017). This would suggest that dendritic
spine remodeling and microglial activation are a reciprocal, bidi-
rectional interaction of neurons and microglia in the recovering
cortex after stroke. While the results of RNASeq analysis indicate
that SCFAs modulate primarily microglial activation in this pro-
cess, the detailed interaction of neurons and microglia as well as
the directionality of their association will require further experi-
mental studies. Finally, microglia activation has been associated
with neuronal plasticity and function beyond morphological re-
organization and spine remodeling. We have recently demon-
strated that microglia monitor neuronal function at the cell soma
and this somatic interaction are altered during pathology after
stroke (Cserép et al., 2019), a process that could likely contribute
to the functional changes observed in cortical calcium imaging
and behavioral outcomes. However, the contribution of SCFAs
to this somatic cell– cell interaction is so far unknown.
A large part of previous experimental studies with SCFA have
focused on their effect on circulating immune cells. SCFAs mod-
ulate the polarization of lymphocyte subsets, such as the ratio of
anti-inflammatory regulatory T cells (Treg) to proinflammatory
TH17 cells (Arpaia et al., 2013; Haghikia et al., 2015; Park et al.,
2015; Asarat et al., 2016), as well as their migratory behavior
between organs (Nakamura et al., 2017). Importantly, lympho-
cyte invasion to the ischemic brain is a hallmark of poststroke
neuroinflammation (Iadecola and Anrather, 2011). It is therefore
likely that SCFAs may not exclusively act directly on resident
microglia per se, but also via the peripheral effects of SCFAs,
which change lymphocyte function. The altered peripheral lym-
phocytes later invade the injured brain and indirectly influence
the cerebral inflammatory milieu. Indeed, T cells have been con-
sistently identified in several reports as the invading leukocyte
subpopulation with the largest impact on stroke outcome with
partially divergent functions of T-cell subsets (Kleinschnitz et al.,
2010). On one hand, immunosuppressive Treg cells provide a
neuroprotective function by suppressing an overshooting in-
flammatory reaction to the brain infarct (Liesz et al., 2015); on
the other hand, the proinflammatory TH1 and TH17 cells induce
secondary neurotoxicity and lead to infarct expansion with wors-
ened functional outcome (Shichita et al., 2009; Gelderblom et al.,
2012). In addition to the impact of SCFAs on T-cell polarization,
alternative mechanisms of immunoactive SCFA effects might be
mediated via regulation of micro-RNA expression (so far mainly
studied in cancer) or by modulating the production of reactive
oxygen species; however, these pathways are still under investi-
gation and require further exploration in stroke.
Several experimental stroke models have been established for
modeling focal ischemic brain injury in rodents. While some
stroke models use occlusion of a large cerebral artery, such as
intraluminal occlusion of the MCA by a suture or the direct, distal
MCA occlusion model, other stroke models induce artery occlu-
sion using other strategies, such as end arterial occlusion by pho-
tosensitive dyes or vasoconstriction using endothelin-1 (Fluri et




al., 2015; Kumar et al., 2016). All of these experimental stroke
methods only model certain elements of the highly complex
pathophysiological events of stroke in human patients. Yet, each
model provides the advantage to be particularly useful in analyz-
ing specific targets of stroke interventions, acute neuroprotec-
tion, reperfusion, delayed apoptosis, inflammation, or chronic
repair mechanisms (Carmichael, 2005). The PT stroke model,
which was the main animal model used for most experiments in
this study, was previously suggested as particularly suitable for
analyzing recovery mechanisms after stroke, and is still widely
used in this research domain (Carmichael, 2005; Murphy and
Corbett, 2009). Disadvantages of this model are that it does not
allow local collateral reflow and shows a profound local edema
during the acute phase. Therefore, this model is not useful for
studies to investigate acute neuroprotective agents or reperfusion
therapies. On the other hand, PT stroke allows precise position-
ing of the lesion in functionally defined brain areas (i.e., the mo-
tor cortex in our study). Moreover, the highly reproducible and
confined cortical lesion allows for a more detailed analysis of
pathophysiological processes in the perilesional cortex compared
with other stroke models; which are less consistent in the lesion
localization.
Surprisingly, despite this obviously pronounced effect of lym-
phocytes in poststroke pathology, their role in activating or in-
hibiting microglial activation has so far barely been investigated.
We have observed indirect evidence for T-cell effects on micro-
glial activity in previous experiments, in which depletion of cir-
culating Treg cells affected microglial activation and cytokine
release (Liesz et al., 2009). Additional indirect evidence comes
from studies demonstrating T-cell interaction and particularly
the influence of T cell-secreted cytokines on multiple other cell
types in the healthy and injured brain, such as T cell-derived
interferon-gamma on animal behavior (Walsh et al., 2015;
Filiano et al., 2016). Yet, to our knowledge, the role of T cells as
indirect cellular mediators of microbiota-derived SCFAs on the
brain has so far not been studied. In this study, we unequivocally
demonstrate, for the first time, that T cells are crucial to mediate
the immunomodulatory effects of SCFA on brain resident micro-
glia because, in lymphocyte-deficient mice, this effect became
abolished. This finding is also in accordance with our previous
proof-of-concept experiments showing that circulating T cells
were key in facilitating the impact of the gut microbiome on
stroke outcome in germ-free versus recolonized animals as well as
in mice with a healthy versus a dysbiotic microbiome (Singh et al.,
2016, 2018). These previous reports by us and independent re-
ports by others have also consistently identified a translocation of
lymphocytes from the intestinal immune compartment to the
poststroke brain, providing a cellular link by these circulating and
highly motile cells across the gut– brain axis (Benakis et al., 2016;
Singh et al., 2016).
Together, this study identified SCFAs as critical metabolites
derived from the gut microbiome affecting T-cell function and
thereby indirectly modulating the neuro-regenerative milieu.
This expands our current understanding of the mechanisms
along the gut– brain axis in acute brain injury and recovery where
poststroke dysbiosis affects the production of key microbiota-
derived metabolites, their impact on immunological homeosta-
sis, and finally the capability for efficient functional recovery. The
efficacy of SCFAs for promoting recovery in an experimental
stroke model on a functional as well as morphological level opens
up novel therapeutic possibilities for improving recovery of hu-
man stroke patients. Future studies should validate the proregen-
erative effect of SCFAs on poststroke recovery before further
translational development. Based on the findings from this study
and indications for efficacy and similar modes of actions in pri-
mary autoimmune brain disorders (Melbye et al., 2019), it is well
conceivable that SCFA supplementation could be used as a safe
and practical add-on therapy to stroke rehabilitation. However,
further studies will be required to test the efficacy of this approach
in a post-treatment paradigm, in combination with common co-
morbidities and comedications, and finally validate in a confir-
matory, multicenter preclinical study design before further
translation to human stroke patients can be considered (Llovera
et al., 2015; Llovera and Liesz, 2016).
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Swidsinski A, Loening-Baucke V, Krüger M, Kirsch S (2012) Central ner-
vous system and the colonic bioreactor: analysis of colonic microbiota in
patients with stroke unravels unknown mechanisms of the host defense
after brain injury. Intestinal Research 10:332.
Tan J, McKenzie C, Vuillermin PJ, Goverse G, Vinuesa CG, Mebius RE, Macia
L, Mackay CR (2016) Dietary fiber and bacterial SCFA enhance oral
tolerance and protect against food allergy through diverse cellular path-
ways. Cell Rep 15:2809 –2824.
Thion MS, Low D, Silvin A, Chen J, Grisel P, Schulte-Schrepping J, Blecher R,
Ulas T, Squarzoni P, Hoeffel G, Coulpier F, Siopi E, David FS, Scholz C,
Shihui F, Lum J, Amoyo AA, Larbi A, Poidinger M, Buttgereit A, et al.
(2018) Microbiome influences prenatal and adult microglia in a sex-
specific manner. Cell 172:500 –516.e516.
van de Wouw M, Boehme M, Lyte JM, Wiley N, Strain C, O’Sullivan O, Clarke
G, Stanton C, Dinan TG, Cryan JF (2018) Short-chain fatty acids: mi-
crobial metabolites that alleviate stress-induced brain-gut axis alterations.
J Physiol 596:4923– 4944.
Villa A, Gelosa P, Castiglioni L, Cimino M, Rizzi N, Pepe G, Lolli F, Marcello
E, Sironi L, Vegeto E, Maggi A (2018) Sex-specific features of microglia
from adult mice. Cell Rep 23:3501–3511.
Walsh JT, Hendrix S, Boato F, Smirnov I, Zheng J, Lukens JR, Gadani S,
Hechler D, Gölz G, Rosenberger K, Kammertöns T, Vogt J, Vogelaar C,
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SCFA concentrations are reduced after stroke. (A) Plasma concentration (µM) showing 
a decrease of total SCFA (sum of acetate, propionate and butyrate) in mice 3 days after 
fMCAo stroke surgery (grey bars) compared to sham (open bars). N=4 per group (Mann-
Whitney U test). (B) No difference of body weight in grams at baseline (BL) until D42 post 
PT in mice supplemented with SCFA (grey line) or control (black line). N=14/15 per group 
(2-way ANOVA with Holm-Sidak correction for multiple testing). (C) Lesion size as meas-
ured in pixels did not differ between SCFA (grey bar) and control mice (open bar) at any 
time points. N=11/10 and statistical test with multiple T tests per time point and Holm-Sidak 







































































Figure 1-1. SCFA concentrations are reduced after stroke. 
(A) Plasma concentration (µM) showing a decrease of total SCFA (sum of ace ate, propionate a d 
butyrate) in mice 3 days after fMCAo stroke surgery (grey bars) compared to sham (open bars). N=4 per 
group (Mann-Whitney U test). (B) No difference of body weight in grams at baseline (BL) until D42 post 
PT in mice supplemented with SCFA (grey line) or control (black line). N=14/15 per group (2way ANOVA 
with Holm-Sidak correction for multiple testing). (C) Lesion size as measured in pixels did not differ 
between SCFA (grey bar) and control mice (open bar) at any time points. N=11/10 and statistical test 






SCFA supplementation does not alter tissue injury in 3 focal stroke models. Infarct vol-
ume from Nissl staining in mice supplemented with control mix (open bar) or SCFA (grey 
bar). (A) 24 h after PT, N=10 per group; (B) 14 d after PT, N=10/9 per group; (C) 5 d after 
dMCAo, N=6/9 per group; (D) 14 d after dMCAo, N=9/8 per group; and (E) 14 d after 
fMCAo, N=5/7 per group. Statistical analyses were performed using the Mann-Whitney U 
test. (F) As in Figure 2E, histogram of the relative frequency (fraction) of spines found at 
different lengths 14 d after PT in the contralateral cortex (bin width = 0.2 µm). (G) Quanti-
fication of short (0.2 µm) and long (1.4 µm) spines in control (open bars) and SCFA (grey 
bars) treated mice. N=4/5 per group, Mann-Whitney U test. (H) The size in pixels of synap-
ses stained with VGlut1 (left) and Homer1 (right). Quantification revealed larger synapse 
areas in the peri-lesional cortex which was significantly ameliorated with SCFA supplemen-
tation. Contra: contralateral hemisphere; ipsi: ipsilateral hemisphere, N=3/4 mice (3 sections 
per mouse), statistical analysis performed with Kruskal-Wallis test with Dunn's multiple 



















































































































































































Figure 2-1. SCFA supplementation does not alter tissue injury in 3 focal stroke models. 
Infarct volume from Nissl staining in mice supplemented with control mix (open bar) or SCFA (grey 
bar). (A) 24h after PT, N=10 per group; (B) 14d after PT, 10/9 per group; (C) 5d after dMCAo, 
N=6/9 per group; (D) 14d after dMCAo, N=9/8 per group; and (E) 14d aft r fMCAo, N=5/7 per 
group. Statistical analyses were performed using the Mann-Whitney U test. (F) As in Figure 2E, 
histogram of the relative frequency (fraction) of spines found at different lengths 14d after PT in 
the contralateral cortex (bin width = 0.2µm). (G) Quantification of short (0.2µm) and long (1.4µm) 
spines in control (open bars) and SCFA (grey bars) treated mice. N=4/5 per group, Mann-Whitney 
U test. (H) The size in pixels of synapses stained with VGlut1 (left) and Homer1 (right). Quantifica-
tion revealed larger synapse areas in the peri-lesional cortex which was significantly ameliorated 
with SCFA supplementation. Contra: contralateral hemisphere; ipsi: ipsilateral hemisphere, n=3/4 







SCFA supplementation increases plasma concentrations. Mice were pre-treated with an-
tibiotic mix for 4 weeks, and then additionally given control (ABX, open bars) or SCFA 
supplementation (ABX+SCFA, grey bars). Total plasma concentration (µM) of total SCFA 
(acetate, propionate and butyrate) showing significant increase after SCFA supplementation 


























Figure 3-1. SCFA supplementation increases plasma concentrations. 
Mice were pre-treated with antibiotic mix for 4 weeks, and then additionally given control (ABX, 
open bars) or SCFA supplementation (ABX+SCFA, grey bars). Total plasma concentration (µM) 
of total SCFA (acetate, propionate and butyrate) showing significant i crease after SCFA supple-






SCFA supplementation does not affect cerebral endothelial expression. Relative mRNA 
expression (RE) for the tight-junction and adhesion molecules Claudin-5 (left), ICAM-1 
(middle) and VCAM-1 (right) from the peri-lesional cortex in control (open bars) and SCFA 


















































Figure 4-1. SCFA suppleme tation do s not affect cerebral endothelial expression. 
Relative mRNA expression (RE) for the tight-junction and adhesion molecules Claudin-5 (left), 
ICAM-1 (middle) and VCAM-1 (right) from the peri-lesional cortex in control (open bars) and SCFA 
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